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Abstract to study 
Ostrich organs/tissue/fluids were screened for plasma kallikrein-like, tissue kallikrein-like and tonin-like 
activity in a continuous-fluorogenic-assay system using Pro-Phe-Arg-7-amino-4-methylcoumarine, Phe-
Arg-7-amino-4-methylcoumarine and Val-Leu-Arg--7-amino-4-trifluoro-methylcoumarine as substrates.  
Ostrich liver and kidney showed the highest specific plasma kallikrein-like activity.  Ostrich adrenal 
glands and kidney showed the highest specific tissue kallikrein-like and tonin-like activity.  Ostrich high 
molecular weight kininogen was purified from plasma and low molecular weight kininogen was partially 
purified.  The N-terminal amino acid sequences of both high- and low molecular weight kininogens from 
ostrich plasma were determined.  Ostrich plasma high molecular weight kininogen was purified as a 118 
kD protein.  The purified high molecular weight kininogen inhibits the cysteine proteinase papain at a ratio 
of one molecule HKG to two molecules of papain.  Ornitho kinin-like molecules were detected in ostrich 
urine using reverse phase HPLC.   
Opsomming tot studie 
Volstruis orgaan/weefsel/vloeistowwe was ontleed vir plasma kallikrein-tipe, weefsel kallikrein-tipe en 
tonin-tipe aktiwiteite in n kontinue-fluoreserende-bepalings sisteem waarin Pro-Phe-Arg-7-amino-4-
metielkomarien, Phe-Arg-7-amino-4-metielkomarien en Val-Leu-Arg-7-amino-4-trifluoro-metielkomarien 
as substrate gebruik was.  Volstruis lewer en niere het die hoogste spesifieke plasma kallikrein-tipe 
aktiwiteit getoon.  Volstruis byniere en niere het die hoogste spesifieke weefsel kallikrein-tipe en tonin-
tipe aktiwiteit getoon.  Volstruis hoë molekulêre massa kininogeen was vanaf plasma gesuiwer en lae 
molekulêre massa kininogeen was gedeeltelik gesuiwer.  Die N-terminale aminosuur volgorde van beide 
hoë- en lae molekulêre massa kininogeen vanaf volstruis plasma was bepaal.  Volstruis plasma hoë 
molekulêre massa kininogeen is gesuiwer as n 118kD protein.  Die gesuiwerde hoë molekulêre massa 
kininogeen inhibeer die cysteine protease papain met n verhouding van een molekul HKG teen twee 
molecules papain.  Ornitho kinien-tipe molekules was bespeur in volstruis uriene deur middel van trufase 
HPLC.   
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1.1. The Kallikrein-kinin system (KKS) 
The kallikrein-kinin system (KKS) is involved in many important physiological and 
pathophysiological processes such as allergy (Geppetti et al., 1994), arthritis (Bhoola et 
al., 1992), post-myocardial infarction (Wollert and Drexler, 1997; Brilla and Maisch, 
1994), hypertension (Ponchon and Elghozi, 1995; Privitera et al., 1994), diabetes 
mellitus (Vora et al., 1997; Jaffa et al., 1992; Zuccollo et al., 1996), inflammation and 
coagulation (Cicala and Cirino, 1998), smooth muscle contraction and relaxation 
(Mentlein and Roos, 1995) and the regulation of bone metabolism (Lerner, 1994).  With 
respect to functional aspects, the KKS can be divided into a plasma KKS (pKKS) and 
tissue (glandular) KKS (tKKS).  It is generally assumed that the pKKS participates in 
the activation of coagulation, inflammation and circulatory shock      (Damas, 1996).  
The tKKS plays a role in many secretory functions and the regulation of local blood 
flow in different organs.   
1.1.1 Production of kinin 
 
The components of both pKKS and tKKS are found in plasma. In plasma the serine 
protease, plasma kallikrein (PK; EC 3.4.21.34), liberates the nonapeptide bradykinin 
(BK) from the protein precursor high molecular weight kininogen (HKG).  In tissue, 
active tissue kallikrein when released from tissue-prokallikrein by proteolytic enzymes 
liberates the decapeptide kallidin, also called lysyl-bradykinin (LBK), from low 
molecular weight kininogen (LKG). Tissue kallikreins (TK) mediate a broad spectrum of 
biological effects including vasodilation and vasoconstriction (Madeddu et al., 1997), 
pain (Tracey and Walker, 1995) and inflammation (Geppetti et al., 1994).  Activation of 
TK occurs following tissue injury, disease, infection and inflammation.  Kinin 
production may occur independent of these systems, as cellular proteases released from 
mast cells and basophils during acute inflammation also stimulate kinin formation 
(Lupke et al., 1982; Proud et al., 1985).  Enzymes that possess the capacity to release 
kinins from kininogens are collectively called kininogenases, which include enzymes 
such as trypsin, plasmin and snake venom (Borthrops jararaca) proteases (Müller-
Esterl, 1989).  When inactive Hageman factor (Factor XII; FXII) binds to negative 
surfaces, such as damaged basement membranes and endothelial cells, this binding 
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activates FXII that then liberates the active PK from pre-PK.  Plasma kallikrein then 
releases BK from HKG by hydrolysis of a Lys-Arg and an Arg-Ser bond to yield a 
nonapeptide with arginine at both amino and carboxy terminals.  The plasma-KKS thus 
participates in surface-dependent activation of blood clotting, fibrinolysis, regulation of 
vascular tone and inflammation (Bhoola et al., 1992).  An overview of the molecular 
interactions participating in the pKKS and tKKS is shown in figure 1.1.   
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Figure 1.1:  An overview of the molecular interaction of the components of the pKKS and tKKS.  NE, 
neutrophil elastase liberates a kinin fragment (Kinin-F) from LKG; LKG-F1, LKG fragment 1 after kinin 
is liberated from LKG; HKG-F1 and HKG-F2, respectively fragment 1 and fragment 2 after kinin is 
liberated from HKG.  Intravenous infusion of vasopressin (VP) [antidiuretic hormone] was reported to 
stimulate both the release of urinary kallikrein and the intrarenal formation of kinin in the dog and rat.  
Oxytocin (OX) is a renal kallikrein releaser (Katori & Majima. 1996).  It is well known that aldosterone 
(AD) accelerates the synthesis of TK.  PK liberates BK from Kinin-F and arginine aminopeptidase P  
(Arg-APP) liberates BK from kallidin.  This diagram was constructed from literature using Microsoft 
Word 2000; most of the data being taken from Raidoo and Bhoola (1998).   
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1.1.2 Cellular action of kinin 
 
Two kinin receptors (B1 and B2) have been shown to mediate the biological effects of 
kinins and related peptides (Regoli and Barabe, 1980).  The constitutive B2 receptor that 
accounts for the majority of the physiological effects of BK is a member of the super-
family of G-protein-coupled (Ga and Gq) rhodopsin-like receptors characterised by 
seven transmembrane regions connected by three extracellular and three intracellular 
loops (Burch and Axelrod, 1987).  The receptor protein consists of 364 amino acids, is 
highly glycosylated, exists in multiple isoforms at 69 kD with isoelectric points of pH 
6.8-7.1 and contains the BK binding site at the amino-terminal part of the third 
extracellular loop (Abd Alla et al., 1993, 1996).  The kinin B1 receptor is rapidly 
upregulated in immunopathology under the influence of inflammatory mediators 
[cytokines (interleukin-1β), endotoxins (lipopolysaccharides)] and growth promoters     
(Marceau, 1995).  Structurally, this receptor also has the characteristics of a classical G-
protein-coupled receptor and is composed of 353 amino acids, which have a 36% 
homology to the amino acid sequence of the B2 receptor (Menke et al., 1994).  LBK also 
acts on B2 receptors, but in addition, can act on B1 receptors following conversion to BK 
by the action of aminopeptidases (Walker et al., 1995).  The primary agonists for B1 
receptors, des-Arg9-bradykinin (des-Arg9-BK) and/or des-Arg10-kallidin (des-Arg10-
LBK) are generated from BK and LBK, respectively, by the action of kininase I-
carboxypeptidase M (KI-CPM).  The existence of a B3 kinin receptor as proposed by 
Farmer and deSaito, (1994) and/or B2 receptor subtypes (Hall, 1992; Seguin et al., 1992) 
await the discovery of selective agonists and antagonists that can reliably distinguish B3 
and B2 receptor heterogeneity. 
Cellular actions following kinin receptor stimulation are mediated by all of the known 
second messenger systems, as well as the participation of nitric oxide (NO), especially 
on neurons and blood vessels     (figure 1.2).  Vasodilation and vasoconstriction are 
regulated by several endocrine, paracrine and neurogenic factors.  Perivascular nerves 
release the classical transmitters acetylcholine or noradrenaline, the neuropeptides 
calcitonin gene-related peptide (CGRP), substance P (SP), neuropeptide Y (NPY) and 
others as co-transmitters.  Like the endocrine/paracrine peptides; angiotensin II (AT II) 
and BK, these neuropeptides are strong vasoactive effectors.  As with other signal-
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transmitting substances, these peptides have to be inactivated after their interaction with 
receptors; otherwise, a constant stimulus would be produced.  Bioactive peptides are 
degraded and thereby mostly inactivated by cell surface-bound or soluble proteases 
(Checler, 1993; Kenny and Hooper, 1991; Lucius and Mentlein, 1991).  The metabolism 
of BK to des-Arg9-BK and L-arginine by the kininase I group of enzymes, either close to 
or within endothelial cells or in synaptic clefts, provides the primary substrate for the 
formation of endothelium-derived NO (EDNO) (relaxing factor).  The released L-
arginine acts as the substrate for NO synthase, which rearranges the guanidino nitrogen 
to produce NO (Bhoola et al., 1992; Erdos, 1990).  This functional link is of 
considerable physiological importance because several studies have suggested that NO 
may be a transmitter or neuromodulator at synaptic junctions (Bult et al., 1990;                      
Schachter et al., 1991).   
. . . . . . .. . . 
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Figure 1.2:  The cellular interaction of the components of the KKS.  BK is produced via the proteolytic 
action of PK on HKG and from the proteolytic action of arginine aminopeptidase M (Arg-APM) on LBK.  
In cancerous patients high amounts of 3-hydroxyproline-BK [Hyp(3)-BK] is detected.  Hyp(3)-BK is 
formed via the action of hydroxy-4-prolinase on kinin.  Kinin is degraded to different components via the 
action of several kininases: Arg-APP = arginine aminopeptidase P, KI-CPN = kininase type I 
carboxypeptidase N; KI-CPM = kininase type I carboxypeptidase M, KII-ACE = kininase type II 
angiotensin converting enzyme, KII-NEP = kininase type II neutral endopeptidase; in a zinc dependent 
manner.  KII-ACE circulates as a dimer and its catalytic activity is zinc dependent.  Several of the kinin 
products exert agonistic and antagonistic activity on the kinin receptors type B2 (B2-R) and B1 (B1-R).  
NO, nitric oxide; e/iNOS, endothelial / inducible nitric oxide synthase; PGE2, prostaglandin E2; ONOO-, 
peroxynitrite; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor; O2-, superoxide 
anion radical (O2.-); TNF, tumor necrosis factor; IL, interleukin; PKC, protein kinase C; IP3, 
inositoltriphosphate (IP3); cAMP, adenosine 3,5-cyclic monophosphate; PLC, phospholipase C.  This 
figure was compiled from multiple sources using Microsoft word 2000.   
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1.1.3 Synthesis of KKS components 
 
Plasma kallikrein, HKG and circulating kininases are synthesised in the liver.  The 
ability of tissues to synthesise TK, LKG, kininases and B1 and B2 receptors is variable.  
The genes coding for the three members of the human TK family of structurally related 
serine proteases, which exhibit a diverse range of enzymic actions, have been 
characterised.  TK is encoded by the KLK1 gene and is expressed in the pancreas, 
salivary gland and kidney.  In the human prostate, the physiological function of the 
product of the human KLK2 gene is still unknown, while the KLK3 gene which codes 
for human prostate specific antigen was identified by Clements (1994).  These genes are 
located on the long arm of chromosome 19, where one gene is associated with 
transforming growth factor (Evans et al., 1988).  The use of specific cDNA probes in 
nucleic acid hybridisation techniques has made it possible to detect TK mRNA in the 
pituitary and various brain regions of the rat (Chao et al., 1983, 1987).   
A detailed analysis of the cDNA data indicates that a single kininogen gene, containing 
11 exons, codes for the various domains in HKG and LKG in the human genome 
(Kitamura et al., 1985).  The HKG and LKG molecules are produced by alternate 
splicing of the gene transcript.  The products of exons 1, 2 and 3 code for kininogen 
domain 1 (D1); exons 4, 5 and 6 for D2; exons 7, 8 and 9 for D3 (which inhibits 
thrombin activation of platelets and platelet aggregation) (Jiang et al., 1992); and exon 
10 codes for D4 (which contains BK), D5 (which, being rich in histidine, glycine and 
lysine, is responsible for binding to anionic surfaces) (Dela Cadena and Colman, 1992) 
and D6 (which is only present in HKG and is responsible for complex formation with 
prekallikrein) (Tait and Fujikawa, 1987).  The physiological significance of the 
differences in the regulation of pKKS and tKKS is an unanswered question and currently 
under investigation.   
1.1.4 Physiological control of KKS 
 
The renal KKS produced in the distal nephron in the kidney may play a role in sodium 
metabolism with other renal depressor systems in addition to its own action.  There 
exists a close relation between renal dopamine, prostaglandins and KKS.  Dopamine 
. . . . . . .. . . 
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augments the activity of the renal KKS by increasing renal prekallikrein synthesis and 
kallikrein specific activity and by suppression of the kallikrein inhibitors (Iimura et al., 
1988).  Local blood flow and salt-water homeostasis are closely linked to two different 
endocrine systems, namely the renin-angiotensin-aldosterone system (RAAS) and the 
kallikrein-kinin system (Bhoola et al., 1992).  The RAAS stimulates blood pressure and 
increases salt and water re-uptake in the kidney via angiotensin II (AT II) and 
aldosterone.  It is widely accepted that aldosterone increases renal synthesis and urinary 
excretion of kallikrein in humans and animals (Margolius et al., 1974; Nolly et al., 
1994). The KKS opposes the effect of the RAAS by reducing peripheral vascular 
resistance and lowering the blood pressure directly by releasing NO and indirectly by 
generating prostacyclins from the endothelial cells via the B2-receptors, although this 
concept is still controversial (Hilgenfeldt et al., 1998; Toda & Okamura, 1989).  There is 
increasing evidence that the kidney plays an important role in the long-term blood 
pressure regulation and in the pathogenesis of hypertension (Margolius, 1989).  Kinins 
have been implicated in the control of renal blood flow, glomerular filtration and inhibit 
sodium reabsorption or accelerate its excretion (Scicli and Carretero, 1986).  Kallidin 
has a marked inhibitory effect on arginine vasopressin-stimulated water permeability in 
the kidney        (Schuster et al., 1988).  In view of the fact that NaCl seems to play a 
crucial role in the blood pressure regulation and salt-water homeostasis, the 
physiological interaction between RAAS and KKS is of great importance in 
understanding hypertension.  To understand how the systems interact, it is important to 
give an overview of RAAS and its main components. 
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1.2. The renin-angiotensin-aldosterone system 
Intervention studies have shown that several different ACE inhibitors (e.g. captopril) 
lower blood pressure, glomerular capillary pressure, urinary albumin excretion and 
glomerular injury (Zatz et al., 1986; Anderson et al., 1989; Anderson et al., 1992).  
Studies with specific AT II receptor antagonists have generally tended to duplicate those 
findings (Anderson et al., 1993; Remuzzi et al., 1993), suggesting that suppression of 
AT II is the predominant mode of action of ACE inhibitors.  The close interaction 
between the KKS and RAAS can be seen in figure 1.3 depicting the main components of 
the two systems.   
Figure 1.3:  A schematic representation of the metabolic effects, the main molecular components and the 
control points [*] between the KKS and RAAS.  Kallikrein (KLK) converts kininogen (KG) to kinin and 
also serves to activate pro-renin to renin.  Activated renin converts angiotensinogen to angiotensin I     
(AT I).  Angiotensin converting enzyme (ACE) converts AT I to AT II and also serves to inactivate kinin.  
ACE inhibitors (captopril) have been introduced as antihypertensive agents that will augment the level of 
kinin to promote the generation of prostaglandins (PGS) and endothelium derived nitric oxide (EDNO) 
and prevent the formation of AT II (Dietze et al., 1996).   
 
The anti-hypertensive effect of ACE inhibitors may be relevant to the inhibition of 
kininase II or to increased levels of kinin in the plasma.  Perindopril is an ACE inhibitor 
that causes hypotensive effects in spontaneously hypertensive rats (SHR) on low- and 
high-NaCl diets, which is attenuated by the BK       B2-receptor antagonist HOE 140 
(Bouaziz et al., 1994).  Captopril slightly increases the BK level in the arterial blood of 
anaesthetised rats, but not sufficient to reduce systemic blood pressure (Majima et al., 
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1995).  Most of the beneficial effects of ACE inhibitors like ramipril are reversed by pre-
treatment with HOE 140 and these beneficial effects may be related to the formation of 
nitric oxide and prostacyclin enhanced by BK release (Linz et al., 1993). 
1.3. Clinical importance of the KKS 
 
1.3.1 Vasculature 
 
Since the afferent arteriole in the kidney is a well-documented site for the localization of 
human renin and the connecting tubule is the site for TK, this anatomical proximity 
points to a physiological relationship between the two humoral regulators of renal blood 
flow.  TK activates pro-renin in vitro, however, the Km for the conversion of pro-renin to 
renin is much higher than the Km for the release of kinins and therefore in vivo 
conversion of pro-renin is unlikely.  Kinins and TK stimulate the release of renin from 
isolated rat glomeruli with the afferent arteriole attached.  ACE primarily vasoconstricts 
the efferent arterioles of juxtamedullary and cortical nephrons.  BK decreases both 
afferent and efferent arteriolar resistance, with the decrease generally being 
proportionally greater in the afferent than in the efferent arteriole.  Therefore, paracrine-
formed kinins may participate in a complex manner in the homeostatic control of renal 
blood flow and glomerular filtration, both by a direct vasodilatory action on the renal 
vessels and indirectly by increasing the resistance of efferent arterioles through the 
formation of AT II as a result of the release of renin from the smooth muscle cells of the 
afferent arteriole (Bhoola et al., 1992).   
The presence of a variety of peptide receptors that are linked to conventional 
intracellular second messengers on the luminal and abluminal surfaces of endothelial 
surfaces implies that complex signal transduction occurs between and within endothelial 
cells of the blood-brain barrier (BBB).  Autocoids (such as histamine, BK, eicosanoids 
and free radicals) released by trauma, ischaemia, seizures and inflammation, influence 
cerebrovascular resistance, capacitance vessels and the permeability of the BBB under 
pathological conditions.  Recent data suggests that the passage into the brain of 
compounds that are normally excluded by the BBB can be facilitated by the infusion of 
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BK into the lumen of cerebral blood vessels, as well as the application of BK into the 
abluminal vessel wall.  Plasma and vascular kinins stimulate the production of EDNO, 
free radicals, H2O2, leukotrienes, prostacyclin and endothelium-derived hyper polarizing 
factor (which regulates the function of vascular smooth muscle) and endothelial 
interactions with blood cells.  Although the predominant effect of BK is to cause 
relaxation of isolated human, rabbit and cat cerebral arterioles it is well accepted that BK 
can both contract and dilate vascular smooth muscle via either B1 or B2 receptors, 
depending on the particular vessels.  The vascular relaxant effects of BK are mediated 
by either increased prostacyclin or increased cyclic GMP production secondary to the 
increased formation of NO.  The BK-induced increased vascular permeability, which 
results in extravasation of plasma constituents, as well as specific cellular elements of 
blood, is due to the formation of fenestration in the walls of microvascular tissue.  The 
fenestration is due to contraction of vascular endothelial cells secondary to the calcium-
dependent activation of contractile proteins.  The combined vasodilatation and increased 
vascular permeability will promote local blood flow and facilitate plasma extravasation.  
Administration of small doses of BK into the cerebral ventricles has been shown to 
produce a rise in systemic blood pressure by centrally mediated effects.  Using 
antibodies to specific peptide sequences of the B2 receptor and standard 
immunolabelling techniques, immunoreactive B2 receptors have been localized in both 
endothelial and vascular smooth muscle cells of various systemic and cerebral blood 
vessels of the rat and humans, demonstrating that kinin receptors are indeed present on 
vascular tissue.  Furthermore, increased labelling for B1 receptors was demonstrated in 
atherosclerotic human blood vessels and in porcine blood vessels following 
inflammation, seeming to suggest that this class of kinin receptor is induced by vascular 
damage (Raidoo and Bhoola, 1998).   
1.3.2 Sodium accumulation 
 
Bradykinin is a potent natriuretic agent, as well as being a renal vasodilator.  However, 
the contribution of the KKS to Na+ excretion in the renal tubules may be minimal under 
physiological conditions since nearly 95% of the Na+ filtered by the renal glomeruli is 
reabsorbed before reaching the cortical collecting tubules.  However, excess Na+ is not 
. . . . . . .. . . 
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reabsorbed before the cortical collecting tubules, which possess B2-receptors.  Therefore, 
the renal KKS acts as a sort of floodgate against Na+ retention.  Once sodium begins to 
accumulate in the body, either by excess salt loading or by aldosterone release by 
angiotensin II, the floodgate for retained sodium opens and the kinin generated in the 
cortical collecting duct inhibits sodium reabsorption and accelerates the excretion of 
sodium, thus preventing accumulation there-of.  In contrast, lack of kinin generation in 
the collecting duct closes the floodgate; and a low dose of sodium or a release of 
aldosterone by angiotensin II may initiate the accumulation of sodium in the serum, 
cerebrospinal fluid and erythrocytes (Katori & Majima, 1996).  The reduction on the 
gate size, together with the increase in renin release, may cause hypertension due to the 
sodium accumulation.  Renal kallikrein may be released into the basolateral side and 
kinin released in the interstitial space may play some role in vasodilation (Majima et al., 
1994).  The major site of action of bradykinin, in relation to the regulation of systemic 
blood pressure, is not on the basolateral side of the collecting duct, but on the luminal 
side.  Kinin generated in the cortical collecting duct inhibits the reabsorption of sodium 
on the luminal side and accelerates the sodium excretion to prevent the development of 
hypertension.  Luminally produced kinins illicit the formation of prostaglandin E2 
(PGE2) from the collecting duct cells (CDs) into the CD-fluid.  PGE2 in the distal tubule 
(DT) or CD fluids can thus enhance the natriuretic action of kinins.  The primary cause 
of hypertension has not been identified despite intensive research on the various 
mechanisms that may be involved in its development.  The hypothetical possibility that 
hypertension results from either an excess of vasoconstrictive substances or a deficiency 
of vasodilating substances has led to research into the roles of the RAAS and the KKS 
(Katori and Majima, 1996).  Along the nephrons from the connecting tubules to the 
collecting duct, the kidney is equipped with all the components of the kallikrein-kinin-
system.  Kinins are known to inhibit sodium and chloride reabsorption in the collecting 
tubular cells through distributed B2 receptors and to increase the secretion of sodium and 
water.  The system does not appear to be active in sodium and water excretion, unless 
there is a tendency for sodium to accumulate in the body.  Once this condition is met, 
kinin generated by renal kallikrein causes the excretion of sodium and water.  Reduction 
of kinin generation either by reduced excretion of renal kallikrein, as in spontaneous 
hypertensive rats, or through a deficiency of LKG in the plasma, as in mutant BN-Ka 
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rats, may cause accumulation of sodium in cells such as the erythrocytes and probably 
the vascular smooth muscle cells and in the body fluids, such as cerebrospinal fluid.  The 
reduced excretion of urinary kallikrein in hypertensive patients and hypertensive models, 
has not yet been clearly established.  Drugs that enhance the renal-KKS, such as urinary 
kininase inhibitors or accelerators of urinary kallikrein excretion, may be useful as a new 
approach for controlling essential hypertension. 
1.3.3 Wound healing and Inflammation 
 
Bradykinin and prostaglandins are important chemical mediators of oxidative and 
inflammatory phases of tissue repair.  BK stimulates a marked release of 
cyclooxygenase products in association with inflammatory cell invasion (Weber et al., 
1995).  BK induces release of PGE2 from infarcted tissue and the levels of PGE2 remain 
increased throughout the fibrogenic phase.  Both BK and PGE2 may actively participate 
in the ensuing inflammatory response to myocardial ischemic injury and as an indirect 
effect interfere with subsequent fibrous tissue formation.  Treatment of rats with acute 
transmutal myocardial infarction either with a BK-B2 receptor antagonist (HOE140) or 
cyclooxygenase inhibitor (indomethacin) results in altered wound healing (reduced 
fibrous tissue deposition).  Infarct area, a measure of scar thickness (or thinning), was 
significantly less at week 4 in rats receiving either HOE140 or indomethacin treatment 
(Noda et al., 1993).  Gross evidence of endocardial fibrosis, although still present in 
indomethacin-treated rats at week 4, was completely absent in rats treated with HOE140.  
B2-receptor blockade is therefore associated with reduced fibrous tissue deposition.  
Bradykinin may contribute to healing by thwarting inflammatory cell responses.  In 
acute myocardial infarction models, lisinopril (an ACE inhibitor) has been shown to 
reduce infarct size.  This beneficial effect has been, in part, ascribed to both bradykinin 
and prostaglandin anti-ischaemic actions.  Interference with B2-receptor binding and 
reduction in prostanoid production will reduce inflammatory response and this could 
influence subsequent fibrogenesis.  Bradykinin's proinflammatory properties may be 
intimately related to cyclooxygenase products (Frimm et al., 1995).  Prostaglandin 
synthase inhibition retards acute inflammatory cell invasion, extracellular matrix protein 
synthesis and fibroblast growth.  It also decreases collagen accumulation in different 
. . . . . . .. . . 
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models of tissue injury and is suggested by infarct expansion and myocardial rupture 
with cyclooxygenase inhibitors.  BK influences inflammation by modulating leukocyte 
activity through the generation of nitric oxide (Moncada, 1992).  Bradykinin has also 
been found to stimulate collagen formation in human fetal lung fibroblasts.  
Prostaglandins are integral to the appearance of collagenase and other neutral 
proteinases.  They trigger collagenase synthesis in activated macrophages while 
indomethacin blocks prostaglandin synthesis and eliminates collagenase activity in these 
cells.  The observed infarct thinning, therefore, may be due to an effect on both 
inflammatory and fibroblast-like cells (Frimm et al., 1995).   
The inflammatory response to injury consists of the activation of several protective 
mechanisms involving different cellular systems.  Among the mechanisms and systems 
that exert their effects rapidly, peptide transmitters released from peripheral endings of 
primary sensory neurons (evoking neurogenic inflammation) play a major role in the 
response to tissue injury (Geppetti et al., 1994).  Following injury, the kinins kallidin 
and BK are formed from tissue and plasma precursors respectively (Regoli and Barabe, 
1980).  Kinins are powerful stimulants of sensory nerves and exert part of their 
inflammatory actions indirectly by releasing sensory neuropeptides (Geppetti, 1993).  
Nerve damage due to trauma or disease often leads to pain.  A typical inflammatory 
response would involve three main aspects:  recruitment of leukocytes 
(polymorphonuclear leukocytes in the acute phase, macrophages and T-cells in the 
chronic phase); release of soluble mediators (kinins, clotting factors, complement 
fragments and eicosanoids) and a cascade of activation and mediator release involving 
both resident cells and leukocytes (figure 1.4).   
When peripheral nerves are injured, macrophages are recruited to the damaged nerve 
where they contribute to the removal of degenerating axons and myelin sheaths.  
Macrophages secrete a wide range of substances (PGE2, PGI2, which sensitize primary 
afferents directly; cytokines, leukotriene and nitric oxide) which cause hyperalgesia 
directly or indirectly.  When activated by leukotriene B4 or by formylated chemotactic 
peptides, polymorphonuclear leukocytes appear to release an eicosanoid (8R, 15S-
diHETE), which has been shown to cause hyperalgesia and activate nociceptors.  
Selective activation of postganglionic sympathetic terminals by 6-hydroxy dopamine 
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produces plasma extravasation.  Plasma extravasation induced by noxious stimuli is 
decreased by surgical or chemical sympathectomy.  Sympathectomy eliminates 
postganglionic sympathetic terminals, which release noradrenaline as a neurotransmitter.  
It therefore reduces the level of noradrenaline, which would otherwise sensitize or 
activate primary afferents to produce hyperalgesia.  Nerve injury results in the up-
regulation of substance P (proinflammatory peptide) receptor binding sites on the 
Schwann cells.  The Schwann cells elicit prostaglandin production in response to 
substance P stimulation.  Disruption of normal maintenance conditions by nerve damage 
signals such as transcription and synthesis of cytokines or growth factors by the 
Schwann cells (which contribute not only to the repair of nerve damage; but also to the 
hyperalgesia, which often accompanies nerve injury) stimulate prostaglandin production.  
Mast cells can be triggered to release histamine (and 5-hydroxytryptamine in rodents) by 
agents such as neuropeptides and might therefore contribute to peripheral hyperalgesia.  
Fibroblasts are also potent sources of inflammatory mediators.  T-8 lymphocytes 
contribute to hyperalgesia following nerve damage as well (Ansselin and Pollard, 1990).   
 
. . . . . . .. . . 
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Figure 1.4:  Four cell types that may release inflammatory mediators to cause hyperalgesia following 
nerve damage.  Macrophages are probably the most important.  Mediators with a direct action on 
nociceptors are shown in bold.  Hyperalgesia may be due to a ligand (such as 5HT) increasing the 
permeability of an ion channel, or to G-protein mediated increase in the activity of an enzyme such as 
PLA2 or adenylyl cyclase, leading in turn to an increase in cation permeability and a decrease in threshold.  
AA = arachidonic acid; ADO = adenosine; ATP = adenosine triphosphate; cAMP = cyclic adenosine 
monophosphate; BK = bradykinin; CGRP = calcitonin gene-related peptide; diHETE, dihydroxyeicosa-
tetraenoic acid; G = G-protein; 5HT = 5 hydroxytryptamine; IL = interleukin; LTB4 = leukotriene B4; 
NPY = neuropeptide Y; PGE2 = prostaglandin E2; PGG2 = prostaglandin G2; PGH2 = prostaglandin H2; 
PGI2 = prostaglandin I2; PIP2 = phosphatidylinositol bisphosphate; PLA2 = phospolipase A2; SP = 
substance P; TNF, tumor necrosis factor (Tracey and Walker, 1995).   
 
1.3.4 The effect of BK in vascular permeability enhancement and tumor growth   
 
NO is generated by NO synthase, using L-arginine and oxygen as substrates.  In acute 
and chronic inflammation, inducible nitric oxide synthase (iNOS) is usually induced by 
various cytokines such as interferon γ and tumor necrosis factor α.  At the site of viral 
infection, iNOS is induced simultaneously with xanthine oxidase which generates 
superoxide anion radical (O2.-) and H2O2 (Akaike et al., 1996).  It is known that O2.- and 
NO react extremely rapidly at diffusion rate limited velocity to form peroxynitrite 
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(ONOO-).  ONOO- is highly reactive to nitrate tyrosine residues in proteins or oxidize 
sulfhydryl and other groups (Crow and Beckman, 1995; Rubbo et al., 1996).  ONOO- 
and NO2 generated can activate a number of procollagenases (proMMPs) that are 
derived from fibroblasts (skin) or macrophages at inflammatory and cancer tissue.  
Degradation of matrix proteins and blood vessels by collagenases, together with the 
gained elastase activity derived from polymorphonuclear leukocytes (PMN), will 
facilitate vascular permeability and extravasation into the interstitium.  ONOO- is 
capable of enhancing the vascular permeability in the normal skin as well as tumor 
tissues.  The enhanced vascular permeability and retention effect brought about by 
ONOO- involve the activation of proMMP (Wu et al., 1998).  The cause of enhanced 
permeability might be through the activation of proMMP, which results in destruction of 
the matrix tissue and might also include the activation of the kinin cascade.  MMP 
inhibitors block the vascular permeability of tissue/skin and cancer tissue.  The ascitic 
and pleural fluids of human and animal carcinomatosis contain excessively high 
amounts of both 3-hydroxyprolyl-BK (Hyp3-BK) and BK and both are responsible for 
the fluid accumulation (Matsumura et al., 1991).  The BK antagonist HOE 140 can 
suppress the vascular permeability of solid tumor in the skin.  BK is also known to 
activate NO production via activation of endothelial nitric oxide synthase (eNOS) 
(Palmer et al., 1988).  This indicates that BK is coupled with the NO system, tumor 
growth, metastasis and cachexia (figure 1.5).  NO generation contributes to the 
angiogenic property of vascular endothelial growth factor (VEGF).   
. . . . . . .. . . 
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Figure 1.5:  Pathological and pathophysiological effects of BK, NO and related compounds in cancer and 
infection.  VEGF, vascular endothelial growth factor; eNOS/iNOS, endothelial / inducible nitric oxide 
synthase; MMP, matrix metalloproteinase; ONOO-, peroxynitrite; O2*-, superoxide anion radical; IL, 
interleukin; TNF, tumor necrosis factor; PMN, polymorphonuclear leukocytes; MØ, macrophage; α1PI,  
α1-proteinase inhibitor.  Taken from Maeda et al. (1999).   
 
VEGF performs its angiogenic process via NO generation; BK will do similarly via NO 
generation and thus sustain tumor growth by supplying both nutrient and oxygen and 
also by triggering angiogenesis (Chan et al., 1996).  BK antagonists can suppress the 
growth of human lung and other tumor cell lines, being attributed to the induction of 
apoptosis by the antagonists (Maeda et al., 1999).  Most bacteria produce proteases that 
activate one or more steps in the KKS.  Bacterial cell surface components can also 
activate the KKS.  Streptococcus pyogenes produces exotoxin B thiol protease, which 
can generate BK directly from HKG.  On the other hand, both BK and chemotactic 
peptide C5a, that initiate the recruitment of neutrophils to the site of infection (Clearly et 
al., 1992), are effectively degraded by the bacterial cell associated C5a-peptidase.  NO-
BK interaction and formation of NO2 and ONOO-, which will activate MMP with 
concomitant inactivation of α1-PI, thus elevates the activity level of both MMP and 
neutrophil derived elastase.  The elevated level of protease appears to be a critical issue 
in the pathogenesis of infection and cancer (Maeda et al., 1999).  MMP inactivates α1-PI 
via proteolytic activity and ONOO- inactivates α1-PI via an active site methionine that is 
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involved in its anti-protease activity (figure 1.5).   
1.3.5 The role of kinins in neurogenic inflammation 
 
Neurogenic inflammation consists of a series of responses caused by the release of the 
peptide transmitters substance P (SP), neurokinin A (NKA) and calcitonin gene-related 
peptide (CGRP) from peripheral terminals of primary sensory neurons.  These 
neurogenic mechanisms evoke tissue specific responses, such as bronchoconstriction and 
seromucous gland secretion in the airways and contraction of the smooth muscle in the 
iris and urinary bladder (Holzer 1991).  Bronchoconstriction is a major symptom of 
allergy and markedly contributes to the narrowing of airway lumen in sensitised 
individuals.  Tachykinins, by activation of both neurokinin 1 (NK1) and neurokinin 2 
(NK2) receptors, are powerful bronchospastic agents (Bertrand et al., 1993).  Kinins 
release NO from endothelial cells, thereby causing relaxation of vascular smooth muscle 
cells and vasodilatation (figure 1.6).   
Figure 1.6:  The cellular systems, mediator and neurotransmitters that contribute to the plasma 
extravasation and bronchoconstriction that follow exposure to antigen in the airways of sensitised guinea 
pigs. The antigen-antibody complex causes a first phase of extravasation, during which kinins are released.  
Kinins stimulate sensory nerves that, in releasing tachykinins activating NK1 and NK2 receptors; 
contribute markedly to anaphylactic plasma extravasation and bronchoconstriction (Geppetti et al., 1994).   
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Chapter 2 
Introduction to the present study 
 
Nothing is known about the KKS in the ostrich.  South Africa has a rich history of farming ostriches.  It is 
known from experience through farming with this animal that wound healing in the ostrich does not occur 
rapidly.  It is also known that this bird is very susceptible to inflammation, bacterial- and viral diseases.   
Currently a market for ostrich meat is developing, but the largest income for this industry comes from the 
ostrich hide.  Ostrich leather products are in big demand in overseas markets.  The ostrich industry in 
South Africa is absolutely dependant on the ability of the ostrich farmer to raise healthy adult birds.  The 
biggest problem for the farmers is that the ostrich has little to no ability to resist infectious diseases.  Most 
of the fatalities are due to inflammation of the digestive system.  Viral contamination somehow lowers the 
defense system of the body, which allows bacterial infection of the digestive tract, subsequent 
inflammation causes swelling of the intestine and an inability to excrete digested foods.  Eventually the 
intestine pops out at the anus, an effect similar to that observed in patients at the late stage of HIV.  The 
studies done by Maeda et al. (1999) clearly showed that bacterial exotoxin B cleaves BK from HKG.  It is 
therefore possible that the KKS may play a major role in the final effects of the infectious diseases.  
Ostrich farmers are able to save some birds by physically returning the intestines to the inside and closing 
the anus with stitches until the body has retained the ability to resist the infection.  Developing 
pharmaceutical products to resist activation of the KKS, most probably at the receptor level, may improve 
the ability of the farmer to raise healthy adult birds.  Since the KKS plays a major role in all of these 
processes, it was decided to investigate the KKS system in the ostrich.   
The study was initiated to further complement research being conducted within the Department of 
Biochemistry and Microbiology at UPE on blood coagulation factors in ostriches.  Preliminary results 
from these studies had shown the ostrich to lack several intrinsic coagulating factors and hence it became 
important to investigate the nature of the plasma KKS to provide knowledge on the contact activation 
system.  At first an approach to this system was made by attempting to measure kallikrein activity in 
several tissues.  However, it was soon realised that this approach was faced by the problem of very low 
levels of kallikreins in the ostrich, in some cases not even being detectable.  Eventually we were able to 
obtain detectable kallikrein-like activity by using a fluorogenic assay system.  Since kallikrein activities 
were too low to attempt purification we purified the kininogen substrate from ostrich plasma.  This 
kininogen molecule was biochemically characterized for its Mr, N-terminal sequence, amino acid 
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composition and cysteine proteinase inhibitory activity.  It was also decided to optimise a novel kinin 
assay system, since the final proof for the presence of a kallikrein would be the liberation of kinin from 
kininogen.  We were able to optimise an HPLC kinin assay system using purified ostrich kininogen as 
substrate, detecting the kinin produced by comparing the elution times to that of standard kinins.   
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Detection of kallikrein activity 
in the Ostrich 
 
 
 
Table of contents to chapter 3 
3.1. Introduction__________________________________________________________________________ 24 
3.1.1 Plasma Kallikrein (PK)______________________________________________________________ 24 
(a) The localisation of PK ______________________________________________________________ 24 
(b) The structural characteristics of PK ____________________________________________________ 24 
(c) Molecular interactions of PK _________________________________________________________ 24 
(i) How do pre-PK, HKG, EC and FXI interact?___________________________________________ 25 
(ii) The processing of the coagulation complex ____________________________________________ 26 
(iii) The inhibition of the complex activation ______________________________________________ 27 
3.1.2 Tissue Kallikrein (TK) ______________________________________________________________ 28 
(a) Stimuli for kallikrein excretion________________________________________________________ 29 
(b) Functional importance ______________________________________________________________ 30 
3.1.3 Substrate specificities of kallikreins ____________________________________________________ 30 
(a) Hydrolysis of fluorogenic peptides by human TK with Abz-F-R as the acyl group and different leaving 
groups 31 
(i) Substitution at P1 ________________________________________________________________ 31 
(ii) Substitution at P2 ________________________________________________________________ 32 
(iii) Substitution at P3, P1, P1 and P2 ____________________________________________________ 32 
(b) Hydrolysis of fluorogenic peptides by human TK with human kininogen sequence flanking the scissile 
bond Met-Lys ___________________________________________________________________________ 33 
(i) Substitution at P1_________________________________________________________________ 33 
(ii) Substitution at P2 ________________________________________________________________ 33 
(c) Cleavage of Arg-Xaa bonds __________________________________________________________ 33 
(d) Cleavage of the Met-Lys bond ________________________________________________________ 34 
(e) Cleavage of the Phe-Lys bond ________________________________________________________ 34 
(f) Amidase activity ___________________________________________________________________ 35 
(g) Protein substrate cleavage____________________________________________________________ 36 
(h) Inhibition characteristics_____________________________________________________________ 37 
(i) PCI-derived peptide substrates of kallikreins _____________________________________________ 38 
(j) Other serpin derived substrates________________________________________________________ 39 
3.1.4 Primary structures of TK and PK ______________________________________________________ 39 
 23 
3.2. Materials and methods____________________________________________________________________ 41 
3.2.1 Reagents _________________________________________________________________________ 41 
3.2.2 Methods _________________________________________________________________________ 41 
(a) Sample collection and processing ______________________________________________________ 41 
(i) Plasma_________________________________________________________________________ 41 
(ii) Urine __________________________________________________________________________ 41 
(iii) Tissue _________________________________________________________________________ 41 
(b) Extraction of kallikrein ______________________________________________________________ 42 
(c) Enzymatic assays with fluorogenic substrates ____________________________________________ 42 
(i) Assay conditions _________________________________________________________________ 43 
(ii) Activation of pro-kallikrein ________________________________________________________ 45 
(d) Protein determination _______________________________________________________________ 46 
(e) SDS-PAGE _______________________________________________________________________ 46 
(f) Isolation of urinary kallikrein _________________________________________________________ 46 
3.3. Results ________________________________________________________________________________ 48 
3.3.1 Ostrich kallikrein-like activity determination _____________________________________________ 48 
3.3.2 Kallikrein isolation from urine ________________________________________________________ 52 
3.4. Discussion _____________________________________________________________________________ 54 
3.4.1 Kallikrein activity detection __________________________________________________________ 54 
(a) TK-like activity____________________________________________________________________ 54 
(b) PK-like activity ____________________________________________________________________ 54 
(c) Tonin-like activity__________________________________________________________________ 54 
3.4.2 Kallikrein isolation _________________________________________________________________ 54 
 
. . . . . . .. . . 
 
 24 
1.4. Introduction 
 
1.4.1 Plasma Kallikrein (PK)  
(a) The localisation of PK   
At present it is generally accepted that plasma prekallikrein (pre-PK), the zymogen of 
the serine proteinase plasma kallikrein (PK; EC 3.4.21.34) is encoded by a single gene, 
synthesized in hepatocytes and secreted into the blood stream (Bhoola et al., 1992).  
However, it has recently been shown that pre-PK mRNA is also present in the kidney, 
adrenal gland, placenta, brain, heart, lung, trachea, endothelial cells (EC) and leukocytes 
(Hermann et al., 1999).   
(b) The structural characteristics of PK 
The prekallikrein molecule is a single-chain glycoprotein (pI 8.9) that exists in two 
forms with molecular masses of 85 and 88 kD, both of which are present in human 
plasma (Mandle & Kaplan, 1977).  Seventy five percent of pre-PK circulates in plasma 
as a heterodimer complex bound to HKG (Mandle et al., 1976).  The active enzyme is 
generated in the early phase of the intrinsic pathway of blood coagulation.  The human 
PK contains 619 amino acids, consisting of a heavy chain (HC) of 371 amino acid 
residues from the NH2-terminus linked to a catalytic light chain (LC) of 248 residues.  
Hydrolysis of a single    Arg-Ile bond in positions 371 and 372 results in the formation 
of the two-chain proteinase held together by a disulphide bridge (Seidah et al., 1989).  
The active site consists of a catalytic triad of His415, Asp464 and Ser559 (Mandle & 
Kaplan, 1977).  The Asp464 provides specificity for substrate binding and the preferential 
cleavage at the COOH-terminus of basic amino acids.   
(c) Molecular interactions of PK 
The HC of the pre-PK molecule is considered to contain the region that interacts with 
activated factor XII (FXII) (Veloso et al., 1987).  The HC contains four domains 
arranged in sequential tandems of 90 residues each.  Each of the four domains is bridged 
by 6 half-cysteine residues, except the last one, which carries two additional half-
cysteine residues to link together the HC and LC.  The amino acid sequences of the 
repeat segments show considerable homology with FXI (Chung et al., 1986).  The 
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tandem repeats in the molecule may themselves play a role in promoting clotting, 
aggregation of neutrophils and are involved in the binding of pre-PK to domain 6 of 
HKG.  In the HKG-pre-PK complex the pre-PK molecule is oriented towards FXII, 
which will activate pre-PK.  Once it has been activated, PK releases bradykinin from 
HKG by hydrolysis of Lys-Arg and Arg-Ser bonds to give a peptide with arginine at 
both NH2 and COOH-terminals (Pierce & Webster, 1966).  This leaves a two-chain 
kinin-free kininogen that is disulfide linked and separable on reduction (Thompson et al, 
1978).  PK by itself does not release bradykinin from LKG, however in the presence of 
neutrophil elastase it will form bradykinin.  First, neutrophil elastase cleaves a fragment 
from LKG from which PK readily releases bradykinin.  Such an important mechanism 
may exist in vivo for kinin generation from LKG, which is present in plasma (Bhoola et 
al., 1992).  The two proteinases, PK and FXIIa, generated during contact activation can 
be involved in a number of subsequent processes.  Both enzymes can activate 
granulocytes (Wachtfogel et al., 1986) and the complement system (DiScipio, 1982).  
FXIIa activates factor XI (FXI) and in this manner triggers the intrinsic blood 
coagulation cascade.  Furthermore, PK is an efficient activator of urokinase-type 
plasminogen activator precursor and thus provides a link to the fibrinolytic system 
(Ichinose et al., 1986; Hauert et al., 1989).   
(i) How do pre-PK, HKG, EC and FXI interact?   
Pre-PK specifically binds to domain 6 on HKG in a Zn2+-dependent manner via a 31-
amino acid peptide (SDD31) which spans amino acids 565-595 in the mature sequence 
of human HKG (Kaufmann et al., 1993).   Domain 6 of HKG is capable of specifically 
binding plasma pre-PK or clotting FXI with high affinity (Sugo et al., 1980).  The 
essential structural requirement for the attachment of prekallikrein is contained in amino 
acid residues 565-SDDDWIPDIQTDPNGLSFNPISDFPDTTSPK-595 (SDD31) (Vogel 
et al., 1990).  In contrast, the binding site for FXI stretches over a segment of 58 
residues (position 556 to 613) and overlaps the entire prekallikrein-binding site (Tait & 
Fujikawa, 1987).  Endothelial cells and platelets express binding sites for pre-PK, HKG, 
PK and the pre-PK-HKG complex (Greengard & Griffin, 1984; Gustafson et al., 1986; 
Schmaier et al., 1988; Van Iwaarden et al., 1988).   
. . . . . . .. . . 
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EC express more binding sites for pre-PK (at least 17 million) than for HKG (at least 10 
million), but the bound HKG on the EC increases the binding of PK on these cells 
(Hasan et al., 1995a).  Pre-PK or PK forms an SDS stable 116-kD complex with human 
umbilical vein EC under reduced conditions.  Assembly of the contact proteins, pre-PK 
and HKG, on cultured EC leads to the formation of active kallikrein, which, in turn, 
cleaves HKG, liberating bradykinin and promoting the activation of pro-urokinase (pro-
UK) and the generation of plasmin.  Kallikrein formation on EC is critically dependent 
on the sequential binding of HKG and pre-PK (Motta et al., 1998).   
The histidine rich domain (domain 5) of HKG attaches the molecule to its receptor on 
the cell membrane through a Zn2+ bridge, thereby providing a mechanism for 
internalisation of circulating kininogen into EC, platelets and neutrophils (Gustafson et 
al., 1989).  Divalent cations (Zn2+) are necessary for the pre-PK-HKG complex 
formation and play an important role in the EC-pre-PK-HKG complex assembly.  Once 
this complex is formed pre-PK is activated by its activators (Motta et al., 1998).  The 
presence of factors XII, αFXIIa, or βFXIIa decreases the activation rate of pre-PK for 
reasons still unknown to us (Leinch et al., 1995).   
(ii) The processing of the coagulation complex 
Endothelial cell-bound exogenous HKG is not substantially cleaved upon binding. PK 
formed on EC in the pre-PK-HKG complex can cleave its receptor and native substrate, 
HKG.   The 120-kD HKG molecules are not cleaved on incubation with EC alone, only 
when PK is incubated (at 20 nmol/L) with the EC-HKG complex.  The 120-kD bands 
totally disappear to form bands at 55-65 kD, 46 kD and 40 kD. Incubations of pro-UK 
with EC increase urokinase activity almost 3-fold over that seen with pro-UK alone.  
The addition of pre-PK and HKG to EC increase the level of urokinase activity an 
additional     1.6-fold.  The Km of pro-UK activation (61-86 nmol/L) is not changed 
when pro-UK is activated in the absence of either pre-PK or HKG compared with that 
seen when both are present (64 nmol/L). However, the Vmax of pro-UK activation (1.4 - 4 
nmol/L/min) on EC is reduced 2.5 to 7.1-fold when either pre-PK or HKG is omitted 
compared with cells preincubated with both HKG and pre-PK (10 nmol/L/min). 
Addition of FXII has little or no effect on the kinetics of pro-UK activation. Little 
activation of plasminogen occurs when it is incubated with EC monolayers alone; a little 
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more plasmin is generated when pro-UK alone is added to plasminogen on EC.  
However, the addition of HKG and pre-PK to pro-UK and plasminogen is associated 
with a 4.3-fold increase in plasminogen activation (Leinch et al., 1995).   
(iii) The inhibition of the complex activation 
Serine proteinase inhibitors such as PMSF (1 mmol/L), SBTI (1 mg/ml), Pro-Phe-Arg-
chloromethylketone (10 µmol/L), or benzamidine (1 mmol/L) do not prevent pre-PK 
activation when added to the complex.  Angiotensin converting enzyme inhibitors, 
lisinopril and enalapril, have no inhibitory effect on the activation of pre-PK either. 
Likewise, phosphoramidon, an inhibitor of neutral endopeptidase and pepstatin A, an 
aspartic acid protease inhibitor, do not interfere with the activity of the pre-PK-
activating enzyme.  However, antipain, cysteine, HgCl2 and 2-mercaptoethanol are 
potent inhibitors of the membrane-associated, pre-PK-activating enzyme, suggesting that 
the activating enzyme is a thiol protease.  Certain metal ion chelators also inhibit pre-PK 
activation when bound to HKG on EC.  EDTA, EGTA, 1,10-phenanthroline, 
bathophenanthroline, or sodium hydrosulfite inhibit the pre-PK-activating enzyme. The 
metalloprotease inhibitor zincov also decreases the activity of the pre-PK-activating 
enzyme.  The inhibitory effect of the metal ion chelators is likely attributed to the 
chelation of the Zn2+ and removal of the pre-PK-HKG complex from the EC membrane, 
rather than to a direct inhibitory effect on the pre-PK-activating enzyme (Leinch et al., 
1995).   
Kallikrein formed on the surface of EC from the pre-PK-HKG complex is positioned to 
exert several potentially important functions.  Cell-bound HKG is cleaved by the formed 
kallikrein on EC, which may be an important control step in this pathway, to release 
kallikrein from its binding site.  Bradykinin formed in proximity to the endothelium may 
be especially potent, because, theoretically, it could engage its receptors before 
inactivation by plasma kininases.  Bradykinin liberation can result in potent tissue 
plasminogen activator release from EC in vivo.  Kallikrein formed from the pre-PK-
HKG complex also activates pro-UK, which, in turn, causes a 4.3-fold increase in 
plasminogen activation on EC.  A small amount of pro-UK can, in this way, be 
converted to two-chain urokinase independent of plasmin, fibrin, or tissue plasminogen 
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activators.  This pathway may potentiate pro-UK activation associated with binding to 
its receptor (Motta et al., 1998).   
Intact vascular endothelium participates in the control of haemostasis by secreting, 
synthesizing and binding different antithrombotic, coagulant and fibrinolytic 
components.  Under physiological conditions, vascular endothelium prevents blood 
coagulation.  However, when it is damaged, its antithrombotic properties are lost (Cicala 
& Cirino, 1998).  Following endothelial damage, tissue factor (TF) is expressed and the 
extrinsic pathway of coagulation is activated.  EC also release tissue plasminogen 
activator (t-PA), a serine protease able to convert plasminogen to plasmin, whose 
function is to degrade fibrin.  The action of t-PA is modulated by tissue plasminogen 
activator inhibitor (t-PAI), which is also released by EC.  The balance between t-PA and 
t-PAI is essential for the modulation of the fibrinolytic pathway          (Preissner, 1990; 
Schiffrin, 1994).  Thrombomodulin, a high affinity receptor protein for thrombin, is 
expressed on the endothelial surface too.  The thrombin-thrombomodulin complex 
activates Protein C (PC), a vitamin K dependent glycoprotein that circulates in plasma as 
a zymogen.  Once PC is activated, it forms a complex with a vitamin K dependent co-
factor, Protein S, on the endothelium.  Activated PC (APC) plays a major role in 
regulating the haemostatic process by inactivating factors Va and VIIa and, at the same 
time, stimulating the fibrinolytic pathway by inactivating plasminogen activator 
inhibitor.  Thus, APC inhibits coagulation and activates the fibrinolytic pathway.  In the 
plasma, APC is slowly inhibited by complex formation with PC inhibitor or α1-
antitrypsin.  On the other hand, thrombin, by activating the protein C pathway, acts as a 
feedback inhibitor of its own production (Esmon, 1992).  It is clear that control of fibrin 
generated during activation of the coagulation cascade is dependent upon a balance 
between procoagulant and anticoagulant factors.  The presence of thrombomodulin on 
the endothelial surface and the integrity of the PC pathway are fundamental 
requirements for a correct balance between coagulation and fibrinolysis (Cicala & 
Cirino, 1998).   
1.4.2 Tissue Kallikrein (TK) 
The glandular kallikreins are serine proteases encoded by a conserved multigene family 
with a high number of members in different species.  In general, the glandular kallikreins 
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are involved in processing polypeptide precursors into their bioactive forms and have 
attracted interest as they liberate kinin from kininogen and release murine epidermal 
growth factor and nerve growth factor from their respective precursors (Drinkwater et 
al., 1988).   
The true TK gene in the kidney is composed of 5 exons and 4 introns, its length being 
about 4.5 kb (Inoue et al., 1989).  TK is released in its active form from glandular tissue 
and the kidney and cleaves kallidin from human LKG (Pierce and Webster, 1961) or BK 
from rat LKG (Kato et. al., 1985). TK is inhibited by aprotinin, plasma α1-antitrypsin 
and kallistatin that are expressed in high levels in the liver and at low levels in the lung, 
salivary gland and kidney (Katori and Majima, 1996).  It has been shown that zinc ions 
inhibit the activity of some members of the TK family.  It has also been postulated that 
zinc reversibly regulates the enzymatic activity of these enzymes (Lövgren et al., 1999).  
Immunoreactive TK may be present in the plasma, but the active kallikrein is 
immediately bound to large amounts of inhibitors present in the plasma and thus is 
inactive.  True TK is an acidic glycoprotein, with apparent molecular mass ranging from 
24 to 45 kD and having pI values close to 4.0.  The kallikrein is synthesised mostly in 
the pro form (Bhoola et al., 1989).   
(a) Stimuli for kallikrein excretion 
Renal perfusion pressure may be one of the major factors controlling urinary kallikrein 
excretion in dogs (Bevan et al., 1974).  A low-sodium diet or salt deprivation always 
accelerates renal kallikrein synthesis and excretion in humans (Margolius et al., 1974) 
and rats (Geller et al., 1972).  The increased kallikrein excretion due to prolonged 
sodium deprivation may be mediated by aldosterone release through activation of the 
renin-angiotensin system, since this increase is reversed by the aldosterone antagonist 
spironolactone and is induced by administration of fluorocortisone, a synthetic sodium 
retaining steroid (Margolius et al., 1974).  Patients with hyper-aldosteronism excrete 
higher amounts of kallikrein in the urine.  Administration of spironolactone to patients 
with primary aldosteronism decreases the high urinary kallikrein level (Margolius et al., 
1974).   
Long-term administration of deoxycorticosterone is reported to increase kallikrein 
excretion.  Excretion of urinary kallikrein varies directly with potassium intake.  It is 
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 30 
well known that aldosterone which accelerates synthesis of kallikrein is synthesised and 
released from the glomerulosa cells of the adrenals.  The glomerulosa cells are sensitive 
to changes in external potassium.  The transduction mechanism used by potassium is 
depolarisation of the membrane with opening of the voltage dependent calcium 
channels.  Adrenalectomy decreased both the kallikrein content in the connecting tubules 
and the Na+/K+ ATPase activity in micro-dissected rabbit nephron, but a single injection 
of aldosterone to adrenalectomized rats caused restoration of the Na+/K+ ATPase 
activity, but not the kallikrein content.  (Marchetti et al., 1984).  Intravenous infusion of 
vasopressin (antidiuretic hormone) was reported to stimulate both the release of urinary 
kallikrein and the intrarenal formation of kinin in the dog and rat.  Oxytocin too is a 
renal kallikrein releaser (Katori and Majima, 1996). 
(b) Functional importance 
The diverse sites of occurrence of TK has led to the suggestion that the functional role of 
this enzyme may be specific to cell types.  Apart from its kininogenase activity (primary 
effect), TK has been implicated in the processing of growth factors and peptide 
hormones.  Human pancreatic kallikrein has been reported to sequentially cleave 
proinsulin to form the active molecule.  Furthermore, TK hydrolyses, at least in vitro, 
other biologically important peptides and proteins such as low-density lipoprotein, the 
precursor of atrial natriuretic factor, prorenin, vasoactive intestinal peptide, 
procollagenase and angiotensinogen (Bhoola et al., 1992).   
1.4.3 Substrate specificities of kallikreins 
Tissue and plasma kallikreins are distinct enzymes, both in their chemical and in their 
enzymic properties.  The latter release bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-
Arg) directly from HKG by the cleavage of a Lys-Arg and an Arg-Ser bond, while the 
former, with the exception of the rat enzyme, cleave a Met-Lys and an Arg-Ser bond to 
release the biologically active peptide kallidin from kininogens (LKG preferentially and 
HKG at a slower rate).  The cleavage specificities are determined by secondary   
enzyme-substrate interactions (Chagas et al., 1995).   
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(a) Hydrolysis of fluorogenic peptides by human TK with Abz-F-R as the acyl group and 
different leaving groups 
Tables 3.1  3.3 present the kinetic data for hydrolysis by human TK of internally 
quenched fluorogenic peptides, which varied in their content of hydrophilic (serine), 
aliphatic (leucine), aromatic (phenylalanine) and basic (arginine) residues at positions 
P1, P2 and P3, respectively.  The model peptide for these fluorogenic substrates, Abz-
F-R-S-S-R-EDDnp (peptide R1), has the sequence of human kininogen at the C-terminal 
side of BK and was hydrolysed by human TK (Km = 0.19 µM and kcat = 1.35 s-1).  The 
glutamine residue in the peptide analogues does not correspond to the P4 residue in 
human kininogen but was introduced as a requirement for the solid phase synthesis of 
the substrates with systematic variations at the P1, P2 and P3 positions.  HPLC analysis 
of the hydrolysates of all the substrates of the R series demonstrated that Arg-Xaa was 
the only bond cleaved.  Enzyme assays were conducted at 30oC in 20 mM Tris-HCl 
containing 1 mM EDTA, at pH 9.0 (Chagas et al., 1995).   
(i) Substitution at P’1  
Hydrolysis of peptides by TK demonstrates a preference of the enzyme S1 subsite for 
arginine (R4, R6 and R9) over serine (R2, R7 and R10), leucine (R3 and R11) and 
phenylalanine (R5) and was characterised by a higher kcat/Km value for peptide R4 with 
arginine in P1.  This characteristic was also demonstrated by the lower Km values for the 
hydrolysis of tetrapeptides R6 and R9 that have respectively Arg-Pro and Arg-Val as the 
leaving group (Table 3.1).   
Table 3.1:  The study of TK specificity at P1 of peptide substrates.  EDDnp, N- (2,4-dinitrophenyl)-
ethylenediamine; Abz, o-aminobenzoic acid (Chagas et al., 1995). 
Peptides P6 P5 P4 P3 P2 P1 P1 P2 P3 P4 P5 
Km 
(µM) 
kcat 
(s-1) 
kcat /Km 
(s-1. mM-1) (X) 
    Abz F R X S R Q EDDnp    P'1 
R2       S     1.50±0.40 1.60±0.20 1067 S 
R3       L     0.60±0.10 1.50±0.10 2500 L 
R4       R     1.30±0.30 7.10±0.20 5462 R 
R5       F     0.40±0.20 0.80±0.10 2000 F 
    Abz F R X P EDDnp      P'1 
R6       R     0.13±0.02 0.06±0.01 462 R 
R7       S     1.40±0.20 0.22±0.01 157 S 
R8       A     1.20±0.20 0.041±0.004 34 A 
    Abz F R X V EDDnp      P'1 
R9       R     0.06±0.01 0.45±0.02 7500 R 
R10       S     0.90±0.10 0.88±0.01 978 S 
R11       L     0.32±0.01 0.006±0.001 19 L 
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(ii) Substitution at P’2  
Hydrolysis of peptides R13 and R16 by TK demonstrates a preference of the enzyme S2 
subsite for arginine over serine (R2 and R15), leucine (R12), valine (R10) and proline 
(R7).  This subsite has no preference for phenylalanine at the S2 subsite, since peptide 
R14 was resistant to cleavage by TK (Table 3.2).   
Table 3.2:  The study of TK specificity at P2 of peptide substrates.  EDDnp, N- (2,4-dinitrophenyl)-
ethylenediamine; Abz, o-aminobenzoic acid (Chagas et al., 1995). 
Peptides P6 P5 P4 P3 P2 P1 P1 P2 P3 P4 P5 
Km 
(µM) 
kcat 
(s-1) 
kcat /Km 
(s-1. mM-1) (X) 
    Abz F R S X R Q EDDnp    P'2 
R2        S    1.50±0.40 1.60±0.20 1067 S 
R12        L    0.18±0.03 0.40±0.02 2222 L 
R13        R    0.12±0.02 1.18±0.08 9833 R 
R14        F    - - - F 
    Abz F R S X EDDnp      P'2 
R15        S    0.47±0.06 0.53±0.02 1128 S 
R7        P    1.40±0.20 0.22±0.01 157 P 
R10        V    0.90±0.10 0.88±0.01 978 V 
R16        R    0.04±0.01 1.01±0.07 25250 R 
 
(iii) Substitution at P’3, P’1, P1 and P2  
Peptides with leucine (R17), serine (R19) and phenylalanine (R18) at position P3 have 
lower susceptibility to TK (Table 3.3).  TK has a preference for arginine at the S1 subsite 
(R16) and for phenylalanine at the S1 subsite (F4) when proline is in P2.   
Table 3.3:  The study of TK specificity at P3, P1, P1 and P2 of peptide substrates.  EDDnp, N- (2,4-
dinitrophenyl)-ethylenediamine; pNA, paranitroanilide; Abz, o-aminobenzoic acid (Chagas et al., 1995). 
Peptides P6 P5 P4 P3 P2 P1 P1 P2 P3 P4 P5 
Km 
(µM) 
kcat 
(s-1) 
kcat /Km 
(s-1. mM-1) (X) 
    Abz F R S S X Q EDDnp    P'3 
R2         R   1.50±0.40 1.60±0.20 1067 R 
R17         L   1.10±0.20 0.61±0.04 554 L 
R18         F   3.0±0.20 0.69±0.02 230 F 
R19         S   2.20±0.92 1.50±0.03 681 S 
    Abz F X S R EDDnp      P1 
R16      R      0.04±0.01 1.01±0.07 25250 R 
F3      F      0.45±0.08 1.65±0.02 3667 F 
    (D) P F X pNA       P1 
R20       R     11±2 1.30±0.30 118 R 
F4       F     39±4 18.00±1.00 462 F 
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(b) Hydrolysis of fluorogenic peptides by human TK with human kininogen sequence 
flanking the scissile bond Met-Lys 
 
(i) Substitution at P1  
TK shows a preference for phenylalanine (F1 and F2) over methionine (M1  M13) in 
the S1 subsite (Table 3.4).   
(ii) Substitution at P’2  
TK has a preference for lysine (M8) over arginine (M7), serine (M9) and leucine (M10) 
at the S2 subsite.  TK shows no preference for phenylalanine (M11) and proline (M12) 
at this site.  The arginine guanidino group plays a role in the specificity of TK for 
arginine at the S2 subsite (compare M2 with M6).   
  Table 3.4:  The study of TK specificity at P1 and P2 of peptide substrates; Abz, o-aminobenzoic acid  
(Chagas et al., 1995).  L.R.C., low rate of cleavage; N.H., no hydrolysis observed 
Peptides P6 P5 P4 P3 P2 P1 P1 P2 P3 P4 P5 
Km 
(µM) 
kcat 
(s-1) 
kcat /Km 
(s-1. mM-1) 
(X) 
M1    Abz L M K R P   1.1±0.1 0.07±0.01 64  
M2 Abz M I S L M K R P   0.7±0.1 0.33±0.02 471  
F1    Abz L F K R P   0.9±0.1 2.0±0.1 2222  
F2 Abz M I S L F K R P   0.8±0.2 4.2±0.04 5250  
M3 Abz M I S L M K R P    L.R.C.   
A1 Abz M I S L A K R P    L.R.C.   
M4 Abz M I S L M R R P    L.R.C.   
M5 Abz M I S L M A R P    L.R.C.   
M6 Abz M I S L M K R (Tos) P    L.R.C.   
M7 Abz M I S L M K R P Q  2±1 0.33±0.01 165  
M8 Abz M I S L M K K P Q  0.9±0.1 1.42±0.08 1578  
M9 Abz M I S L M K S P Q  0.37±0.04 0.04±0.01 108  
M10 Abz M I S L M K L P Q  9±2 0.02±0.01 2  
M11 Abz M I S L M K F P Q   N.H.   
M12 Abz M I S L M K P P Q   N.H.   
M13 Abz M I S L M K R S S   L.R.C.   
 
(c) Cleavage of Arg-Xaa bonds 
The kinetic data for the hydrolysis of the Arg-Xaa bond in the series of peptides by 
human TK [Tables 3.1 and 3.2 (R2 - R16)] confirm the favourable interaction of 
arginine with TK subsites S'1 and S'2.  A similar preference of the S'3 subsite of human 
TK for arginine is also demonstrated by the high kcat/Km value for peptide R2, which has 
arginine at P'3 (Table 3.3).  The kcat/Km values for peptides R6 - R8 confirm the low 
susceptibility of arginine bonds with proline at P'2 to the kallidin-liberating TK         
. . . . . . .. . . 
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(Table 3.1).  This is in accordance with the resistance of the Lys-Arg bonds in 
kininogens to TK (Chagas et al., 1995). 
(d) Cleavage of the Met-Lys bond 
The resistance of the Lys-Arg bond and consequently the cleavage by TK of the Met-
Lys bond in kininogen, was suggested to be due to a poor S'2-Pro interaction based on 
kinetic data for the hydrolysis of synthetic peptides with valine or proline in the P'2 
position.  The non-specific cleavage of Lys-Arg and Met-Lys bonds in the M13 peptide 
and the resistance of M12 to hydrolysis by human TK confirm the importance of proline 
in P3 in orienting the cleavage of the kininogen Met-Lys bond (Table 3.4).  In addition, 
as observed for Arg-Xaa bond cleavage, the substitution of arginine at P'2 for 
hydrophobic or aromatic residues such as leucine or phenylalanine (M10 or M11, 
respectively) impairs the Met-Lys bond cleavage (Chagas et al., 1995). 
(e) Cleavage of the Phe-Lys bond 
The replacement of Met5 in M2 and Met2 in the shorter homologue M1 by phenylalanine 
resulted in interesting novel substrates with Phe-Lys as the only bond susceptible to TK 
(F1 and F2 in Table 3.4).  The kcat/Km values for the hydrolysis of these substrates are 
significantly higher than those for peptides M1 and M2 with Met-Lys as the susceptible 
bond.  The replacement of arginine in peptide R16 by phenylalanine in peptide F3 
resulted in lower kcat/Km values from the hydrolysis of F3 by TK (Table 3.3).  On the 
other hand, the replacement of arginine in R20 by phenylalanine in F4 resulted in a 
substrate with a kcat value one order of magnitude higher (Table 3.3).  The Phe-Xaa bond 
cleavage by TK has the same requirement for bulky and hydrophobic residues at P2 as 
that demonstrated for the Arg-Ser bond cleavage.  The results in tables 3.1 & 3.2 
indicate that the benzene ring of phenylalanine can fit very adequately into the S1 subsite 
of TK.  The surprising efficiency of TK in hydrolysing F4 (Table 3.3), the Phe-Lys bond 
in peptides F1 and F2 (Table 3.4) and the Phe-Ser bond in F3 (Table 3.3) leads to the 
speculation of the existence of natural substrates, other than kininogens, the specificity 
of which could be determined by a pair of bulky hydrophobic residues.  This possibility 
is well supported by the known structure of the P3-P'1 reactive centre (Lys-Phe-Phe-Ser) 
of kallistatin, where the Phe-Ser bond is hydrolysed (Chagas et al., 1995). 
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(f) Amidase activity 
The kinetic parameters in table 3.5 indicate that TK has a preference for hydrophobic 
residues in the S2 subsite and a preference for Phe at P2.  This preference is evident 
considering that Ac-Phe-Arg-pNA has a 6-fold larger kcat/Km value than for Ac-Leu-Arg-
pNA.  X-ray diffraction studies explain this specificity assuming that the Phe side chain 
is the most likely structure to fit properly to the wedge-shaped hydrophobic crevice 
formed between Trp215 and Tyr99 side chains at TK subsite S2.  A comparison of the 
specificity constant (kcat/Km) values shows that Tos-Phe-Arg-pNA is a better substrate 
than Bz-Phe-Arg-pNA and that TK has a preference of Tos over Bz in the P3 position.  
D-amino acid residues with free α-amino groups at the P3 position increase the catalytic 
rate of hydrolysis by TK.  Based on the results in table 3.5, it is evident that a better 
substrate for TK should be D-Val-Phe-Arg-pNA (Sousa et al., 1996). 
  Table 3.5:  Kinetic parameters for hydrolysis of Nα-substituted-L-arginine p-nitroanilides and Nα-
benzoyl-L-arginine ethyl ester by rat TK.  The reaction was carried out in 200 mM glycine/NaOH buffer, 
pH 9.0, at 37oC.  pNA, paranitroanilide;  Tos, p-toluenesulphonyl; Bz, benzoyl; Oet, ethyl ester (Sousa et 
al., 1996).   
 Substrate   [S] range Km kcat kcat/Km  
P3 P2 P1 P1 (µM) (µM) (s-1) (s-1.mM-1) 
 Tos Arg pNA 25 - 166 29±2 0.2±0 7 
 Bz Arg pNA 15 - 125 20±2 3±0 150 
Ac Leu Arg pNA 10 - 112 61±6 54±2 885 
Ac Phe Arg pNA 10 - 110 13±2 71±2 5461 
Bz Phe Arg pNA 15 - 120 40±3 27±1 675 
Tos Phe Arg pNA 20 - 115 44±4 129±4 2932 
D-Val Leu Arg pNA 20 - 120 24±2 526±14 21917 
 Bz Arg OEt 50 - 190 125±15 903±56 7224 
 
As shown in table 3.6 the substrate specificities of two rat glandular kallikrein forms 
(rK2 and rK9) are different.  Their overall specificity for P3 or P2' residues was analyzed. 
Unlike other members of the rat kallikrein family, rK2 and rK9 are able to accommodate 
aromatic residues in the P1 position.  Both proteinases accommodate negatively charged 
residues in the P2 position, but showed a preference for a prolyl residue at that position.  
Bulky and hydrophobic residues, which are preferentially accommodated in S2 by 
kallikrein rK1 (true TK) and several other members of the family, did not fit the rK2 and 
rK9 requirements for hydrolysis.  Both proteinases also showed a preference for 
hydrophobic residues in P2', which confirms the presence of an extended substrate 
binding site on these proteinases (Moreau et al., 1992).   
. . . . . . .. . . 
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Table 3.6:  Cleavage sites in various peptide and protein substrates hydrolysed by rat TK rK2 and rK9.  
PE lysozyme, pyridylethylated lysozyme (Moreau et al., 1992). 
 Substrate  rK2       rK9    
 P3 P2 P1 P1' P2' Residue no. P3 P2 P1 P1' P2' Residue no. 
PE lysozyme Phe Gly Arg PECys Glu 3 - 7 Met Lys Arg His Gly 12 - 16 
 Arg Gly Tyr Ser Leu 21 - 25 Asn Tyr Arg Gly Tyr 19 - 23 
 Asn Ser Arg Trp Trp 59 - 63 Thr Asn Arg Asn Thr 43 - 47 
       Asn Ser Arg Trp Trp 59 - 63 
       PECys Ala Lys Lys Ile 94 - 98 
       Arg Asn Arg PECys Lys 112 - 116 
       Trp Ile Arg Gly PECys 123 - 127 
Oxidized insulin B chain Val Asn Gln His Leu 2 - 6 Gly Glu Arg Gly Phe 20 - 24 
 Val Glu Ala Leu Tyr 12 - 16       
 Gly Glu Arg Gly Phe 20 - 24       
Rat Angiotensinogen His Pro Phe His Leu 6 - 10 His Pro Phe His Leu 6 - 10 
Renin substrate tetradecapeptide His Pro Phe His Leu 6 - 10 His Pro Phe His Leu 6 - 10 
Big-endothelin-1 (human) Val Pro Tyr Gly Leu 29 - 33 Val Pro Tyr Gly Leu 29 - 33 
Substance P Gln Gln Phe Phe Gly 5 - 9       
 Gln Phe Phe Gly Leu 6 - 10       
 
(g) Protein substrate cleavage 
Kallikreins in the rat consist of 13 family members, each with different substrate 
specificities.  Kallikreins rK2, rK7, rK9 and rK10 are strongly inhibited by SBTI, while 
rK1 and rK8 are not inhibited by SBTI.  Aprotinin inhibits all the rat kallikreins except 
rK9.  All the rat kallikreins are inhibited by α1-proteinase inhibitor, except rK1 (TK).  
Kallistatin irreversibly inhibits rK1.  This makes the task of identifying TK from extracts 
difficult.  In the ostrich the family tree of kallikreins has not been identified and most 
likely they too share similar properties to kallikreins of other species.  Protein substrates 
are appropriate tools for investigating the substrate specificity of kallikreins and possibly 
discriminating between the activities.  Both rK2 and rK9 accommodate a prolyl residue 
in the P2 position, whereas a bulky, hydrophobic residue is generally preferred by other 
kallikreins (Moreau et al., 1992).  Somatostatin is a regulatory peptide, found in the 
central nervous system, peripheral nerves and gastrointestinal and urogenital tracts.  It is 
synthesized as preprosomatostatin (116 amino acids), which is first converted into 
prosomatostatin (96 amino acids) and then processed to the active forms SS-28 and SS-
14.  SS-14 exerts inhibitory effects on a wide spectrum of physiological functions, such 
as gastrointestinal motility, gastric acid production, pancreatic enzyme secretion, insulin 
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and glucagon secretion and production of immunoglobulins.  SS-14 is degraded in the 
brain by endo-oligopeptidase 24.15 and metalloprotease 24.11 at the Phe6-Phe7, Thr10-
Phe11 and Asn5-Phe6 bonds, as well as by endo-oligopeptidase 24.16, which digests it at 
two sites, Phe6-Phe7 and Thr10-Phe11.  TK has been shown to hydrolyse the reactive 
centre loop of human kallikrein binding protein (kallistatin) after the Phe-Phe pair at the 
Phe-Ser bond.  SS-14 is susceptible to hydrolysis by TK and their tissue co-distribution 
in mammals, mainly in the hypothalamus, pancreas and kidney, suggest a physiological 
role for TK in the metabolism of SS-14 (Pimenta et al., 1997). 
(h) Inhibition characteristics 
Under normal conditions the KKS is well regulated by inhibitors that limit the 
concentrations of the active components.  True TK is not inhibited by soybean trypsin 
inhibitor (SBTI).  Aprotinin (Trasylol, basic pancreatic trypsin inhibitor [BPTI]) found 
in high concentration in the lung and pancreas, does inhibit TK strongly.  Plasma α1-
antitrypsin (α-1-proteinase inhibitor) does not inhibit urinary TK, but inhibits the rest of 
the TK-family members.  Kallikrein binding protein inhibits human TK and is expressed 
in high levels in the liver and at low levels in the lung, salivary gland and kidney (Katori 
& Majima., 1996).  This inhibitor binds specifically to the active TK but not to the 
inactive or active site-blocked forms.  Additionally, it binds to elastase and 
chymotrypsin but not to PK, urokinase, or collagenase (Bhoola et al., 1992).  Protein C 
inhibitor, present in plasma and urine, is a relatively non-specific heparin-dependent 
serine proteinase inhibitor that inhibits a variety of proteases, including TK (Ecke et al., 
1992).  Benzamidine also strongly inhibits true TK.  Peptide analogues resembling the 
amino acid sequence on the carboxyl terminus of the kinin moiety within the kininogen 
molecule appear to be effective inhibitors for the active site of the kallikrein molecule.  
The most potent of these is Ac-Ser-Pro-Phe-Arg-Ser-Val-Gln-NH2 (Bhoola et al., 1989).  
An important functional site in serine protease inhibitors (serpins), the reactive centre, is 
the site of cleavage by the serine protease.  The amino acids which form the peptide 
bond cleaved by the protease are designated the P1 and P'1 amino acids of the reactive 
centre and are important determinants of the specificity of the inhibitor (table 3.7).  The 
difference in the reactive centre of protease inhibitors has been reported and the 
indication is that the divergence extends within given species (Yoon et al., 1987).  The 
differences in the sequences of the reactive loops in serpin family members indicate that 
. . . . . . .. . . 
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it should be possible to develop specific substrates for the individual serpin proteinases 
(Bourgeois et al., 1997).   
Table 3.7:  The amino acid sequence in the region of the reactive centre of serine proteinase inhibitors.  
Bovine pancreatic trypsin inhibitor (BPTI), α1-PI Pittsburgh, soybean and lima bean trypsin inhibitor, α1-
antichymotrypsin (HUMA1ACM), contrapsin (MUSCNT), mouse α1-proteinase inhibitor (MUSA1PI), 
α2-antiplasmin (A2-AP), rat kallikrein binding protein (RKBP), plasminogen activator inhibitor (PAI) and 
human α1-antitrypsin (HUMA1ATM) are compared to the presumptive reactive centre region of Spi-1 
and Spi-2  (Yoon et al., 1987; Bourgeois et al., 1997; Chao et al., 1990). 
Protein P5 P4 P3 P2 P1 P1 P2 P3 P4 P5 
Spi-2 Thr Ala Ala Leu Lys Ser Leu Pro Gln Thr 
Spi-1 Ala Thr Val Ile Arg Arg Gln Pro Arg Thr 
MUSCNT Ile Gly Gly Ile Arg Lys Ala Ile Leu Pro 
MUSA1PI Leu Ala Val Pro Tyr Ser Met Pro Pro Ile 
HUMA1ACM Lys Ile Thr Leu Leu Ser Ala Leu Val Glu 
HUMA1ATM Glu Ale Ile Pro Met Ser Ile Pro Pro Glu 
HUMATIII Val Ile Ala Gly Arg Ser Leu Asn Pro Asn 
A1-PI Pittsburgh Glu Ala Ile Pro Arg Ser Ile Pro Pro Glu 
BPTI Thr Gly Pro Cys Lys Ala Arg Ile Ile Arg 
A2-AP Ala Met Ser Arg Met Ser Leu Ser Ser Phe 
Antitrypsin-rat Glu Ala Val Pro Met Ser Leu Pro Pro Gln 
Mouse KBP Val Asn Phe Arg Ile Leu Ser Arg Arg Thr 
RKBP Val Thr Ala Ala Leu Lys Ser Leu Pro Gln 
Rat kallistatin Phe Ala Thr Phe Phe Ser Ala Gln Pro - 
Human kallistatin Ala Ile Lys Phe Phe Ser Ala Gln Thr - 
Heparin cofactor II Gly Phe Met Pro Leu Ser Thr Gln Val Arg 
C1-inhibitor Ile Ser Val Ala Arg Thr Leu Leu Val - 
Endothelia PAI Ile Val Ser Ala Arg Met Ala Pro Glu Glu 
Bowman-Birk Inhibitor  Arg Cys Thr Lys Ser Asn Pro Pro Gln 
Pancreatic TI  Gly Pro Cys Lys Ala Arg Ile Ile Arg 
Subtilisin Inhibitor  Met Cys Pro Met Val Tyr Asp Pro Val 
SBTI  Pro Ser Tyr Arg Ile Arg Phe Ile Arg 
LBTI     Lys Ser Ile Pro Pro Gln 
 
(i) PCI-derived peptide substrates of kallikreins 
PCI-derived peptides (Abz-FRSARQ-EDDnp, Abz-TFRSARQ-EDDnp, Abz-
FTFRSARQ-EDDnp) were hydrolyzed by two forms of human TK (hK1 and hK2), but 
both cleaved the substrates at the expected    R-S bond (Bourgeois et al., 1997).   
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(j) Other serpin derived substrates 
The reactive loop of kallistatin is cleaved after the FF pair, an unexpected feature (Table 
3.7).  The TK substrates [(D) PFR-AMC and (D) PFF-AMC] were assayed with hK1 
and hK2, but only (D) PFR-AMC was cleaved by both enzymes.  It was found that hK1 
rapidly cleaves the substrate Abz-AIKFFSAQ-EDDnp at the expected site (FF-S), but 
was resistant to hydrolysis by hK2.   This implies that kallistatin may not inhibit hK2.  
Modification of the kallistatin-derived substrate to Abz-AIKFFSRQ-EDDnp, replacing 
the P'2 Ala with Arg, greatly improved the hydrolysis by hK1.  Modification of the PCI-
derived substrate Abz-TFRSARQ-EDDnp to Abz-TFFSARQ-EDDnp decreased the TK 
activity to the substrate, but this substrate was now completely resistant to hK2 and can 
be used to discriminate between the enzymes. This principle can be used to distinguish 
between TK-like enzymes (Bourgeois et al., 1997). 
1.4.4 Primary structures of TK and PK 
The protein sequences of rat, human and mouse TK and PK were aligned using 
ClustalW and shown in figures 3.1 and 3.2, respectively.  The N-terminal and C-terminal 
sequences of both kallikreins are fairly conserved between species.  This would allow 
one to design directional primers that can be used to amplify the genes of the kallikreins 
from RNA or DNA extracts.  The cysteine moiety is also conserved between species.    
1       10         20         30         40         50         60 
MWFLILFLAL SLGRNDAAPP VQSRVVGGYN CEMNWQVAVY YFGEYLCGGV LIDPSWVITA 
MWFLVLCLAL SLGGTGAAPP IQSRIVGGWE CEQHWQAALY HFSTFQCGGI LVHRQWVLTA 
MRFLILFLAL SLGGIDAAPP VQSRIVGGFN CEKNWQVAVY RFTKYQCGGI LLNVNWVLTA 
*:**:*:*** ***:.::*** :***:***.: *:..**:*:* .*..::***: *:...**:** 
        70         80         90        100        110        120 
AHCATDNYQV WLGRNNLYED EPFAQHRLVS QSFPHPGFNQ DLIWNHTRQP GDDYSNDLML 
AHCISDNYQL WLGRHNLFDD ENTAQFVHVS ESFPHPGFNM SLLENHTRQA DEDYSHDLML 
AHCHNDKYQV WLGKNNFLED EPSAQHRLVS KAIPHPDFNM SLLNEHTPQP EDDYSNDLML 
***..*:**: ****:*:.:* *..**:::** .::***:**: :*: :**:*: .::::::::* 
       130        140        150        160        170        180 
ITDGVKVIDL PIEEPKVGST CLASGWGSIT PDGLELSDDL QCVNIDLLSN EEAHKEEVTD 
ITDAVKVVEL PTQEPEVGST CLASGWGSIE PENFSFPDDL QCVDLKILPN DKAHVQKVTD 
ITDVVKPIDL PTEEPKLGST CLASGWGSIT PVKYEYPDEL QCVNLKLLPN EKAHIEKVTD 
***.*::::* *::**::*** *********: *...:.:*:* ***::.:*:* ::** ::**: 
       190        200        210        220    226 
LMLCAGEMDG GKDTCKGDSG GPLICNGVLQ GITSWGFNPC GEPKKP 
FMLCVGHLEG GKDTCVGDSG GPLMCDGVLQ GVTSWGYVPC GTPNKP 
DMLCAGDMDG GKDTCAGDSG GPLICDGVLQ GITSWGPSPC GKPNVP 
.***:*.::* *****.**** ***.*.**** *:****. ** * *::* 
Figure 3.1:  Alignment of rat-, human-, and mouse tissue kallikreins respectively.  The consensus of the 
alignment is shown below the multiple alignment of the sequences: (*) consensus across the species 
aligned, (:) consensus only varies between two amino acids across the species aligned, (.) consensus varies 
between three amino acids across the species aligned.  The cysteine residues are boxed.  The sequences for 
rat, human and mouse TK were taken from Fahnestock (1994), Chen et al. (1995) and Hosoi et al. (1998), 
respectively.   
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        10         20         30         40         50         60 
MILFKQATYF ISLFATVSCG CLTQLYENAF FRGGDVASMY TPNAQYCQMR CTFHPRCLLF  
MILFNRVGYF VSLFATVSCG CMTQLYKNTF FRGGDLAAIY TPDAQYCQKM CTFHPRCLLF  
MILFKQVGYF VSLFATVSCG CLSQLYANTF FRGGDLAAIY TPDAQHCQKM CTFHPRCLLF 
****::::** :********* *::***.*:* *****:*::* **:**:**:: ********** 
        70         80         90        100        110        120 
SFLPASSIND MEKRFGCFLK DSVTGTLPKV HRTGAVSGHS LKQCGHQISA CHRDIYKGVD  
SFLAVTPPKE TNKRFGCFMK ESITGTLPRI HRTGAISGHS LKQCGHQISA CHRDIYKGLD  
SFLAVSPTKE TDKRFGCFMK ESITGTLPRI HRTGAISGHS LKQCGHQLSA CHQDIYEGLD 
***::::.:: :.******:* :*:*****:: *****:**** *******:** **:***:*:* 
       130        140        150        160        170        180 
MRGVNFNVSK VSSVEECQKR CTNNIRCQFF SYATQTFHKA EYRNNCLLKY SPGGTPTAIK  
MRGSNFNISK TDNIEECQKL CTNNFHCQFF TYATSAFYRP EYRKKCLLKH SASGTPTSIK  
MRGSNFNISK TDSIEECQKL CTNNIHCQFF TYATKAFHRP EYRKSCLLKR SSSGTPTSIK 
***:***:** ::::*****: ****::**** :***.:*::: ***:.****. *.:****:** 
       190        200        210        220        230        240 
VLSNVESGFS LKPCALSEIG CHMNIFQHLA FSDVDVARVL TPDAFVCRTI CTYHPNCLFF  
SADNLVSGFS LKSCALSEIG CPMDIFQHSA FADLNVSQVI TPDAFVCRTI CTFHPNCLFF  
PVDNLVSGFS LKSCALSEIG CPMDIFQHFA FADLNVSQVV TPDAFVCRTV CTFHPNCLFF 
..:*::**** **:******* *:*:****.* *:*::*::*. *********: **:******* 
       250        260        270        280        290        300 
TFYTNVWKIE SQRNVCLLKT SESGTPSSST PQENTISGYS LLTCKRTLPE PCHSKIYPGV  
TFYTNEWETE SQRNVCFLKT SKSGRPSPPI PQENAISGYS LLTCRKTRPE PCHSKIYSGV  
TFYTNEWETE SQRNVCFLKT SKSGRPSPPI IQENAVSGYS LFTCRKARPE PCHFKIYSGV 
*****:*::* ******:*** *:**:**::: :***::**** *:**::::** ***:***:** 
       310        320        330        340        350        360 
DFGGEELNVT FVKGVNVCQE TCTKMIRCQF FTYSLLPEDC KEEKCKCFLR LSMDGSPTRI  
DFEGEELNVT FVQGADVCQE TCTKTIRCQF FIYSLLPQDC KEEGCKCSLR LSTDGSPTRI  
AFEGEELNAT FVQGADACQE TCTKTIRCQF FTYSLLPQDC KAEGCKCSLR LSTDGSPTRI 
:*:*****:* **:*:::*** ****:***** *:*****:** *:*:***:** **:******* 
       370        380        390        400        410        420 
AYGTQGSSGY SLRLCNTGDN SVCTTKTSTR IVGGTNSSWG EWPWQVSLQV KLTAQRHLCG  
TYGMQGSSGY SLRLCKLVDS PDCTTKINAR IVGGTNASLG EWPWQVSLQV KLVSQTHLCG  
TYEAQGSSGY SLRLCKVVES SDCTTKINAR IVGGTNSSLG EWPWQVSLQV KLVSQNHMCG 
:*:.****** *****:.::: ::****:::* ******:*:* ********** **::*.*:** 
       430        440        450        460        470        480 
GSLIGHQWVL TAAHCFDGLP LQDVWRIYSG ILNLSDITKD TPFSQIKEII IHQNYKVSEG  
GSIIGRQWVL TAAHCFDGIP YPDVWRIYGG ILSLSEITKE TPSSRIKELI IHQEYKVSEG  
GSIIGRQWIL TAAHCFDGIP YPDVWRIYGG ILNLSEITNK TPFSSIKELI IHQKYKMSEG 
**:**:**:* ********:* ::******:* **:**:**:. **:*.***:* ***.**:*** 
       490        500        510        520        530        540 
NHDIALIKLQ APLNYTEFQK PICLPSKGDT STIYTNCWVT GWGFSKEKGE IQNILQKVNI  
NYDIALIKLQ TPLNYTEFQK PICLPSKADT NTIYTNCWVT GWGYTKEQGE TQNILQKATI  
SYDIALIKLQ TPLNYTEFQK PICLPSKADT NTIYTNCWVT GWGYTKERGE TQNILQKATI 
::******** :********* *******:** :********* ***::**.** :******::* 
       550        560        570        580        590        600 
PLVTNEECQK RYQDYKITQR MVCAGYKEGG KDACKGDSGG PLVCKHNGMW RLVGITSWGE  
PLVPNEECQK KYRDYVINKQ MICAGYKEGG TDACKGDSGG PLVCKHSGRW QLVGITSWGE  
PLVPNEECQK KYRDYVITKQ MICAGYKEGG IDACKGDSGG PLVCKHSGRW QLVGITSWGE 
***:****** :*:**:*::: *:******** .********* ******:*:* :********* 
       610        620        630      638 
GCARREQPGV YTKVAEYMDW ILEKTQSSDG KAQMQSPA  
GCGRKDQPGV YTKVSEYMDW ILEKTQSSDV RALETSSA  
GCARKEQPGV YTKVAEYIDW ILEKIQSSKE RALETSPA 
         **:*::**** ****:**:** ****:***:. :*:::*:* 
Figure 3.2:  Alignment of human-, mouse-, and rat plasma kallikreins respectively.  The consensus of the alignment is 
shown below the multiple alignment of the sequences: (*) consensus across the species aligned, (:) consensus only 
varies between two amino acids across the species aligned, (.) consensus varies between three amino acids across the 
species aligned.  The cysteine residues are boxed.  The sequences for human, rat and mouse PK were taken from 
Chung et al. (1986), Seidah et al. (1989) and Beaubien et al. (1991), respectively.   
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1.5. Materials and methods 
 
1.5.1 Reagents 
High molecular range and low molecular range SDS-PAGE markers; N-[2-
hydroxyethyl]piperazine-N-[2-ethanesulfonic acid] (HEPES); 7-amino-4-trifluoro-
methylcoumarin (AFC); 7-amino-4-methylcoumarine (AMC); DL-Val-Leu-Arg-
AFC.2HCl; Pro-Phe-Arg-AMC; Phe-Arg-AMC; porcine pancreatic TK (EC 3.4.21.35); 
SBTI; Aprotinin; and LBTI were purchased from Sigma.  LBTI-Sepharose-4B and 
Aprotinin-Sepharose-4B affinity resins were prepared according to the method of 
Kobayashi (1992).  DEAE Toyopearl ion-exchange resin was purchased from 
Pharmacia.   
1.5.2 Methods 
(a) Sample collection and processing 
(i) Plasma 
Ostrich plasma was collected intravenously into vacuated siliconised glass tubes 
containing trisodium citrate.  The samples were collected by hand and centrifuged within 
30 minutes from collection at 3000g for 30 minutes at 22oC.  Pooled plasma was stored 
at 80oC in 50 ml aliquots, thawed at 25oC and left at room temperature before being 
used for isolation or assays.   
(ii) Urine 
Ostrich urine was collected upon sacrifice by opening of the abdomen and cutting the 
bladder.  Urine was collected with a funnel, through cheesecloth into a plastic container 
containing 2 mM EDTA and 0.02 % NaN3.  The collected urine was separated into 
aliquots and transported in plastic bags on ice.  At the laboratory the urine was stored at 
20oC until being thawed at 25oC and centrifuged at 11,000 g for 10 minutes at 4oC.  
The supernatant was dialysed against deionised water and freeze-dried to a powder that 
was stored at 20oC.   
(iii) Tissue 
At the abbatoir ostrich tissue from the heart, liver, kidneys, adrenal glands, pancreas, 
spinal cord, brain, pituitary glands and lungs were freed from blood and connective 
. . . . . . .. . . 
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tissue, cut into 5 cm cubes and frozen in liquid nitrogen without delay.  The time from 
animal sacrifice till freezing was less than 15 minutes.  The frozen tissue was powdered 
with a Waring blendor in the presence of liquid nitrogen.  The powdered tissue was 
stored at 20oC until extraction could be done.   
(b) Extraction of kallikrein 
To 6 g of powdered tissue was added 60 ml extraction buffer.  The extraction buffer 
consisted of 0.1 M HEPES at pH 7.0, containing 0.15 M NaCl, 0.05 % Triton X-100, 2 
mM ZnCl2, 2 mM CaCl2 and 0.02 % NaN3.  The mixture was homogenised for 5 
seconds at low rpm on ice with a Janke and Kunkel D7813 170 W Ultra turrax.  The 
extraction was continued with a Teflon glass homogeniser (three strokes) and left on ice 
for 20 minutes.  The extract was centrifuged at 4oC for 10 minutes at 11,000 g and the 
supernatant was filtered at 4oC through Whatmann filter paper to remove fat.  The 
extract was then stored at 20oC.   
(c) Enzymatic assays with fluorogenic substrates 
Total kallikrein-like activity in the fluids, tissue and glandular extracts were assayed 
using DL-Val-Leu-Arg-AFC (Chan et al., 1993), Pro-Phe-Arg-AMC and Phe-Arg-AMC 
as substrates.  From previous assays done on extracts using DL-Val-Leu-Arg-AFC as 
substrate, it was found that the concentration of kallikrein in ostrich extracts was very 
low or non-detectable.  Assays performed with colorimetric substrates (e.g. Val-Leu-
Arg-pNA) gave no positive KLK activity; indicating very low levels of KLK in ostrich 
tissue.  Therefore it was decided to assay for kallikrein activity using Phe-Arg-AMC, 
since TK has a 6-fold higher preference for Phe-Arg-AMC than for Leu-Arg-AMC 
(Sousa et al., 1996).  TK activity was determined by means of the Phe-Arg-AMC 
substrate in the presence of LBTI (Chan et al., 1993).  Tonin activity was determined by 
means of the Phe-Arg-AMC substrate in the presence of aprotinin (Chan et al., 1993).     
PK-like activity was calculated from the difference between the total kallikrein-like 
activity and the TK activity.  Pro-Phe-Arg-AMC is the preferred substrate for PK 
according to literature.  By screening each extract with these substrates we wanted to 
determine which organs to use as a source of TK or PK.   
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(i) Assay conditions 
The assay was optimized on a RF-1501 Shimadzu Spectrofluorimeter set at the desired 
excitation and emission wavelengths for each substrate/product.  Most of the assays in 
literature use a stop reaction to determine kallikrein activity.  The reaction mixture is 
incubated at 37oC and stopped after 30 minutes with either an acid (acetic acid) or a base 
(NaOH).  In this laboratory we found that the stop reagents used (TCA, acetic acid, HCl, 
NaOH) contributed to quenching of fluorescence.  Therefore we decided to optimize the 
assay under continuous conditions at 22oC.   
The assay buffer consisted of 0.2 M Tris-HCl at pH 8.2 containing 0.1 mM EDTA, 0.1 
% PEG 6000 and 0.02 % NaN3.  The substrates were dissolved in DMSO at stock 
concentrations of 10 mM (0.1 mM final in assay) and stored in aliquots at 20oC.  The 
inhibitors were prepared on the day of the assay: LBTI (to measure TK activity) was 
dissolved in assay buffer at a 5 mg/ml stock (0.1 mg/ml in assay) concentration and 
aprotinin (to measure tonin activity) was dissolved at a 2 mg/ml stock (0.04 mg/ml in 
assay) concentration and stored on ice.  The assay mixture consisted of 10 µl sample, 10 
µl inhibitor, 5 µl substrate made up with assay buffer to a total volume of 500 µl.  The 
sample was pre-incubated with or without inhibitor in assay buffer at 22oC for 20 
minutes.  The assay was started by the addition of the substrate and the progress was 
followed for the initial 3 minutes at 22oC from which the fluorescence produced per 
minute was determined.  The fluorescence per minute produced by the sample was then 
converted to product formed per minute from the standard curves of fluorescence as a 
function of product concentration (figure 3.3).  Standard curves of product produced as a 
function of [TK] were measured to determine the amount of TK-like activity produced 
per sample assayed with different substrates (figures 3.4 to 3.6).   
. . . . . . .. . . 
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Figure 3.3:  Calibration curves relating fluorescence to the concentration of AFC (A) and AMC (B) in the 
assay buffer system.  A: AFC was dissolved in DMSO and serially diluted with DMSO.  To 10 µl of the 
AFC dilution was added assay buffer to a final volume of 500 µl and the fluorescence was read at 405 nm 
excitation and 500 nm emission.  B: AMC was dissolved in DMSO and serially diluted with DMSO.  To 
10 µl of the AMC dilution was added assay buffer to a final volume of 500 µl and the fluorescence was 
read at 380 nm excitation and 460 nm emission.   
 
   
0 0.5 1 1.5 2 2.5 3 3.5
[TK] (nM)
0
20
40
60
80
100
120
dF
I/m
in
.
0 0.5 1 1.5 2 2.5 3 3.5
[TK] (nM)
0
10
20
30
40
d[
A
FC
]/m
in
. (
nM
)
 
Figure 3.4:  Calibration curves relating fluorescence produced per minute (A) and concentration of AFC 
produced per minute (B) to TK concentration in an assay system using DL-Val-Leu-Arg-AFC as substrate.  
A:  DL-Val-Leu-Arg-AFC was dissolved in 100% DMSO to a concentration of 10 mM.  Commercial 
pancreatic tissue kallikrein was dissolved in assay buffer and serially diluted.  To 10 µl of the TK dilution 
was added 5 µl substrate and assay buffer to a final volume of 500 µl and the fluorescence was read at 405 
nm excitation and 500 nm emission.  A standard curve of fluorescence produced per minute versus 
concentration of TK (nM) was set up from which fluorescence produced can be related to product 
concentration (B).   
 
A B 
A B 
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Figure 3.5:  Calibration curves relating fluorescence produced per minute (A) and concentration of AMC 
produced per minute (B) to TK concentration in an assay system using Pro-Phe-Arg-AMC as substrate.  
A:  Pro-Phe-Arg-AMC was dissolved in DMSO to a concentration of 10 mM.  Commercial pancreatic 
tissue kallikrein was dissolved in assay buffer and serially diluted.  To 10 µl of the TK dilution was added 
5 µl substrate and assay buffer to a final volume of 500 µl and the fluorescence was read at 380 nm 
excitation and 460 nm emission.  A standard curve of fluorescence produced per minute versus 
concentration of TK (pM) was set up from which fluorescence produced can be related to product 
concentration (B).   
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Figure 3.6:  Calibration curves relating fluorescence produced per minute (A) and concentration of AMC 
produced per minute (B) to TK concentration in an assay system using Phe-Arg-AMC as substrate.  A:  
Phe-Arg-AMC was dissolved in DMSO to a concentration of 10 mM.  Commercial pancreatic tissue 
kallikrein was dissolved in assay buffer and serially diluted.  To 10 µl of the TK dilution was added 5 µl 
substrate and assay buffer to a final volume of 500 µl and the fluorescence was read at 380 nm excitation 
and 460 nm emission.  A standard curve of fluorescence produced per minute versus concentration of TK 
(nM) was set up from which fluorescence produced can be related to product concentration (B).   
 
(ii) Activation of pro-kallikrein 
Plasma used in the kallikrein assay was activated by the addition of Zn2+ and Ca2+ in a 
glass container (providing negative surface for activation of PK).  The tissue/organ 
homogenates contained Zn2+ and Ca2+ in the extraction buffer (pH 7.0), which initiated 
the activation of kallikreins by proteolytic enzymes present in the extract.  Urine 
prokallikrein was activated by the addition of 50-µl porcine pancreatic trypsin (type 
XIII, 10 µg/ml) at a ratio of 1:1 (v/v) to the dissolved powdered urine.  The activation 
A B 
A B 
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mixture was left at room temperature for 20 minutes.  Activation was stopped by the 
addition of LBTI (125 µg/ml, final) to the activation mixture.  The activation mixture 
was incubated at room temperature for 30 minutes to ensure that trypsin activity was 
eliminated.  TK activity was measured as described in section 3.2.2.(c).i.  The activation 
assay for urine measures activated TK and was not optimized for the detection of 
activated PK.  For the isolation of the pro-enzyme, powdered urine was not activated 
before isolation.   
(d) Protein determination 
Samples were assayed for protein content using the bicinchoninic acid microtitre plate 
assay with BSA as standard (Stoscheck 1990).   
(e) SDS-PAGE 
SDS-PAGE was performed on 9, 10, or 12 % acrylamide gels according to the method 
of Laemmli (1970) in a Bio-Rad Mini Protean II system.  Non-reduced samples were run 
on 9 or 10 % gels and reduced samples on 12 % gels.  The following standards were 
used (Mr values in parenthesis): rabbit muscle myosin (205kD), E. coli β-galactosidase 
(116kD), rabbit muscle phosphorylase b (97kD), rabbit muscle fructose-6-phosphate 
kinase (84kD), bovine serum albumin (66kD), bovine liver glutamic dehydrogenase 
(55kD), chicken egg ovalbumin (45kD), rabbit muscle glyceraldehyde-3-phosphate 
dehydrogenase (36kD), bovine erythrocyte carbonic anhydrase (29kD), bovine pancreas 
trypsinogen (24kD), soybean trypsin inhibitor (20kD), bovine milk α-lactalbumin 
(14.2kD) and bovine lung aprotinin (6.5kD).  The gels were stained with 0.1 % 
Coomassie Blue R-250 in water/methanol/acetic acid (5:4:1).  The gels were destained 
with water/methanol/acetic acid (6:4:2).   
(f) Isolation of urinary kallikrein 
A pilot attempt at the isolation of kallikrein was performed with ostrich urine.  Urinary 
kallikrein is used as a marker of blood pressure sensitivity to salt (Madeddu et al., 1996).  
Urine is a relatively simpler source of kallikrein compared to tissue/organ extracts and 
therefore the purification of kallikrein from urine was expected to be more expedient.   
The presence of kallikrein could not be detected in unprocessed ostrich urine.  
According to the majority of literature urinary kallikrein exists in the pro-form and for 
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this reason it was decided to isolate active PK from urine by using LBTI-Sepharose-4B 
affinity chromatography.  Active urinary TK is then separated from PK and can be 
isolated from urine by using Aprotinin-Sepharose-4B affinity chromatography.  The pro-
forms of each enzyme can be isolated from urine by using DEAE Toyopearl ion-
exchange chromatography in case they do not bind to the affinity resins.   
Seven liters of ostrich urine was freeze-dried to 1.3995 g of powder as described in the 
sample collection procedure [see 3.2.2.(a).ii].  100 ml 0.05 M Tris-HCl at pH 8.0 
containing 0.05 M NaCl, 2 mM EDTA, 0.1 % Brij 35 and 0.02 % NaN3 was used to 
dissolve the powdered urine.  LBTI-Sepharose-4B affinity resin (25 ml), Aprotinin-
Sepharose-4B affinity resin (30 ml) and DEAE Toyopearl ion-exchange resin (250 ml) 
were washed, activated and equilibrated in 0.05 M Tris-HCl at pH 8.0 containing 0.05 M 
NaCl,    2 mM EDTA, 0.1 % Brij 35 and 0.02 % NaN3.  The dissolved urine was then 
loaded onto the LBTI, Aprotinin and DEAE Toyopearl columns connected in series at 
0.5 ml/min at 4oC.  The columns were washed with equilibration buffer until baseline 
was reached (A280nm).  The elution of the affinity resins was done with pH step gradient 
buffers;  
Buffer 1, 0.05 M sodium citrate at pH 5.5 containing 0.5 M NaCl, 2 mM EDTA, 0.1 % 
Brij 35 and 0.02 % NaN3;  
Buffer 2, 0.1 M sodium acetate at pH 4.8 containing 1 M NaCl, 2 mM EDTA, 0.1 % Brij 
35 and 0.02 % NaN3;  
Buffer 3, 0.05 M sodium citrate at pH 2.1 containing 1 M NaCl, 2 mM EDTA, 0.1 % 
Brij 35 and 0.02 % NaN3.   
Buffer 4, 0.05 M Tris-HCl at pH 8.0 containing 2 M NaCl, 2 mM EDTA, 0.1 % Brij 35 
and 0.02 % NaN3 
The elution of the ion-exchange resin was done with buffer 4.   
. . . . . . .. . . 
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1.6. Results 
 
1.6.1 Ostrich kallikrein-like activity determination 
 
Kallikrein-like activity in ostrich plasma was compared to human plasma using Phe-
Arg-AMC, Pro-Phe-Arg-AMC and Val-Leu-Arg-AFC (Table 3.8).  The activities are 
expressed in nM KLK detected per gram protein used in the assay system [see 
3.2.2.(c).i].  In table 3.8 it can be seen that once ostrich plasma is activated a higher 
amount of active TK is detected with the TK-like substrate Val-Leu-Arg-AFC.   
 
Table 3.8:  Comparison of total kallikrein-like specific activity in Ostrich and Human plasma detected by 
using Phe-Arg-AMC, Pro-Phe-Arg-AMC and Val-Leu-Arg-AFC as substrates.   Values are the mean of 3 
experiments.  Act., activated plasma.   
 nM KLK/g nM KLK/g nM KLK/g 
Organs Phe-Arg-AMC Pro-Phe-Arg-AMC Val-Leu-Arg-AFC 
Human Plasma 50.9 2.2 5.3 
Ostrich Plasma 59.8 0.4 28.1 
Ostrich Plasma (act.) 62.1 0.3 376.1 
 
 
Kallikrein-like, TK-like, PK-like and tonin-like activities in human plasma were also 
determined.  Plasma shows, as expected, a higher amount of PK present (figure 3.7).   
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Figure 3.7:  Comparison of total kallikrein-like (KLK-like, uninhibited), TK-like, PK-like and tonin-like 
specific activities in human plasma using Pro-Phe-Arg-AMC as substrate.   
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Kallikrein-like activity in ostrich organs/tissues/fluids were also determined using Phe-
Arg-AMC, Pro-Phe-Arg-AMC and Val-Leu-Arg-AFC (Table 3.9).   
 
Table 3.9:  Comparison of total kallikrein-like specific activity (uninhibited) of different 
tissues/organs/fluids in the Ostrich; it must be taken into account that the assays were done on crude 
extracts; no activity detected therefore means that we were not able to detect any activity under these 
conditions it does not mean that there is no activity at all in the source.   
Source nM KLK/g nM KLK/g nM KLK/g 
 Phe-Arg-AMC Pro-Phe-Arg-AMC Val-Leu-Arg-AFC 
Plasma 60 0.4 28 
Heart 200 0 0 
Liver 72 22 0 
Adrenals 8235 2 0.7 
Brain 792 4 0 
Lung 230 0.4 0 
Kidney 7106 12 0 
Anterior Pituitary 189 1 0 
Posterior Pituitary 305 0.2 0 
Spinal cord 48 0.8 0 
Pancreas 1008 2 23 
Urine 0 0 0 
 
The preferred amino acids, for each subsite of kallikreins, are depicted in figure 3.8.  
Pro-Phe-Arg-AMC is the preferred substrate for PK and is used in commercial Sigma 
kits to detect PK.  The substrate is normally used in a buffer system without any 
inhibitors present, however we included LBTI and aprotinin as inhibitors to determine 
TK and tonin activity on this substrate, respectively.  Pro-Phe-Arg is also the C-terminal 
sequence of mammalian BK and this sequence is not cleaved by TK.  It has been shown 
that Val-Leu-Arg-AFC is susceptible to TK but not to PK (Chan et al., 1993) and we 
therefore used this substrate for TK-like activity.  From the results in table 3.9 the 
indication is that plasma and the pancreas are the best sources for the isolation of TK 
since they showed more TK activity per gram protein using Val-Leu-Arg-AFC as 
substrate.  The liver and kidney were determined to be the best sources of PK since they 
show more activity per gram protein using Pro-Phe-Arg-AMC as substrate.  Phe-Arg-
AMC is a substrate susceptible to kallikreins and tryptic proteases; explaining why the 
activity towards this substrate was so high (Table 3.9).  Since Phe-Arg-AMC produced 
. . . . . . .. . . 
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significant activity we used this substrate in the presence of LBTI and aprotinin to 
determine TK- and tonin-like activity, respectively.  However, activities were always 
confirmed with the Pro-Phe-Arg-AMC substrate in the presence of these inhibitors.   
S3 S2 S1 S'1 S'2 S'3
Kallikrein Subsites
Substrate
Inhibitor
P3 P2 P1 P'1 P'2 P'3
Met Lys
Arg Ser
Arg Pro
PhePro
Arg
Pro
Arg
Met Lys
Ser Pro
Pro
ProVal Leu
Ile
Leu
Ala
LeuSer
non-polar
aromatic
HKG
hydrophobic
Pro Gly Phe
Ser
HKG
SBTI ---- Ser --------- Tyr --------- Arg ----------- Ile ---------- Arg ---------- Phe ---------- SBTI
LBTI --------- Lys ----------- Ser ---------- Ile ----------- Pro ----------- LBTI
Prefered amino acids
His
Val
Asn
Ile
Glu
Asn
Pro
Ala
Leu
Arg
Phe
Tyr
Lys
Gly
His
Trp
Leu
Trp
Tyr
aromatic
charged uncharged
 
Figure 3.8:  A general representation of kallikrein specificity towards natural substrates and inhibitors.  
Data from tables 3.1 to 3.7 were used to determine the preferred amino acids for each subsite.  PK has a 
capacity to accommodate a Pro residue at its S2 subsite.  This feature is not shared by TK.  A Pro residue 
in P2 of kallikrein substrates does not impair complex formation but makes the scissile bond resistant to 
cleavage by all except rat kallikrein.  Tissue kallikrein has a trypsin-like specificity, cleaving chromogenic 
substrates with Arg and Lys, but not Phe, at P1.  The amino acids preferred in each subsite are boxed.  The 
arrow depicts the scissile bond.  This figure was compiled with Microsoft Word 2000.   
 
The levels of TK-like, PK-like and Tonin-like activity as determined using Phe-Arg-
AMC as substrate in the presence of inhibitors is shown in table 3.10.   
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Table 3.10:  Comparison of TK-like (LBTI), PK-like and Tonin-like (Aprotinin) specific activity of 
different organs/tissues/fluids in the Ostrich.   
Source nM KLK/g nM KLK/g nM KLK/g 
 TK-like PK-like Tonin-like 
Plasma 49.2 10.6 31.4 
Heart 150 49.9 97 
Liver 0 0 0 
Adrenals 7105.9 1129.3 884.7 
Brain 153.9 638.2 119.4 
Lung 192.7 37.3 242 
Kidney 1293 5813.2 2274 
Anterior Pituitary 41.2 147.5 51.4 
Posterior Pituitary 111.9 192.5 95.7 
Spinal cord 0 0 0 
Pancreas 536.9 470.6 7.4 
Urine 0 0 0 
 
From the results in table 3.10 it can be seen that the adrenals, pancreas and kidney are 
the best source for TK as determined using Phe-Arg-AMC as substrate in the presence of 
LBTI and is confirmed by Pro-Phe-Arg-AMC (figure 3.9).   
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Figure 3.9:  Comparison of Ostrich TK-like specific activity in tissues/organs/fluids.  A: Phe-Arg-AMC 
as substrate.  B:  Pro-Phe-Arg-AMC as substrate.   
 
Tonin-like activity expressed as KLK specific activity in the presence of aprotinin using 
Phe-Arg-AMC and Pro-Phe-Arg-AMC as substrates was determined.  From these results 
the kidney was determined to be the best source for tonin (table 3.10; figure 3.11).  PK-
like activity was determined from the difference between total kallikrein-like activity 
A B 
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and TK-like activity.  The kidney and liver proved to be the best sources for PK (figure 
3.10), but adrenals and brain also showed good activity levels.   
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Figure 3.10:  Comparison of Ostrich PK-like specific activity in tissues/organs/fluids.  A: Phe-Arg-AMC 
as substrate.  B:  Pro-Phe-Arg-AMC as substrate.   
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Figure 3.11:  Comparison of Ostrich Tonin-like specific activity in tissues/organs/fluids.  A: Phe-Arg-
AMC as substrate.  B:  Pro-Phe-Arg-AMC as substrate.   
 
1.6.2 Kallikrein isolation from urine 
Ostrich urine was chromatographed as described in section 3.2.2.(f).  The eluates from 
the affinity resins were assayed for kallikrein-like activity and those that showed activity 
are shown in figure 3.12.  We expected most of the kallikrein to be in the pro-form or in 
A B 
A B 
 the inhibited form in ostrich urine.  At the stage when this experiment was tested we did 
not have a sensitive assay system for detection of kallikrein-like activity in the ostrich.  
We decided to run each fraction on SDS-PAGE gels to compare the Mr of protein bands 
with values from literature as an indication for the presence of kallikrein-like enzymes.  
Eluates are indicated in figure 3.12, fraction L2 showed KLK-like activity (assayed with 
fluorogenic substrate), upon later analysis.   
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Figure 3.12:  Elution profiles of affinity chromatography of ostrich urin
KLK active eluates.  A, elution profile of fall-through fraction of ostrich
affinity chromatography; B, elution profile of ostrich urine from LBTI-
(L1-L4, related to elution buffers 1-4); C, elution profile of ostrich urin
affinity column (A1-A4, related to elution buffers 1-4); D, SDS-PAGE 
and Aprotinin-Sepharose-4B (A1 A4) affinity chromatography eluates
through peak; 1-4, respective elution buffers as described in section 3.2
indicate Mr in kD.   
 
A                                                     B                                                    C 
A1    A2      A3      A4  L1      L2       L3     L4 FT 
  D53 
e and SDS-PAGE patterns of 
 urine after LBTI- and Aprotinin-
Sepharose-4B affinity column   
e from Aprotinin-Sepharose-4B 
of the LBTI-Sepharose-4B (L2) 
 from Ostrich urine.  FT, fall-
.2.(f).  Numbers next to bands 
. . . . . . .. . . 
 
 54 
1.7. Discussion 
1.7.1 Kallikrein activity detection 
(a) TK-like activity 
In unactivated ostrich plasma, TK seems to circulate in the pro-form, since activated 
plasma showed a more significant increase in TK-like activity over that of unactivated 
plasma (table 3.8).  PK will also cleave Val-Leu-Arg-AFC, but at a much slower rate 
than TK.  Most of the activated activity detected with this substrate can therefore be 
attributed to TK.  The adrenals showed more TK-like activity per gram protein with Phe-
Arg-AMC as substrate; and kidney showed more TK-like activity per gram protein with 
Pro-Phe-Arg-AMC as substrate.  TK-like activity was determined in the presence of 
LBTI and the best source for the isolation of TK will be either the adrenals or the kidney 
of the ostrich (table 3.10; figure 3.9).   
(b) PK-like activity 
Pro-Phe-Arg-AMC is the preferred substrate for PK and using this substrate the liver of 
the ostrich was found to exhibit the highest PK activity per gram protein.  Using Phe-
Arg-AMC as substrate, the highest PK specific activity was determined to be in the 
kidney (figure 3.10).   
(c) Tonin-like activity 
Tonin-like activity was determined with Pro-Phe-Arg-AMC and Phe-Arg-AMC as 
substrates in the presence of aprotinin.  The best source for the isolation of tonin was 
determined to be the ostrich kidney (figure 3.11).  From these results it can be seen that 
the liver, adrenals and the kidney are the best sources for the isolation of TK and PK.  
The total kallikrein-like activity also confirms this result (Table 3.9).  However, it must 
be noted that KLK activity in ostriches can only be detected using fluorogenic 
substrates; in contrast to other species where activity is monitored with colorimetric 
substrates.   
1.7.2 Kallikrein isolation 
A pilot isolation attempt of kallikrein was performed with ostrich urine since it is 
comparatively a purer source than other tissues or fluids.  We were able to detect TK-
like and kallikrein-like activity in isolated fractions from LBTI and aprotinin-Sepharose 
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columns, respectively.  It is important to note that the pilot isolation was completed 
before fluorogenic assays on urine were performed and that we believed KLK in urine to 
be in the pro-form.  The urine samples were assayed without activation and showed no 
KLK activity (Tables 3.9 and 3.10).  The KLK activity detected from LBTI and 
aprotinin affinity columns may then reflect removal of an endogenous inhibitor.  The 
KLK active fractions were subjected to N-terminal sequencing but no sequence could be 
obtained due to insufficient material.  However, from SDS-PAGE patterns (figure 3.12) 
bands of the correct Mr for PK (55-kD, L2) and TK (25-45 kD, A1-A4) were obtained in 
fractions that were KLK active.  From the studies done on the different 
tissues/organs/fluids in the ostrich the kidney is the best overall source of kallikreins.  
However, liver and adrenal glands would also be a good source.   
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Chapter 4 
The isolation and partial 
characterisation of high 
molecular weight kininogen 
from ostrich plasma 
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1.8. Introduction 
1.8.1 General overview of kininogens 
Kininogens are large, single-chain, glycoprotein precursors, with pleiotrophic functions 
(DeLa Cadena & Colman, 1991).  The mature kininogen molecules are synthesised in 
the liver and secreted into the plasma (Müller-Esterl et al., 1985).  The kinins, liberated 
from the kininogens upon proteolysis, are rapidly degraded with a half-life of less than 
15 seconds in the plasma (Stewart and Vavrek, 1986).  Hence the kinins are considered 
to be locally acting hormones.  However, the molecular mechanisms underlying their 
regional release have remained elusive and the functions of the remaining kininogen 
fragments are only now becoming clear.   
1.8.2 Characteristics of kininogens 
(a) Types of kininogens 
Three different types of kininogens have been identified: high molecular weight 
kininogen (HKG), low molecular weight kininogen (LKG) and T-kininogen (TKG). The 
latter variant has been found only in rats and was shown to be the major acute-phase 
reactant in this species (Okamoto & Greenbaum, 1983; Kageyama et al., 1985).  A 
single kininogen gene, called K-kininogen, is present in the human genome and is 
localised to chromosome 3.  The kininogen gene spans over 27kb of DNA and is 
composed of 11 exons.  It is transcribed into a primary transcript that is differentially 
spliced into HKG (mRNA size:      2.3 kb; 626 amino acids; 88-120 kD) and LKG (1.6 
kb; 409 amino acids; 50-68 kD) (Kakizuka et al., 1988; Kakizuka et al., 1990).  The nine 
exons upstream of the bradykinin sequence (which is located in exon 10) code for the 
same amino acids in both kininogens, whereas the portion of exon 10 downstream of the 
kinin sequence is unique to HKG mRNA.  Exon 11 is expressed in LKG mRNA only.  
The TKG gene has extensive sequence homology  (90%) with the K-kininogen gene, 
particularly in the 5-untranslated region and in exon 1 (Furuto Kato et al., 1985; Fung 
and Shcreiber, 1987).  Despite their homology HKG and LKG genes are differentially 
expressed during development and in response to inflammation and injury (Fung and 
Shcreiber, 1987; Chao et al., 1988; El-Dahr & Dipp, 1994).    
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(b) The processing of kininogen 
The sequence of a signal peptide (figure 4.1) on the N-terminal of the heavy chain of 
both pre-HKG and pre-LKG in humans was found to be identical, consisting of 18 
amino acid residues (Takagaki et al., 1985).   
 
BOVINE KININOGEN, HMW I PRECURSOR  
BOVINE KININOGEN, LMW I PRECURSOR 
     Signal peptide 
-18                     1             12           22            32            42 
MKLITILFLC SRLLPSLTQE SSQEIDCNDQ DVFKAVDAAL TKYNSENKSG NQFVLYRITE  
MKLITILFLC SRLLPSLTQE SSQEIDCNDQ DVFKAVDAAL TKYNSENKSG NQFVLYRITE  
********** ********** ********** ********** ********** ********** 
          52            62            72            82           92           102 
VARMDNPDTF YSLKYQIKEG DCPFQSNKTW QDCDYKDSAQ AATGECTATV AKRGNMKFSV  
VARMDNPDTF YSLKYQIKEG DCPFQSNKTW QDCDYKDSAQ AATGECTATV AKRGNMKFSV 
********** ********** ********** ********** ********** ********** 
         112           122           132          142           152           162 
AIQTCLITPA EGPVVTAQYE CLGCVHPIST KSPDLEPVLR YAIQYFNNNT SHSHLFDLKE  
AIQTCLITPA EGPVVTAQYE CLGCVHPIST KSPDLEPVLR YAIQYFNNNT SHSHLFDLKE 
********** ********** ********** ********** ********** ********** 
       CPI I                                                        CALPAIN 
         172           182           192           201          212           222 
VKRAQRQVVS GWNYEVNYSI AQTNCSKEEF SFLTPDCKSL SSGDTGECTD KAHVDVKLRI  
VKRAQRQVVS GWNYEVNYSI AQTNCSKEEF SFLTPDCKSL SSGDTGECTD KAHVDVKLRI 
********** ********** ********** ********** ********** ********** 
          232          242           252           262          272           282 
SSFSQKCDLY PVKDFVQPPT RLCAGCPKPI PVDSPDLEEP LSHSIAKLNA EHDGAFYFKI  
SSFSQKCDLY PVKDFVQPPT RLCAGCPKPI PVDSPDLEEP LSHSIAKLNA EHDGAFYFKI 
********** ********** ********** ********** ********** ********** 
        CPI II                                                          EC 
         292           302           312           322           332          342 
DTVKKATVQV VAGLKYSIVF IARETTCSKG SNEELTKSCE INIHGQILHC DANVYVVPWE  
DTVKKATVQV VAGLKYSIVF IARETTCSKG SNEELTKSCE INIHGQILHC DANVYVVPWE 
********** ********** ********** ********** ********** ********** 
                              BK 
         352           362           372           382          392           402 
EKVYPTVNCQ PLGQTSLMKR PPGFSPFRSV QVMKTEGSTT VSLPHSAMSP VQDEERDSGK  
EKVYPTVNCQ PLGQTSLMKR PPGFSPFRSV QVMKTEGSTT THVKSCEYKG RPQEAGAEPA  
********** ********** ********** **********               * 
                                     His-rich region 
         412           422           432           442          452           462 
EQGPTHGHGW DHGKQIKLHG LGLGHKHKHD QGHGHHGSHG LGHGHQKQHG LGHGHKHGHG  
PQGEVSLPAE SPQLAR---- ---------- ---------- ---------- ----------  
   HKH20 
         472           482           492          502           512           522 
HGKHKNKGKN NGKHYDWRTP YLASSYEDST TSSAQTQEKT EETTLSSLAQ PGVAITFPDF  
---------- ---------- ---------- ---------- ---------- ---------- 
                                      FXI and pre-PK binding region 
         532           542           552          562           572           582 
QDSDLIATVM PNTLPPHTES DDDWIPDIQT EPNSLAFKLI SDFPETTSPK CPSRPWKPVN  
---------- ---------- ---------- ---------- ---------- ---------- 
         592           602 
GVNPTVEMKE SHDFDLVDAL L  
---------- ---------- - 
Figure 4.1:  Comparison of the primary amino acid structures of bovine HKG and LKG.  Numbering is 
according to the amino acid sequence of human HKG.  The signal peptide is boxed.  Two cysteine 
proteinase inhibitor (CPI) domains and bradykinin are boxed.  The calpain-binding domain, EC-binding 
domain, histidine-rich region, positive domain that binds negative surfaces (HKH20) and the FXI and  PK-
binding domains are indicated by embossed amino acids that are underlined.  The consensus sequence 
across the two proteins is indicated by (*).  The protein sequence of bovine LKG was taken from Nawa et 
al.  (1983) and the sequence for bovine HKG was taken from Kitamura et al.  (1983).   
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Proteolysis of the kininogen proteins (HKG and LKG) by kallikreins releases the kinin 
segment and converts the single-chain molecules to two-chain forms, consisting of a 
heavy and a light chain. The heavy chains of HKG and LKG are identical, whereas the 
light chain of HKG is considerably larger than that of LKG and acts as a coagulation 
cofactor (Thompson et al., 1978, Bock & Shore, 1983).  The cleavage of HKG by PK to 
yield two-chain HKG results in a striking change in the conformation of the kininogen 
molecule (Turk et al., 1995).  Prior studies have demonstrated that the two chains of 
cleaved HKG have similar molecular weights, in some studies indistinguishable on 
sodium dodecyl sulfate (SDS) gels    (Bock & Shore, 1983; Schiffman et al., 1980; 
Maier et al., 1983) and in others appear as a heavy chain of 62 kD (N-terminal chain) 
and a light chain of 56 kD (C-terminal chain) (Nakayasa & Nagasawa, 1979; Mori & 
Nagasawa, 1981).  The latter is subsequently cleaved to 45 kD.  Factor XIa has also been 
shown to be capable of cleaving the light chain so as to destroy its coagulant activity 
(Scott et al., 1985).   
(c) The structure of kininogens 
Kininogens exhibit a binding site and act as a co-factor for the activation of prekallikrein 
and factor XI (figure 4.1) (Mandle et al., 1976; Scott & Colman, 1980; Tait & Fujikawa, 
1986).  Kininogens bind specifically, reversibly and saturably to platelets (Greengard & 
Griffin, 1984; Meloni & Schmaier, 1991), neutrophils (Henderson et al., 1994) and 
endothelial cells (Meloni & Schmaier, 1991; Jiang et al., 1992; Hasan et al., 1995a; 
Hasan et al., 1994; Herwald et al., 1995, 1996; Hasan et al., 1995b).  The identity of the 
kininogen binding site(s) on these cell surfaces is still unknown.  In the absence of 
biological signal(s) induced by the binding of their ligand, kininogen, their nature as 
receptors remains to be demonstrated.  Binding studies have revealed that the copy 
number of kininogen binding sites varies extensively among the various cell types, e.g. 
from 103 on platelets to 106 to 107 on endothelial cells.  At least two populations of 
kininogen binding sites seem to be present on cells, viz. one site to which HKG binds via 
its unique light chain (Hasan et al., 1995a) and another site which accepts both HKG and 
LKG via their common heavy chain (Herwald et al., 1995).  It is presently unclear 
whether these sites correspond to two classes of receptor proteins or whether they reflect 
distinct binding properties of a single protein (Herwald et al., 1996).  A domain-like 
structure has been postulated for kininogens (figure 4.2) and recently the shape of HKG 
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has been studied by electron microscopy, describing HKG as an elongated trinodular 
molecule (Karlsrud et al., 1996).  It is well established that kininogens inhibit the 
activity of cysteine proteinases (Sueyoshi et al, 1985; Müller-Esterl et al, 1985) and 
those cysteine proteinase inhibition sites have been mapped to specific domains within 
the kininogen molecule.   
. . . . . . .. . . 
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Figure 4.2:  The assembly of the components of the kinin-forming pathway on endothelial cells (EC).  
The hypothetical scheme depicts the local assembly of prekallikrein (Pre-PK), factor XI (FXI), HKG, 
factor XII (FXII) and complement q protein receptor (gC1qR).  Domain 1 (D1) of HKG contains a light-
affinity binding site for Ca2+.  Domain 2 (D2) contains the papain and cathepsins H, L and S (CP-S/H/L) 
binding site QVVAG (N185-CQRQVVAGLNFRIC-C198), from human HKG; and a binding site for calpain 
CTD20, (N229-CTDNAYIDIQLRIASFSQNC-C248).  Domain 3 (D3) contains the binding site QVVAG for 
cysteine proteinases and cathepsins H, L and S.  The binding site LDC27 (N331-
LDCNAEVYVVPWEKKIYPTVNCQPLGM-C357), where EC dock to HKG via protein 33 (p33) in a Zn2+ 
dependent manner, is also present in domain 3.  The binding sites of EC are distinct from p33 and the  
p33-associated proteins of 60 and 100 kD (p60/p100).  The precise nature of these proteins (trans-
membrane versus extrinsic) is unknown.  Domain 4 (D4) contains the kinin moiety that is liberated by PK 
from HKG.  Domain 5 (D5) contains the histidine rich region (+) HKH20 (N479-
HKHGHGHGKHKNKGKKNGKH-C498) that interacts with negative surfaces and a binding site for FXII 
or gC1qR (gC1qR / FXII) that dock via protein 60 and 100 (p60/p100) that involves zinc bridges (Zn2+).  
Domain 6 (D6) contains a binding site SDD31 (N565-SDDDWIPDIQTDPNGLSFNPISDFPDTTSPK-
C596), for pre-PK or FXI (Pre-PK / FXI), the docking of pre-PK occurs via a Zn2+ dependent manner.  This 
domain also contains a binding site for ferritin.  (Bhoola et al., 1992; Bradford et al., 1993; Herwald et al., 
1996; Colman et al., 1997; Motta et al., 1998; Ogikubo et al., 1998).   
 
(i) Domain 1 
Sequence data have shown that the heavy chain is composed of three tandemly repeated 
cystatin-like domains, designated D1, D2 and D3 (Salvesen et al., 1986; Müller-Esterl et 
al., 1985).  The QVVAG sequence (N185-CQRQVVAGLNFRIC-C198 from human 
HKG) is common to the cysteine proteinase inhibitors (cystatins) and also present in 
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domains 2 and 3 of both HKG and LKG.  Domain 2 and 3 inhibit cysteine proteases, 
including papain and cathepsins S, H and L (Salvesen et al., 1986; Vogel et al., 1988).  
On this basis, the kininogens are classified as family 3 of the cystatin superfamily 
(Barrett et al., 1986a).  Domain 1 in the NH2-terminal end of the protein contains a low 
affinity Ca2+ binding site with unknown function, but does not inhibit cysteine 
proteinases (Higashiyama et al., 1987).   
(ii) Domain 2 
Domain 2 is unique among the cystatins in that apart from inhibiting papain, cathepsins 
S, H and L; it also inhibits calpain (Ylinenjarvi et al., 1995).  This ability has been 
proposed to be due to a specific inhibitory region CTD20 (N229-
CTDNAYIDIQLRIASFSQNC-C248 from human HKG) distinct from the QVVAG 
sequence, forming a continuous surface for interaction with calpain (Bradford et al., 
1993).  Lysosomal cysteine proteinases are the physiological target enzymes for 
kininogens (Barrett et al., 1986b).  It has been demonstrated that human LKG can bind 
two molecules of cathepsins H, L, S and papain independently, with no apparent 
inhibition of cathepsin B (Turk et al., 1995).  
(iii) Domain 3 
Zinc has been known to interact with the imidazole side chain of histidine residues in 
proteins such as carboxypeptidase A.  Zinc ions bind to domain 3 (see figure 4.2) and 
domain 5, causing a re-conformation of HKG, allowing it to interact with cell receptors 
(Greengard and Griffin, 1984).  Zn-α2-glycoprotein is an adhesive protein localised in 
the glandular exocrine epithelium of various human tissues including mammary gland, 
prostate, salivary gland, hepatocytes and the epithelial cells of the proximal and distal 
tubules in the kidney (Tada et al., 1991).  The amino acid sequence of the protein 
contains a cell adhesion sequence (Arg-Gly-Asp), which plays an important role in cell 
adhesion (Takagaki et al., 1994).  Mouse osteoblastic-like cells (MC3T3-E1) adhere to 
Zn-α2-glycoprotein-coated surfaces and the vitronectin receptor takes part in Zn-α2-
glycoprotein-mediated cell adhesion.  LKG and its derivatives promote Zn-α2-
glycoprotein-mediated MC3T3-E1 cell adhesion.  Domain 3 of the common heavy chain 
of both kininogens is responsible for acceleration of adhesion.  It has been shown that 
the amino acid sequence N334AEVYVVPWEKKIYPTVN351, contained within domain 3 
. . . . . . .. . . 
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of human kininogen, accelerates the Zn-α2-glycoprotein-mediated MC3T3-E1 cell 
adhesion up to 210% with no interference in adhesion (Ogikubo et al., 1998).   
Domain 3 inhibits papain, cathepsins S, H and L; but not calpain (Salvesen et al., 1986;               
Ylinenjarvi et al., 1995).  Domain 3 also contains the unique site LDC27 (N331-
LDCNAEVYVVPWEKKIYPTVNCQPLGM-C357), where EC dock to HKG via protein 
33 (p33) in a manner still unknown (Herwald et al., 1995).  The LDC27 site and the p33 
site are distinct from each other.  It has been found that this site also inhibits thrombin-
mediated tissue-type plasminogen activator release and prostacyclin synthesis.  Domain 
3 inhibits thrombin action on platelets (Puri et al., 1991) and cell binding to platelets 
(Kunapuli et al., 1996) and endothelial cells (Herwald et al., 1995) and blocks the 
binding of HKG to neutrophils (Colman et al., 2000).   
(iv) Domain 4 
Domain 4 contains the kinin-moiety (figure 4.3) and the binding site for active 
kallikrein.  The process by which kinin is liberated from the complex is not yet fully 
understood.   
 
Figure 4.3:  The kinin moiety of kininogen.  Arrows indicate the cleavage sites of PK.   
 
(v) Domain 5 
Domain 5 contains the histidine rich region (+) HKH20 (N479-
HKHGHGHGKHKNKGKKNGKH-C498) within fragment 1.2 that interacts with 
negative surfaces and a binding site for FXII or gC1qR (gC1qR / FXII in figure 4.2) that 
dock via protein 60 and 100 (p60/p100).  Binding involves zinc bridges.  Heparin is a 
negatively charged polymer that interacts with protein molecules via electrostatic 
interaction with lysines and/or arginines.  Zn2+ acts as a co-factor for heparin 
neutralization by histidine-rich glycoproteins (Kluszynski et al., 1997).  Zn2+ stabilizes 
 65 
the non-covalent complex formation between domain 5 of HKG and heparin (Lin et al., 
2000).  The activation of the pKKS on EC needs both HKG and Zn2+ (Rojkjaer and 
Schmaier, 1999).   
Fragment 1.2 precedes the light chain and is also called the histidine rich domain 5 
(figure 4.4).  Fragment 1 contains a repeating sequence Gly-His-Lys, which is the same 
peptide reported to prolong the life of liver cells in the rat.  Fragment 2 is especially high 
in histidine content, being more than 25 % of the amino acid residues.   
 
 
 
 
 
 
 
 
Figure 4.4:  The histidine rich domain 5 of bovine HKG that contains fragment 1.2.  The carbohydrate 
units are indicated with CHO.  Plasma kallikrein cleavage sites are indicated with arrows and histidine 
residues are circled (Holzer and Tschesche, 1979).   
 
Fragment 1.2 also contains several PK cleavage sites and the whole fragment is cleaved 
out from HKG upon activation (Holzer and Tschesche, 1979).  Fragment 1.2 is 
extremely rich in basic amino acid residues.  Bovine KG contains 22 histidines, 13 
lysines and 3 arginines in a total of 110 residues.  In general it has been known that basic 
proteins such as protamine, lysozyme and synthetic polylysine inhibit the activation of 
FXII by a negatively charged surface.  Fragment 1.2 alone has also been shown to be a 
potent inhibitor of the contact activation of FXII (Yamamura et al., 2000).  When the 
kininogens are processed by the above mentioned serine proteases, kinin- and fragment 
1.2-free HKG generated from kinin-free HKG lose their inhibitory activity and express 
accelerating activity, contributing to a rapid repair of wounded local tissue (Asakura et 
al., 1992).  Fragment 1.2 of HKG stimulates the cell proliferation of osteoblasts, 
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indicating that kininogen plays a significant role in bone metabolism as well as blood 
coagulation.  It has been hypothesised that the heavy chain inhibits bone resorption 
whereas fragment 1.2 stimulates bone formation (Yamamura et al., 2000).  Furthermore, 
it is also speculated that LKG and its derivatives contribute to cell adhesion via 
vitronectin, Zn-α2-glycoprotein and osteopontin, resulting in local bone formation after 
bone fracture and inflammation (Ogikubo et al., 1998).   
Domain 5 of HKG may also be important in angiogenesis, the formation of new 
capillaries from pre-existing blood vessels.  Angiogenesis consists of the following 
steps: (1) endothelial cell detachment from adhesive proteins; (2) enzymatic degradation 
of the basement membrane by plasmin or plasmin-activated matrix metalloproteinases; 
(3) EC migration into perivascular space; (4) proliferation and (5) tube formation 
(Colman et al., 2000).  The penetration of cells through extracellular matrix is a 
requirement for angiogenesis (Ausprunk and Folkman, 1977; Gross et al., 1983).  The 
expression of cell surface plasmin activity is essential for promoting cell migration 
through extracellular matrix and depends on pro-urokinase (pro-UK), urokinase-type 
plasminogen activator receptor (uPAR), plasminogen and plasminogen activator 
inhibitor type-1.  The uPAR plays a critical part in initiating cell migration and 
enhancing adhesion and regulatory proteolysis on the cell surface by increasing the 
activation of cell-associated plasminogen.  HKG binds to uPAR domains 2 and 3, 
leading to the assembly of a complex consisting of uPAR, pro-UK, HKG and pre-PK on 
the EC surface.  In this complex, pre-PK is converted to PK by an unknown EC cysteine 
proteinase.  PK then cleaves HKG to kinin-free-HKG and pro-UK to UK.  Plasminogen 
is then converted to plasmin by UK.  Plasmin-dependant proteolysis then facilitates EC 
migration.  It has also been shown that domain 5 of HKG (fragment 1.2) inhibits EC 
proliferation (Colman et al., 2000).   
(vi) Domain 6 
Domain 6 contains the site SDD31 (N565-
SDDDWIPDIQTDPNGLSFNPISDFPDTTSPK-C596 from human HKG) where pre-PK 
or FXI (Pre-PK / FXI in figure 4.2) docks to HKG.  Pre-PK contains four homologous, 
unique 90-residue repeat (apple) domains (Chung et al., 1986).  The binding site for 
HKG within pre-PK has been mapped to two discontinuous segments of the native 
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protein (Herwald et al., 1993; Page and Colman, 1991; Page et al., 1994).  The apple 1 
domain in pre-PK (Pre-PK A1) and the apple 4 domain in pre-PK (Pre-PK A4), bind non-
covalently to the N-terminal and C-terminal side respectively on the pre-PK-binding site 
in domain 6 of HKG (figure 4.5).   
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Figure 4.5:  The interaction of PK and HKG.  The prekallikrein apple 1 (Pre-PK A1) and apple 4 (Pre-PK 
A4) domains are pictured in a non-covalent complex with the Pre-PK/FXI binding site (SDD31) in HKG 
domain 6 (HKG D6) (Colman et al., 1997).   
 
The light chain of HKG also shows ferritin-binding capacity.  Ferritin is an iron-binding 
protein that is found in most human tissue and in human serum.  It is a 24-subunit 
protein composed of two chains.  The role of ferritin-binding proteins is uncertain.  
However, it has recently been found that ferritin receptors are present on cells and that 
this interaction plays a role in numerous functions, including suppression of 
myelopoesis, suppression of lymphocyte proliferation and facilitation of iron uptake.  
Ferritin is elevated during acute and chronic inflammation and the observation that 
ferritin and HKG interact suggests that ferritin may modulate some of the effects of 
HKG (Torti and Torti, 1998).   
. . . . . . .. . . 
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1.9. Materials and Methods 
 
1.9.1 Reagents 
Silicone W804 solution, L-cysteine HCl, Bz-Arg-pNA (BAPNA), re-purified SBTI, 
heparin and papain (EC 3.4.22.2) were purchased from Sigma.  Carboxy-methyl-papain-
Sepharose 4B was prepared according to the procedure of Kos et al. (1992).  Blue 
Sepharose affinity resin, Superdex® 200 (26/60) preparative grade gel filtration and 
analytical Mono-QTM HR 5/5 columns were purchased from Pharmacia.  A Q-Hyper 
DTM 10 (4.6 X 100 mm) analytical column was purchased from Beckman.     
1.9.2 Kininogen Purification and Characterisation 
(a) Kininogen assay 
Quantification of kininogens in plasma was done according to the method of Karlsrud et 
al. (1996) using the principle of cysteine proteinase inhibition (CPI).  Commercial 
papain (10.714 mg/ml) was dissolved in a 50 mM phosphate buffer at pH 4.5.  Papain 
was activated for 5 minutes at 22oC by adding 70 µl of the papain solution to 1680 µl of 
a 50 mM sodium phosphate buffer at pH 7.5 containing 0.01 % Triton X-100 and 750 µl 
of a 50 mM cysteine-HCl solution (Sueyoshi et al., 1988).  Samples to be assayed for 
kininogen were diluted or dissolved in a 50 mM Tris-HCl buffer at pH 8.20 containing 
120 mM methylamine and 0.01 % Triton X-100.  50 µl of activated papain was 
incubated with 50 µl of sample (or commercial human HKG for the standard) in 
microtiterplate wells for 30 minutes at 22oC.  The system was standardised using 
BAPNA as substrate.  50 µl of the substrate solution (50 mM Bz-D-L-Arg-pNA in 
DMSO, 25 times diluted in 50 mM Tris-HCl at pH 8.20 containing 120 mM 
methylamine and 0.01 % Triton X-100) was added to each incubated well and the initial 
papain activity (∆A410nm/minute) over 30 minutes was measured at 410 nm with a 
microtitreplate reader at 22oC.  Assuming ε410 nm = 8800 M-1 cm-1 for p-nitroaniline 
(pNA), the change in absorbance per minute at 410 nm was related to amount of product 
(pNA) produced per minute.  Progress curves for the activity of uninhibited papain (at 
concentrations of 3.65, 1.83, 0.91 and 0.23 µM) and inhibited papain (at different HKG 
concentrations of 816, 408, 204 and 26 nM, respectively) are depicted in figure 4.6 (A 
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and C).  From these curves it can be seen that the activity (change in absorbance at 410 
nm) was linear over the incubation time.  The amount of inhibitor present in the assay 
determined the activity detected.  It was decided to depict the amount of KG present in a 
sample by correlating it to the activity of the amount of papain inhibited, resulting in a 
positive linear relationship (figure 4.6.D).  When determining the cysteine inhibitor 
activity data was expressed as that activity remaining after inhibition at different 
concentrations of HKG (figure 4.6.E).   
. . . . . . .. . . 
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Figure 4.6:  Progress curves and standard curves for the kininogen assay.  A:  Progress curves of papain at 
different concentrations (3.65, 1.83, 0.91 and 0.23 µM as indicated); using the cysteine proteinase assay.  
B:  Initial activity (nM pNA/s) of papain at different concentrations (nM); using the cysteine proteinase 
assay.  The concentration of pNA was determined from a standard curve of change in absorbance at 410 
nm vs. concentration of pNA standard.  C:  Progress curves of a constant amount of papain (4.4 µM) 
inhibited at different HKG concentrations (816, 408, 204 and 26 nM as indicated); using the cysteine 
proteinase inhibition assay.  D:  The amount of papain inhibited by HKG is graphed by correlating the 
activity (nM/s) corresponding to each amount of papain inhibited, at different HKG concentrations (nM); 
using the cysteine proteinase inhibition assay.  This curve was used in determining the amount of HKG 
present in a sample corresponding to the amount of papain inhibited.  E:  The residual activity (nM/s) left 
after a constant amount of papain (4.4 µM) was inhibited at different HKG concentrations (nM).  This 
curve was used in determining the inhibitor ratio of the purified ostrich plasma HKG protein.  Inh., 
inhibited; Res., residual; Pap., papain.   
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One cysteine proteinase inhibitory unit (IU) corresponds to the amount of commercial 
human HKG needed to fully inhibit 1 nM of active papain; as determined from the 
calibration curve of active papain inhibited by HKG (figure 4.6, D).  From the plot of 
residual papain activity in the presence of HKG (figure 4.6.E), it can be seen that 4.4 µM 
papain was totally inhibited at an HKG concentration of 860 nM.  According to 
literature HKG has two binding sites for papain and from the results in figure 4.6 it can 
be calculated that the molar ratio of papain to HKG was 5:1.  It is likely, therefore that 
only 40 % of papain, used in the assays, was activated in the papain activation step.  This 
value for activated papain is comparable to published data of 40 % for commercial 
papain and 80 % for re-purified papain      (Sueyoshi et al., 1988).  Since we used 
commercial purified papain in the CPI assays, assuming an activation of 40 % of total 
amount of papain present in the assay, the molar ratio of papain to HKG can be assumed 
to be 2:1 as expected from literature.   
(b) Plasma sample collections 
Initially ostrich blood was collected upon sacrifice into a solution (1/10 of the final 
collection volume) of 0.129 M tri-sodium citrate.  Isolations of kininogen from these 
samples showed degradation of a 120-kD band over time.  To lessen the possibility of 
enzyme activation and consequent KG degradation, it was decided to collect blood 
intravenously using evacuated, siliconised tubes containing respectively: 1) 0.129 M tri-
sodium citrate; 2) 0.5 mg/ml heparin, 20 mM EDTA, 20 mM EGTA, 0.02% (w/v) NaN3 
and 50 mM Tris-HCl at pH 7.40; 3) 10 % oxalate, 20 mM EDTA, 20 mM EGTA, 0.02% 
(w/v) NaN3 and 50 mM  Tris-HCl at pH 7.40; 4) a solution consisting of 20 mM EDTA, 
20 mM EGTA, 0.02% (w/v) NaN3, 0.129 M tri-sodium citrate, 0.65 mg/ml SBTI and 50 
mM Tris-HCl at pH 7.40; and 5) a solution consisting of 20 mM EDTA, 20 mM EGTA, 
0.02% (w/v) NaN3, 0.129 M tri-sodium citrate and 10% iodo-acetic acid.  All possible 
precautions were taken to prevent activation, including siliconisation of glassware at all 
steps during purification.  Samples collected in this way were subjected to initial 
purification of KG using papain affinity chromatography.  In short: collected plasma was 
acid treated; stirred with active papain-Sepharose resin (30 ml) equilibrated in 20 mM 
Tris-HCl at pH 7.40 containing 0.5 M NaCl, 2 mM EDTA, 0.1 % Brij 35 and 0.02 % 
NaN3; and eluted in one step with 0.1 M sodium-carbonate at pH 11.50 containing 2 mM 
EDTA, 1.0 M NaCl and 0.02 % NaN3.  The elution peaks were assayed for CPI activity 
. . . . . . .. . . 
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and the active peaks were analysed with 10 % SDS-PAGE to determine if the 120 kD 
band was present.  It was found that collections using tri-sodium citrated tubes, 
heparinised tubes and tubes containing SBTI resulted in the isolation of the desired 120 
kD band.  Since tri-sodium citrated tubes were comparatively cheaper and easier to work 
with, it was decided to consistently collect all future plasma intravenously using 
vacuated, siliconised tubes containing 0.129 M tri-sodium citrate.   
(i) Method for siliconisation 
Glassware were properly cleaned with Teepol, rinsed with deionised distilled water, 
dried in an oven at 120oC and freed from dust using compressed air.  The cleaned 
glassware were coated with 100 % Silicone W804 solution and baked in an oven at 
120oC for 5 hours.  All glassware was tested before use: uncoated glass retains water and 
coated glass repels water (seen as droplets on the surface).   
(ii) The plasma sample collection procedure 
The samples were collected by hand and centrifuged within 30 minutes from collection 
at 3000g for 30 minutes at 22oC.  Pooled plasma was stored at 80oC in 50 ml aliquots, 
thawed at 25oC and left at room temperature before isolation or assays.  Collection time 
and storage of plasma samples at room temperature was reduced to a minimum to 
prevent activation.   
(iii) Acid treatment of plasma   
According to literature mild acid treatment of plasma dissociates complexes involving 
plasma proteins and prevents the binding of α-macroglobulin to papain (Karlsrud et. al., 
1996).  Applying or omitting the acid treatment step, however, made no difference in the 
auto-degradation of the 120-kD band in the present study.   
To one volume of plasma was added an equal volume of 1/6 N HCl and the mixture was 
incubated for 15 minutes at room temperature with slow stirring.  Then one volume of 
0.1 M sodium phosphate pH 7.6, containing 0.15 M NaCl, 1 mM EDTA and 0.4 % PEG 
was added and followed by one volume of 1/6 N NaOH (Scott and Colman, 1988).   
(c) Purification of kininogen   
The general procedure for the isolation and purification of kininogen consisted of the 
isolation of kininogen from acid treated plasma with a papain affinity resin (Kos et al., 
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1992).  HKG was separated from LKG on a Blue-Sepharose affinity resin (Motta et al., 
1998).  The CPI-active fraction was purified on a Superdex 200® (26/60) gel filtration 
column.  Several alterations to this purification procedure were made to be able to 
understand and interpret the final results.  These alterations will be discussed where 
applicable.   
(i) Papain affinity chromatography of plasma 
A 50 ml aliquot of frozen pooled ostrich plasma was acid-treated as described above.  
The CM-papain-Sepharose-4B resin (30 ml) was washed with elution buffer (0.1 M 
Sodium-carbonate pH 11.50, 2 mM EDTA, 1.0 M NaCl and 0.02 % NaN3) and 
equilibrated in loading buffer (20 mM Tris-HCl pH 7.40, 0.5 M NaCl, 2 mM EDTA, 0.1 
% Brij 35 and 0.02 % NaN3).  The acid-treated plasma was dialysed against the papain 
equilibration buffer.  The dialysate was stirred in, at a slow speed, with the activated 
resin at 4oC overnight.  The resin was packed in a 25 ml siliconised glass column at 0.5 
ml/min, using an Amersham Pharmacia Biotech Äkta FPLC at 22oC, washed with 
equilibration buffer until baseline was reached and KG was eluted in one step with the 
elution buffer.  The pooled fraction was assayed for papain inhibition and the protein 
content was determined.  The active fraction was dialysed against running deionised 
water, freeze-dried and stored at 4oC.   
(ii) Blue-Sepharose affinity chromatography of kininogen 
Blue-Sepharose affinity resin (80 ml) was washed with a 0.1 M sodium acetate buffer at 
pH 6.8, containing 3 M KCl and equilibrated in a 0.1 M sodium acetate buffer at pH 6.8.  
The resin was packed in a 50 ml siliconised glass column at 1 ml/min with FPLC at 
22oC.  The freeze-dried KG fraction from papain affinity chromatography was dissolved 
in equilibration buffer and loaded onto the Blue-Sepharose resin at 0.5 ml/min.  LKG 
was eluted from the resin with 0.1 M sodium acetate buffer at pH 6.8 containing 0.3 M 
NaCl at 1 ml/min.  HKG was eluted from the resin with a 0.1 M sodium acetate buffer at 
pH 6.8 containing 1 M NaCl.  Pooled fractions were assayed for papain inhibition and 
protein content.  The active fractions were freeze-dried and stored at 4oC.   
(iii) Gel filtration chromatography of kininogen 
A Superdex 200® (26/60) gel filtration column was equilibrated in a 50 mM Tris-HCl 
running buffer at pH 8.0 containing 0.15 M NaCl.  Kininogen from Blue-Sepharose 
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chromatography was dissolved in the running buffer, loaded onto the column and 
developed at 2.5 ml/min using an Amersham Pharmacia Biotech Äkta FPLC system.  
The elution profile was monitored at 280nm.  Fractions were assayed for papain 
inhibition activity.  The active pooled fractions were dialysed against running deionised 
water, freeze-dried and stored at 4oC.  The Mr of kininogen samples was determined 
from a calibration curve for Superdex 200® (26/60) established by using urease, IgG, β-
galactosidase, BSA, transferrin, ovalbumin, trypsin and cytochrome c for calibration.   
(iv) Super-Q ion exchange chromatography 
Super-Q ion exchange resin (250 ml) was cleaned, activated and equilibrated in 40 mM 
Tris-HCl at pH 7.90 containing 0.02 % NaN3.  Papain affinity purified kininogen 
fractions were stirred with the resin at 4oC; packed at 0.5 ml/min. and washed with 
equilibration buffer till baseline was reached (A280nm).  Elution was done with 40 mM 
Tris-HCl at pH 7.90 containing 0.5 M NaCl and 0.02 % NaN3 using a linear gradient of 
0  0.5 M NaCl over 2L (1 ml/min).   
(v) Q-HyperDTM 10 chromatography of kininogen 
A Q-Hyper D 10 µm (4.6 mm X 100 mm) Beckman analytical column was washed with 
2M NaCl, regenerated and equilibrated in 0.1 M Tris-HCl at pH 8.0 containing 0.02 % 
NaN3.  A Beckman HPLC (128 Solvent module) system operated by System Gold was 
used to run samples on the column.  Samples were routinely loaded with a 507 
Autosampler and the elution profile was followed with a 168 diode array detector set at 
215 nm and 280 nm.  Elution was done with a linear gradient of 0  0.5 M NaCl over 30 
ml at a flowrate of 1 ml/min.  The elution buffer consisted of 0.1 M Tris-HCl at pH 8.0 
containing 2 M NaCl and 0.02 % NaN3.  The column was routinely cleaned with 2M 
NaCl after each batch of 10 samples were analysed.   
(vi) Mono-QTM HR 5/5 chromatography of kininogen 
A Mono-QTM HR 5/5 Pharmacia analytical column was cleaned, regenerated and 
equilibrated in 50 mM Tris-HCl at pH 7.40 containing 2 mM EDTA and 0.02 % NaN3.  
Samples were loaded at 0.5 ml/min and the resin was washed with equilibration buffer 
until baseline was reached (A280nm).  Elution was done (1 ml/min) with 50 mM Tris-HCl 
at pH 7.40 containing 1M NaCl, 2mM EDTA and 0.02% NaN3 using an Amersham 
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Pharmacia Biotech Äkta FPLC.  The elution gradient consisted of a series of step 
increments of increasing concentration of NaCl (0.1 M, 0.2 M, 0.3 M, 0.4 M and 0.5 M).   
(d) Liver sample collection and extraction 
According to literature, kininogens are synthesized in the liver and exported into the 
plasma.  Kininogen is probably exported into the blood stream as a complex with the 
associated proteins for each domain (see figure 4.2).  The likelihood of activation is 
considered to be lower in tissue than in plasma and therefore we attempted the isolation 
of an intact kininogen molecule from the liver.   
(i) Collection of liver 
Ostrich liver was freed from blood and connective tissue, cut into 5 cm cubes and frozen 
in liquid nitrogen.  The time from animal sacrifice till freezing was less than 15 minutes.  
The frozen liver was powdered with a Waring blendor in the presence of liquid nitrogen 
and the powder was stored at 20oC.   
(ii) Extraction of kininogen from liver 
To 6 g of powdered liver was added 60 ml extraction buffer.  The extraction buffer 
consisted of 0.01 M PIPES at pH 6.0, containing 0.1 M NaCl, 0.3 mg/ml purified SBTI, 
2 mM EDTA, 0.1 % Triton X-100 and 0.02 % NaN3.  The mixture was homogenised for 
5 minutes with a Teflon homogeniser using polypropylene tubes and left on ice for 20 
minutes.  Homogenisation was done on ice.  The homogenate was filtered through 
cheesecloth and centrifuged for 30 minutes at 30,000 g at 4oC.  The supernatant was 
filtered at 4oC through Whatmann filter paper to remove fat.  The final extract was 
stirred with activated papain-Sepharose resin (30 ml) at low speed at 4oC overnight.  The 
loaded resin was packed in a 40 ml siliconised glass column at 0.5 ml/min. using an 
Amersham Pharmacia Biotech Äkta FPLC at 22oC.  The resin was washed with running 
buffer (20 mM Tris-HCl pH 7.4, 0.5 M NaCl, 2 mM EDTA, 0.1 % Brij 35 and 0.02 % 
NaN3) till baseline was reached (A280 nm).  KG was eluted from the resin in one step with 
elution buffer (0.1 M Sodium-carbonate pH 11.50, 2 mM EDTA, 1.0 M NaCl and 0.02 
% NaN3) at 1 ml/minute.  The profile was followed at 280 nm and 3 ml fractions were 
collected over the elution peak.  The peak was assayed for CPI activity and the active 
fraction was analysed on 10 % SDS-PAGE.   
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(e) Protein assay of samples 
Samples were assayed for protein content using the bicinchoninic acid microtitre plate 
assay with BSA as standard (Stoscheck 1990).   
(f) Electrophoresis of samples 
(i) SDS-PAGE 
SDS-PAGE was performed on 9, 10, or 12 % acrylamide gels according to the method 
of Laemmli (1970) in a Bio-Rad Mini Protean II system.  Non-reduced samples were run 
on 9 or 10 % gels and reduced samples on 12 % gels.  The following standards were 
used (Mr values in parenthesis): rabbit muscle myosin (205kD), E. coli β-galactosidase 
(116kD), rabbit muscle phosphorylase b (97kD), rabbit muscle fructose-6-phosphate 
kinase (84kD), bovine serum albumin (66kD), bovine liver glutamic dehydrogenase 
(55kD), chicken egg ovalbumin (45kD), rabbit muscle glyceraldehyde-3-phosphate 
dehydrogenase (36kD), bovine erythrocyte carbonic anhydrase (29kD), bovine pancreas 
trypsinogen (24kD), soybean trypsin inhibitor (20kD), bovine milk α-lactalbumin 
(14.2kD) and bovine lung aprotinin (6.5kD).  The gels were stained with 0.1 % 
Coomassie Blue R-250 in water/methanol/acetic acid (5:4:1).  The gels were destained 
with water/methanol/acetic acid (6:4:2).   
(ii) Preparative SDS-PAGE 
Preparative SDS-PAGE was done according to the method of Laemmli (1970) using a 
SE 600 Hoefer system.  Gels were cast, 3 mm thick, with a single well comb and left 
overnight to polymerise.  Samples containing a protein content of 100 µg were loaded 
under non-denaturing conditions in a loading buffer containing SDS.  A potential 
difference of 200 V was applied across the gel and samples were run at 25 mA for 15 
hours at 4oC.   
Gels were washed in deionised distilled water for 10 minutes, put in a solution of 0.1 M 
KCl and left on ice at 4oC till the protein bands appeared as white precipitates.  The 
bands of interest were cut from the gels, washed in polypropylene tubes containing 
deionised water for 20 minutes at 4oC.   Extraction of the protein was done by crushing 
the gels with a Teflon homogeniser in a 20 mM Tris-HCl buffer at pH 7.4 containing 0.1 
% SDS.  These crushed gels were left at 4oC overnight.  The supernatant, containing the 
extracted protein, was dialysed against 8 M Urea for 60 minutes.  The dialysate was then 
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dialysed against running deionised water overnight.  The resulting retentate was freeze-
dried and stored at 4oC.   
(g) N-terminal sequencing and amino acid analysis 
Proteins were subjected to SDS-PAGE (10 % gels).  The gels were electro-transferred 
onto polyvinylidine difluoride membranes and stained with 0.1 % Coomassie Blue R-
250 in water/methanol/acetic acid (5:4:1).  The membranes were destained with 
water/methanol/acetic acid (6:4:2).  Visible protein bands were excised and subjected to 
NH2-terminal sequence analysis by an automated FITC-PITC double-coupling method 
using a Shimadzu PSQ-1 gas-phase protein sequencer (Muramoto et al., 1978; 
Muramoto et al., 1993).  Sequence alignment was done by Blitz search at the European 
Molecular Biology Laboratory and a tblastn search at the National Center for 
Biotechnology Information Blast network server.  SwissProt release 30, EMBL release 
41 and GenBankTM release 88 were searched for homologous sequences applying 
program default parameters.  Multiple sequence alignment was done with Clustal W 
release 1.8.  For amino acid analysis the fractions were hydrolysed in 6 M constant 
boiling HCl containing 1 % (w/v) phenol in evacuated pyrex tubes for 22 h at 110oC and 
dried under vacuum (Muramoto and Kamiya, 1990).  The hydrolysates were derivatized 
with DABS-Cl and analysed by reverse phase HPLC.   
(h) Kinetic studies 
All assays were performed according to the conditions of the CPI assay as described in 
section 4.2.2.(a).   
(i) Determining Km for papain 
Papain assays were repeated at three different concentrations of BAPNA (667, 334 and 
167 µM in the assay) according to the CPI assay conditions using a constant 
concentration of papain (4.3 µM in the assay).   
(ii) Inhibition of papain by ostrich HKG 
Three different concentrations of papain (4.4, 3.3 and 2.2 µM) were each inhibited at 
four concentrations of HKG (198.5, 99.2, 49.6 and 24.8 nM).  The residual papain 
activity, remaining after inhibition was determined as well as the activity of each papain 
concentration without any inhibitor present.   
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1.10. Results 
 
1.10.1 Purification of kininogen 
(a) CM-papain-Sepharose-4B chromatography 
Plasma collected intravenously using tri-sodium citrated tubes yielded 150-, 120-, 97- 
and 66-kD bands on SDS-PAGE after papain affinity chromatography (figure 4.7) [see 
section 4.2.2.(c).(i)].  Using the same method for the liver samples 150-, 84-, 66- and 55-
kD bands were observed (figure 4.7).  There was a change in gel pattern observed in all 
samples upon storage.  The most common gel pattern revealed prominent 120-kD, 84-
kD, 66-kD and 55-kD bands (leftmost gel pattern in figure 4.7).   
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Figure 4.7:  The isolation of kininogen from Ostrich plasma and liver using papain affinity 
chromatography.  The arrow indicates the elution step at pH 11.50.  The pooled KG fraction (bold line) 
showed CPI activity.  The non-reducing SDS-PAGE patterns of pooled KG fractions from plasma and 
liver are shown on the right.  Upon storage of the eluted fractions a different pattern appeared (shown next 
to elution peak).   
 
It was thought that KG was isolated in a complex with PK, in different forms, or was 
undergoing proteolysis/degradation, since repeated efforts to isolate KG with the papain 
affinity resin consistently produced the characteristic multiband SDS-PAGE pattern.  It 
was decided to elute fractions from the papain affinity column using stepwise 
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sequentially different pH range buffers (figure 4.8).  Elution was done sequentially with: 
1) loading buffer containing 0.15 M NaCl; 2) 0.1 M sodium acetate buffer at pH 6.0 
containing 0.15 M NaCl; 3) same as buffer 2 at pH 4.0; 4) same as buffer 2 at pH 2.0; 5) 
0.1 M sodium carbonate buffer at pH 9.0 containing 2 mM EDTA, 0.5 M NaCl, 0.02 % 
NaN3; 6) same as buffer 5 at pH 10.50; 7) same as buffer 5 at pH 11.50 containing 1 M 
NaCl.  Fractions were assayed for CPI activity and kallikrein-like activity.  CPI activity 
was found in the pH 11.50 fraction and kallikrein-like activity in the pH 4.0 fractions.   
Since the liver is the site of KG synthesis, it was decided to isolate KG from liver using 
papain-affinity chromatography as well.  Ostrich liver was prepared as described before 
[see section 4.2.2.(d)].  The supernatant was dialysed against the loading buffer and 
elution was done with the pH 11.50 buffer as for plasma.  These results and the SDS-
PAGE patterns of the fractions (figure 4.7), indicated that we were isolating the PK-KG-
complex or that the sample was degraded by proteolytic activity upon storage.   
 
Figure 4.8:  Non-reducing SDS-PAGE gel patterns of ostrich plasma eluted from papain affinity resin 
using pH step gradients.  The pH step used for each elution is indicated at the top of each lane and 
numbers next to gels indicate Mr in kD.   
 
Active papain fractions were also subjected to preparative SDS-PAGE and eluted as 
described under section 4.2.2.(f).(ii).  Although the proteins were separated, CPI-activity 
could not be recovered from the gels (figure 4.9).  This could have been due to a lack of 
refolding of the separated proteins to the active forms.   
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Figure 4.9:  SDS-PAGE gel patterns of bands eluted from preparative SDS-PAGE.  Papain-affinity 
isolations were subjected to preparative SDS-PAGE; bands eluted and re-electrophoresed to check purity.  
No fractions revealed CPI-activity.  Each lane represents an individual band eluted from the preparative 
gel.  A:  lanes 1n to 8n are the re-electrophoresed non-reduced SDS-PAGE gel patterns of the eluted bands 
from preparative SDS-PAGE.  B:  lanes 1r to 8r are the re-electrophoresed reduced SDS-PAGE gel 
patterns of the samples loaded in A.     
 
(b) Blue-Sepharose-4B chromatography 
The CPI-active freeze-dried fractions from the papain-Sepharose affinity step were 
dissolved in loading buffer and eluted as described in section 4.2.2.(c).(ii).  The 0.3 M 
NaCl step (expected to contain LKG) and the 1 M NaCl step (expected to contain HKG) 
produced CPI-active fractions.  Both fractions contained the 55-, 60-, 66-, 84-, 97- and 
120-kD bands (figure 4.10).  Only the light chains of LKG and HKG are different, which 
indicate that they should form similar complexes.  The SDS-PAGE band patterns 
therefore should not be too different, as was the case here.  It can be seen that the 1 M 
NaCl fraction seems to contain the HKG form.   
A B 
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Figure 4.10:  Blue-Sepharose chromatography of papain-affinity isolated KG.  FT, fall through fraction.  
The SDS-PAGE gel patterns of each peak are shown with predominant bands labelled for size.   
 
(c) Gel filtration chromatography 
CPI-active fractions from Blue-Sepharose chromatography were dissolved in, or 
dialysed against, the gel filtration running buffer and loaded onto the Superdex 200® 
(26/60) gel filtration column as described in section 4.2.2.(c).(iii).  The resulting elution 
profiles are depicted in figure 4.11.   
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Figure 4.11:  Superdex 200® (26/60) elution profile of Blue-Sepharose purified KG fractions.  Bs03, 
Blue-Sepharose fraction eluted with 0.3 M NaCl; bs10, Blue-Sepharose fraction eluted with 1 M NaCl.  
ConA represents a Mono Q purified fraction (subjected to concanavalin A chromatography) that was 
available in the laboratory from prior work.  Mr values of peaks are indicated above arrows of the 
respective peaks.  The Mr values were determined from calibration of the Superdex 200 column.   
 
CPI-activity was found in the 118 kD peak (120 kD SDS-PAGE).  The 62 kD and 150 
kD peaks had too little protein for the CPI assay to detect activity.  Sequence analysis 
data indicated that the purified 118-kD peak is HKG (Table 4.3).   
(d) Purification summary of kininogen 
Tables 4.1 and 4.2 represent a summary of the purification procedure of HKG and LKG 
from plasma, respectively.  By these procedures 450 µg of purified HKG was obtained 
from 50 ml plasma and 1.75 mg of partially purified LKG was obtained from 50 ml 
plasma.  HKG was purified 227-fold with a yield of 11.9 % and LKG was purified 79.5-
fold with a yield of 16.1 %.   
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Table 4.1:  Summary of the purification of HKG from ostrich plasma 
Procedure Total Protein 
(mg) 
Total Activity 
(IU) 
Specific Activity 
(IU/mg) 
Yield (%) Purification 
Plasma (acid treated) 862.50 13251200 15364 100 1 
Papain-Sepharose 9.15 5176000 565683 39.1 36.8 
Blue-Sepharose 2.4 2034676 847782 15.4 55.2 
Superdex G-200 (26/60) 0.45 1571640 3492533 11.9 227.3 
 
Table 4.2:  Summary of the purification of LKG from ostrich plasma 
Procedure Total Protein 
(mg) 
Total Activity 
(IU) 
Specific Activity 
(IU/mg) 
Yield (%) Purification 
Plasma (acid treated) 862.50 13251200 15364 100 1 
Papain-Sepharose 9.15 5176000 565683 39.1 36.8 
Blue-Sepharose 1.75 2136022 1220584 16.1 79.5 
 
1.10.2 Characterisation of kininogen 
 
(a) Kinetic studies with HKG 
The Km for BAPNA of papain (used at a constant concentration of 4.3 µM in the CPI 
assays for detection of KG in samples) was determined by using three different 
concentrations of BAPNA (667 µM, 334 µM, 167 µM) with no inhibitors present as 
described in section 4.2.2.(h).(i).  Vmax and Km of papain was determined from the Eadie-
Hofstee plot (figure 4.12).  Vmax was found to be 230 nM/s and Km was found to be 3.62 
mM.   
. . . . . . .. . . 
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Figure 4.12:  Determination of kinetic parameters for papain in the CPI assay.  A; Progress curves for 
papain (concentration used in CPI assays) incubated at different BAPNA concentrations [667, 334, 167 
µM] as indicated.  B; Michealis-Menten plot.  C; Lineweaver-Burk plot.  D; Eadie-Hofstee plot.   
 
The initial velocity (residual papain activity; nM/s) of different concentrations of papain 
(4.4, 3.3 and 2.2 µM) was determined at varying concentrations of HKG (198.5, 99.2, 
49.6 and 24.8 nM) (figure 4.13).  From the results of this study ostrich HKG inhibits 
papain with an E:I ratio of 5.8:1 and assuming that 40 % of papain was activated, the 
corrected E:I ratio is 2.3:1.  We can assume that one molecule of ostrich HKG inhibits 
two molecules of activated papain.   
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Figure 4.13:  Determination of the enzyme/inhibitor ratio of HKG in the CPI assay.  A, initial velocity vs. 
papain concentration at HKG concentrations of 198.5 nM (●), 99.2 nM (▲), 49.6 nM (▼) and 24.8 nM 
(◊).  B, initial velocity vs. HKG concentration using papain concentrations of 4.4 µM (■) and 2.2 µM (▲).   
 
(b) N-terminal sequence, alignment and amino acid analysis of kininogen 
The N-terminal amino acid sequence of ostrich HKG and LKG was aligned with the 
amino acid sequences of chicken, rat, bovine and human HKG.  It was found that the N-
terminal amino acid sequences of ostrich kininogens correspond closer with the N-
terminal amino acid sequence of HKG from the chicken, but with a much lesser degree 
to those from rat, bovine and human sources (Table 4.3).   
 
Table 4.3:  Sequence alignment of ostrich LKG and HKG fractions with Chicken, Rat, Bovine and Human 
HKG.  Identical amino acids between the species aligned are boxed.  1, Sequence was taken from Kimura 
et al. (1989); 2, Sequence was taken from Kitagawa et al. (1987); 3 Sequence was taken from Nawa et al. 
(1983); 4, Sequence was taken from Takagaki et al. (1985).   
Source Size (kD) Alignment Sequence 
  QEEDAQEMDCNDESLFQAVDTAL Rat HKG2 
  QES-SQEIDCNDQDVFKAVDAAL Bovine HKG3 
  QESQSEEIDCNDKDLFKAVDAAL Human HKG4 
  TPLPFEFSDCDDPDVLEAVDTAL Chicken HKG1 
Plasma 60 TPLPFAKSDTLDPDVLEA Ostrich LKG 
 97 GPLPFAFSDCDDPDVLEAVDTAL Ostrich HKG 
 120 GPLPFAFSDCDDPDVLEAVDTAL Ostrich HKG 
 
From the alignments in table 4.3 ostrich LKG showed 78, 22, 28 and 22 % identity to 
chicken, rat, bovine and human HKG, respectively.  Ostrich HKG was 91, 39, 43 and 39 
% identical with chicken, rat, bovine and human HKG, respectively.  The amino acid 
composition of the 120 kD and 97 kD ostrich HKG proteins were compared to the amino 
acid composition of porcine and human HKG (Table 4.4).   
(µM) (nM) 
A B 
377 nM 
720 nM 
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Table 4.4:  Amino acid composition of HKG from Ostrich plasma and H- and L-chains (HC, LC) of HKG 
from Porcine and Human plasma.  a Data was taken from Mashiko et al. (1998), L-chain here is the sum of 
fragment 1.2 and L-chain as described in literature.  ND, unable to determine amino acid composition 
because of the method used to analyse the amino acids.  Asx, asparagine or aspartate; CM-cys,      
carboxy-methylated-cysteine; Glx, glutamine or glutamate.   
Amino Acid HKG-120 kD HKG-97 kD HKG-HC HKG-HC HKG-LC HKG-LC 
(mol. %) Ostrich Ostrich  Porcinea Humana Porcinea Humana 
Ala 8.0 8.4 6.2 6.5 3.9 3.1 
Arg 4.5 3.9 2.0 2.9 1.4 3.1 
Asx 4.8 10.7 10.8 12.5 8.4 11.6 
CM-cys ND ND 4.2 3.3 0.8 0.2 
Glx 10.9 12.3 14.3 13.6 11.4 13.1 
Gly 9.3 5.2 5.1 4.8 12.2 12.2 
His 2.7 1.7 3.2 1.1 9.7 11.1 
Ile 5.6 4.4 4.3 5.8 3.4 4.0 
Leu 7.7 7.6 7.2 6.4 5.6 4.9 
Lys 10.1 9.0 8.1 8.6 8.9 8.9 
Met ND ND 0.5 0.7 1.3 1.5 
Phe 4.3 3.5 3.8 4.5 2.4 2.3 
Pro 7.1 7.2 5.2 4.2 9.5 7.6 
Ser 8.6 7.9 8.6 6.1 8.2 7.2 
Thr 7.2 8.1 6.9 7.9 6.0 6.7 
Trp ND ND ND ND ND ND 
Tyr 3.8 4.1 3.4 4.0 1.0 0.7 
Val 5.4 6.0 6.2 6.9 6.0 1.9 
Total 100 100 100 99.8 100.1 100.1 
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1.11. Discussion 
We encountered the same purification problems with the isolation of intact ostrich HKG 
as were described by Mashiko et al.  (1998) for porcine HKG.  We were always able to 
isolate kininogen, but the isolation mixture consisted of intact, degraded and two-chain 
kininogens.  By modifying the procedures of sample collection, treatment and isolation 
we were able to isolate an intact molecule.  It was decided to use papain-affinity 
chromatography as an initial step for purification since the interaction between papain 
and kininogen is very strong.  However, subsequent indications of proteolytic 
degradation of the sample upon storage were evident.  This degradation could be 
ascribed to either a protease being isolated with the kininogen, or that kininogen was 
being cleaved by papain at the affinity step, or that we were actually isolating the 
coagulation complex with pre-PK (being the precursor protease that would cleave 
kininogen upon activation during the purification procedure).  Sequence analysis of the 
120 kD and 97 kD (non-reducing SDS-PAGE) protein-bands indicated that they were 
identical with respect to the N-terminal 23 amino acids having been sequenced (Table 
4.3).  Amino acid analysis further indicated that the 97 kD protein could represent a 
degradation product of the 120 kD protein, with the fragment 1.2 region being excised.  
Table 4.4 shows the amino acid analysis of the 120 kD and 97 kD proteins; and it can be 
seen that the molar % of the amino acids are comparable except for His (2.7 to 1.7), Gly 
(9.3 to 5.2) and Asx (4.8 to 10.7) for the 120 kD and 97 kD proteins, respectively.  
Fragment 1.2 is rich in His, Gly and Lys (figures 4.1 and 4.4) and their loss would have 
a concomitant increase in the percentage acidic amino acids in the 97 kD protein.  The 
papain domains are located within domains 2 and 3 of HKG (Figure 4.2) and if papain 
were responsible for the degradation of HKG we would expect an N-terminal 
degradation product of much less than 97 kD (between 20 and 60 kD).  The implication 
that fragment 1.2 was being excised indicates that active PK was responsible for the 
degradation.  These results indicated that we were isolating the coagulation complex 
with the papain affinity chromatography step.  None of the alternative purification 
methods (Mono-Q, Hyper-D, Super-Q or preparative SDS-PAGE) improved the purity 
of intact HKG.  Lanes 2r, 4r and 8r in figure 4.9 B contained the 120 kD, 97 kD and 60 
kD bands, respectively, which indicated that we were able to isolate the intact (120 kD) 
HKG and LKG (60 kD) molecules by this procedure.  From the intensities of the gel 
. . . . . . .. . . 
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patterns it can be seen that the 120 kD band was extensively reduced to smaller bands 
(figure 4.9.B).  However, this method of preparative SDS-PAGE also left us with a CPI-
inactive kininogen molecule.  From purification table 4.1 it can be seen that the gel 
filtration step (figure 4.11) greatly improved the purity of HKG.  Mashiko et al. (1998) 
devised a method, using DEAE Sephadex A-50 chromatography to separate HKG from 
other contact factors and a zinc-chelating Sepharose-4B chromatography step to purify 
HKG from porcine plasma.  Using these methods could possibly improve the isolation of 
intact HKG and LKG from ostrich plasma.   
Gel filtration chromatography (figure 4.11) revealed the size of the pure, intact HKG 
molecule under   non-reducing conditions to be 118 kD.  Kinetic analysis of this fraction 
revealed an enzyme:inhibitor ratio of 2:1 for the inhibition of papain by ostrich HKG 
(figure 4.13).   
Table 4.3 shows the N-terminal sequence of ostrich HKG and LKG aligned with 
chicken, rat, bovine and human HKG.  The amino acid sequences align to the N-terminal 
side of human, rat, bovine and chicken HKG which indicates that we were isolating N-
terminally intact proteins.  The N-terminal 23 amino acid sequence of ostrich HKG (120 
kD) resembled the N-terminal sequence of chicken HKG with 91 % sequence identity, 
whereas with the rat, bovine and human molecules sequence identity was much lower 
(39  43 %).  The proposed degradation of the 120 kD protein to the 97 kD protein has 
to occur either within the protein or at the C-terminal side because of their identical N-
termini.  A comparison of the amino acid composition data of the two proteins gave 
evidence that the degradation took place within fragment 1.2 of HKG (Table 4.4).  
Furthermore, the amino acid composition of the 97 kD protein resembled the amino acid 
composition of the heavy chain of human and porcine HKG.  This lends further support 
that fragment 1.2 has been excised in the 97 kD protein.  The ostrich LKG N-terminal 
sequence (table 4.3) differed from that of HKG at four positions but was obtained from a 
partially purified fraction.  It is unclear therefore whether these are true substitutions or 
merely artifacts of the sequencing.   
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1.12. Introduction 
Kinins are potent bioactive peptides formed by the enzymic action of kininogenases on 
kininogen.  Kallidin is released from LKG by TK (Werle et al., 1961) and bradykinin 
from HKG by PK (Fiedler, 1979).  Conversion of kallidin to bradykinin may occur 
through the removal of the NH2-terminal lysine by aminopeptidases.  Another 
endogenous analogue, Met-Lys-bradykinin, is formed by pepsin and by uropepsin 
. . . . . . .. . . 
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(Guimaraes et al., 1976).  Other mammalian kinins with the sequence of  Ile-Ser-
bradykinin (T-Kinin) and Met-Ile-Ser-bradykinin (Met-T-Kinin) have been described 
(Okamoto & Greenbaum, 1983; Sakamoto et al., 1987).  Hyp3-kinin is formed by 
hydrolysis of human kininogen by kallikrein, suggesting that the kinin moiety of the 
kininogen is probably posttranscriptionally modified.  Hydroxyl-4-prolinase selectively 
hydroxylates proline residues in proteins containing the sequence Pro-Pro-Gly or Ala-
Pro-Gly (McGee et al., 1971; Maier et al., 1988) a motif present in kinins.  Mammalian 
kinins possess a highly conserved structure that shows a remarkable degree of homology 
with insect, amphibian skin, reptilian and avian (ornitho) kinins (Bhoola et al., 1992) 
(Table 5.1).   
Table 5.1:  The amino acid sequence of the kinin family of peptides (Bhoola et al., 1992; Semba et al., 2000).   
Species    1 2 3 4 5 6 7 8 9   
BK    Arg Pro Pro Gly Phe Ser Pro Phe Arg   
LBK   Lys Arg Pro Pro Gly Phe Ser Pro Phe Arg   
Met-LBK  Met Lys Arg Pro Pro Gly Phe Ser Pro Phe Arg   
T-kinin  Ile Ser Arg Pro Pro Gly Phe Ser Pro Phe Arg   
Met-T-kinin Met Ile Ser Arg Pro Pro Gly Phe Ser Pro Phe Arg   
T-kinin-Leu  Ile Ser Arg Pro Pro Gly Phe Ser Pro Phe Arg Leu  
Whale kinin    Arg Pro Pro Gly Phe Ser Pro Phe Arg   
Ornitho kinin    Arg Pro Pro Gly Phe Thr Pro Leu Arg   
Vespa kinin M   Gly Arg Pro Hyp Gly Phe Ser Pro Phe Arg Ile Asp 
Vespa kinin-X   Ala Arg Pro Pro Gly Phe Ser Pro Phe Arg Ile Val 
 
The cellular actions of kinins are mediated by their ability to stimulate the release of 
many second-generation mediators, e.g. platelet-activating factor, leukotrienes, 
prostaglandins, substance P (neurogenic inflammation), acetylcholine and noradrenaline 
(sympathetic nerves).  Kinins also stimulate the secretion of renin from the kidney 
(Beierwaltes et al., 1985), release of vasopressin from the neurohypophysis (Baertschi et 
al., 1981) and secretion of catecholamines from the adrenal medulla (Staszewska-
Barczak & Vane, 1967).   
1.12.1 Bradykinin (BK) 
BK, which stimulates type C nociceptive nerve fibres, is known to release excitatory 
amino acid neurotransmitters in regions of intracerebral haemorrhage and facilitate 
acetylcholine secretion at synapses (Ogura et al., 1990).  BK also stimulates 
adrenocorticotrophic hormone release from the pituitary gland following 
 91 
intracerebroventricular injection (Madeddu et al., 1992).  Although the stimulation of 
pain receptors by BK following acute injury and inflammation has been shown to occur 
via B2 receptors     (Hall, 1992), it has been suggested that after an inflammatory assault, 
both B2 and B1 receptors may play an important role in the transduction of nociceptive 
information (Davis & Perkins, 1994; Davis et al., 1994).  The induction of B1 receptors 
may be one of a number of adaptive mechanisms that occur peripherally and centrally 
following the prolonged activation of nociceptors during inflammation or injury (Dray & 
Perkins, 1993).  The greater effectiveness of the specific B1 antagonist, des-Arg9- 
(Leu8)-BK, over des-Arg1 (Hyp3, Thi5, D-Tic7, Oic8)-BK (HOE 140, icatibant), the 
specific B2 antagonist, in reversing the persistent inflammatory hyperalgesia in rats 
further supports the fact that the B1 receptor is important in mediating the hyperalgesia 
of chronic inflammation (Perkins et al., 1993).  In the neonatal rat spinal cord with 
functionally attached tail, BK-induced activation of nociceptors in the tail activated 
capsaicin-sensitive peripheral nerve fibres (C-fibres) and evoked concentration-
dependent depolarisation in the ventral root of the spinal nerve (Dray et al., 1992a).  
This activation was consistently attenuated with cyclooxygenase inhibitors 
(indomethacin, aspirin and paracetamol) and the protein kinase C inhibitor staurosporine 
(Dray et al., 1992b).  Prolonged administration of BK consistently produced a selective 
desensitisation of these receptors and neurons, while pre-treatment with 5-
hydroxytryptamine (5-HT) and various prostaglandins significantly enhanced the 
responses of these peripheral nociceptors to thermal and chemical stimuli (Rueff & 
Dray, 1992, 1993a,b).  The release of prostaglandins, histamine and other inflammatory 
mediators can also be induced by BK.  BK has been shown to induce sympathetic 
postganglionic neuron-derived mediators that enhance synovial plasma extravasation                         
(Green et al., 1993b,c), which can be modulated by sympathetic co-transmitters (Green 
et al., 1993a) and opioid receptor agonists and antagonists (Green et al., 1992).  Direct 
injection of BK into the dorsal peri-aqueductal grey area of the rat brain, elevated pain 
thresholds and induced a dose-dependent increase in aversion reactions, similar to that 
produced by morphine administration.  The inhibition of these effects by naloxone 
suggests that these BK-induced responses may be mediated by release of endogenous 
opioids (Burdin et al., 1992).  In addition to stimulating peripheral pain sensory fibres 
directly, BK also sensitises them to other stimuli such as mechanical deformation (Rang 
. . . . . . .. . . 
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et al., 1991).  In the anaesthetized rat, electrophysiological recordings of the responses 
of dorsal horn sensory neurons to subcutaneous injection of formalin, a powerful 
noxious irritant, was found to produce an acute initial peak of neural activity lasting 10 
minutes, followed for 20 minutes by a prolonged second phase of increased neural 
activity that lasted for at least 1 hour.  The effect of peripheral and intrathecal 
administration of HOE 140 and indomethacin on these responses showed that B2 
receptor stimulation accounted for both phases of the response peripherally and only the 
second phase centrally, whereas prostaglandins mediated both phases of the response 
peripherally and only the second phase centrally (Chapman & Dickenson, 1992; 
Dickenson et al., 1992).  Intrathecal administration of BK and kallidin was also shown 
to produce an initial nociceptive response followed by an analgesic effect (Laneuville et 
al., 1989), which may be due to desensitisation of small primary afferent nerve terminals 
by the initial intense kinin stimulation.  During inflammatory pain, BK and cytokines 
play a central role in activating dormant nociceptors via cyclooxygenase metabolites and 
sympathomimetic amines to a state of hyperalgesia, during which they may be activated 
by previously ineffective stimuli (Ferreira et al., 1993b).  The ability of HOE 140 to 
inhibit in a dose-dependent manner the hyperalgesic responses to BK, carrageenan and 
lipopolysaccharide suggests that the noxious effects of these stimuli are mediated by B2 
receptors.  Also, the ability of antisera to tumor necrosis factor (TNF-α) and antibodies 
and receptor antagonists of interleukins 1, 6 and 8 to inhibit the BK induced 
hyperalgesia shows that the BK-mediated hyperalgesia is initiated by the cascade of 
cytokine release (Davis & Perkins, 1994; Ferreira, 1993; Ferreira et al., 1993a).  These 
findings, coupled with the presence of kinin receptors in the dorsal root ganglion, 
substantia gelatinosa of the spinal cord and within the thalamus, indicate that BK may 
have a modulatory role in the sensory pathway.  Recently, using both normal and 
kininogen-deficient rats, antagonists to both 5-HT and neurokinin receptors, as well as 
inhibitors to KII-ACE and cyclooxygenase, Damas et al. (1997) demonstrated that the 
hyperalgesia induced by a subplantar injection of collagenase was largely dependent on 
interactions between BK and 5-HT, while prostanoids played only a minor role and 
substance P was not significantly involved.  5-HT has been shown to be a potent 
sensitising agent towards the algesic effects of BK (Hong & Abbott, 1994).  The acute 
intracerebral administration of nonphysiological doses (1-10 mg) of BK has also been 
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reported to produce an increase in systemic blood pressure, a biphasic change in 
behaviour, alterations in electroencephalogram recordings, hyperthermia, alteration in 
brain amine levels and antidiuretic effects due to increased vasopressin release (Bhoola 
et al., 1992).  The coupling of kinin receptors to multiple second messenger systems 
indicates that there could be modulation of transduction signals if multiple pathways are 
recruited.  The particular second messenger system activated may vary in different cell 
types and may account for the varying effects of BK observed in different tissues.  As 
receptor-coupled activation of second messengers frequently results in phosphorylation 
of different membrane and cytoplasmic proteins, the variable effects of BK may also be 
explained in terms of the type of protein phosphorylated and its rate of 
dephosphorylation (Raidoo & Bhoola, 1998).   
1.12.2 Metabolism of kinin 
 
Kininases, the enzymes that hydrolyse and inactivate kinins (Erdos, 1979), have been 
demonstrated in various areas of the rat brain by both bio- and fluorometric assay 
systems (Iwaki et al., 1984; Kariya et al., 1981).  The two main families of kinin 
inactivating peptidases are called KI and KII (Erdos, 1990).  The KI family includes 
plasma KI-carboxypeptidase N (KI-CPN) (Erdos & Sloane, 1968) and the cell 
membrane enzyme KI-CPM (Skidgel et al., 1984, 1989), both of which remove Arg9 
from the kinin molecule, thereby producing the B1 receptor agonists des-Arg9-BK and 
des-Arg10-LBK.  The KII group of enzymes, KII-angiotensin-converting enzyme (KII-
ACE) (Erdos, 1979; Skeggs et al., 1956; Vane, 1969; Yang & Erdos, 1967) and KII-
neutral endopeptidase (KII-NEP) (Almenoff & Orlowski, 1983; Gafford et al., 1983) 
liberate the C-terminal dipeptide Phe8-Arg9 from BK or LBK. KII-ACE further degrades 
the remaining carboxy terminus by cleaving the dipeptide Ser6-Pro7 (Erdos, 1979;                
Guder & Hallbach, 1988).  Peptide neurotransmitters cleaved by KII-NEP include 
enkephalins, substance P and neurotensin. Peptide bonds involving proline residues are 
often resistant to the attack of proteases due to its unique cyclic and imino structure 
(Mentlein, 1988).  In particular, sequences with proline in the penultimate N- or C-
terminal positions prevent cleavage by nonspecialised exopeptidases.  N-terminal Arg-
Pro-Pro- in BK, Tyr-Pro-Ser- in NPY or C-terminal -His-Pro-Phe in AT II are such 
protective structures.  However, proline-containing sequences can be overcome by 
. . . . . . .. . . 
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certain specialised proline-specific/ -selective enzymes (Mentlein, 1988), namely 
aminopeptidase P (APP) (cleaving Xaa--Pro), dipeptidyl peptidase II and IV (Xaa-
Pro/Ala--Yaa-, Yaa not Pro-), or carboxypeptidase P and lysosomal prolyl 
carboxypeptidase (-Pro/Ala--Xaa, Xaa Pro).  Whereas dipeptidyl peptidase II and prolyl 
carboxypeptidase are soluble lysosomal enzymes, the three others are plasma membrane 
bound and therefore can act on intercellular signal molecules.  Dipeptidyl peptidase IV 
participates as a regulatory protease at the surface of endothelial and other cells in the 
degradation of bio-active peptides like substance P (Heymann & Mentlein, 1986; Wang 
et al., 1994), NPY, peptide YY (Mentlein et al., 1993) or subsequent to action of APP on 
BK (Orawski et al., 1987).  Purified APP liberates the N-terminal residues from BK and 
NPY (Harbeck & Mentlein, 1991; Mentlein & Dahms, 1994; Orawski et al., 1987).  
Liberation of N-terminal Arg from BK suffices to eliminate its biological activity to all 
receptor subtypes (Regoli et al., 1993).  However, APP appears less important than 
endopeptidase-24.11 in the inactivation of the vasodilatory BK (Mentlein & Roos, 
1995).  Carboxypeptidase P (CPP) is a rarely investigated integral membrane metallo-
enzyme detected previously in renal and intestinal brush border membranes (McDonald 
& Barrett, 1986).  The action of purified pig kidney CPP on AT II and III has been 
demonstrated (Hedeager-Sorensen & Kenny, 1985).  Carboxypeptidase P may also 
cleave BK after removal of C-terminal Arg by carboxypeptidase M.  Aminopeptidases 
N, A and carboxypeptidase M are surface peptidases of smooth muscle cells, which are 
implicated in initial or in subsequent degradation steps of vasoactive peptides.  
Aminopeptidase N liberates N-terminal amino acids (acidic ones and Pro with only low 
activities) from peptides up to about 30 residues provided that they are unblocked, have 
no Pro in the penultimate position, or a N-terminal cysteine ring (Heymann & Mentlein, 
1986; McDonald & Barrett, 1986; Mitzutani et al., 1993).  Carboxypeptidase M, 
previously detected in membranes from placenta, lung and kidney, anchored probably by 
a GPI moiety (Checler, 1993), is structurally, immunologically and catalytically distinct 
from carboxypeptidase N, which is a soluble serum glycoprotein.  However both 
carboxypeptidases liberate C-terminal basic residues from peptides (Kenny & Hooper, 
1991).  Carboxypeptidase N has been shown to be responsible for the generation of            
[des-Arg9]-BK in human plasma.  Carboxypeptidase M takes the same role at smooth 
muscle cells.    [Des-Arg9]-BK is a far better ligand for B1 receptors than intact BK and 
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the reverse is true for the B2 receptor subtype (Regoli et al., 1993).  Although these 
kininases rapidly inactivate kinins, the continued release and formation of active TK 
maintains kinin production in pathophysiological states.   The kidney is rich in kininases 
that are distributed all along the nephron.  Kininases, which inactivate plasma kinins, are 
distributed in two major parts of the nephron; namely in the proximal tubules and 
medullary-collecting duct.  Kininase II is concentrated in the proximal tubules along the 
brush border membrane of the cells and in the medullary collecting duct (Marchetti et 
al., 1987).  Neutral endopeptidase (KII-NEP) and angiotensin converting enzyme (KII-
ACE) are also present in the outer surface of the brush border plasma membrane of the 
proximal tubules and to a lesser extent in the vesicular organelles both in the apical 
cytoplasm and on the basal infoldings of the proximal tubule cells (Schultz et al., 1988).  
Biochemical analysis of rat urine indicates that NEP accounts for 68% of the total 
kininase activity in rat urine, while kininase II and kininase I account for 23 % and 9 % 
respectively (Ura et al., 1987).  Urine NEP accounts for more than half of the renal 
kininases in humans.  The degradation pathway of BK in rat urine is completely 
different from that in rat or human plasma.  In the latter, the major metabolite of BK 
during incubation with plasma in vitro is BK- (1-5) or Arg-Pro-Pro-Gly-Phe, whereas 
during incubation of BK with rat urine, BK- (1-6) is the major metabolite and BK- (1-5) 
was not detected.  Further analysis of kininases in rat urine revealed that the main 
kininases are NEP and carboxypeptidase Y-like exopeptidase.  KII-ACE inhibitors such 
as captopril or lisinopril scarcely inhibit the activity of these enzymes, but ebenolactone 
B, isolated from culture medium of actinomycetes, inhibits the activity of 
carboxypeptidase Y-like kininases in rat urine, without inhibiting plasma kininases 
(Katori and Majima, 1996).   
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1.13. Materials and methods 
1.13.1 Reagents 
Lys-Bradykinin acetate salt (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), Bradykinin 
acetate salt (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), Ile-Ser-Bradykinin acetate salt 
(Ile-Ser- Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), porcine pancreatic tissue kallikrein, 
high and low molecular weight marker proteins were purchased from Sigma.  Partisil 5 
C8 preparative reverse phase column was purchased from Whatman.  Capcell C18 (4.6 
mm X 250 mm) analytical reverse phase column was purchased from Shiseido.   
1.13.2 Methods 
(a) Ostrich plasma collection 
Ostrich plasma was collected intravenously and stored as described in section 
3.2.2.(a).(i).   
(b) Ostrich urine collection 
Ostrich urine was collected and stored as described in section 3.2.2.(a).(ii).   
1.13.3 Kinin detection using HPLC 
(a) Kinin detection using a preparative reverse phase C-8 column 
A preparative reverse phase C-8 column was equilibrated in distilled deionised water 
containing 0.075 % (v/v) TFA.  The sample was loaded onto the resin at a flow-rate of 1 
ml/min.  The column was then washed with equilibration buffer until baseline was 
reached.  A linear gradient of 0  25 % of an CH3CN solution containing 0.075 % (v/v) 
TFA was applied over 1 minute.  During this step unwanted protein was washed from 
the resin.  Standard kinins eluted between 25 and 30 % of CH3CN, hence the bound 
kinin was eluted from the resin with a linear gradient of 25  50 % CH3CN over a period 
of 9 minutes.  The resin was then cleaned with a 100 % CH3CN step.   
(b) Kinin assay using an analytical reverse phase Capcell C-18 column 
The kinin assay was optimised with a Capcell C18 reverse-phase column on a Beckman 
HPLC (128 Solvent Module and 168 Diode Array Detector).  Commercial Ile-Ser-BK 
acetate (reptilian kinin), mammalian BK acetate and mammalian kallidin (Lys-BK) were 
used as standards.  The column was equilibrated in deionised distilled water containing 
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0.075 % (v/v) TFA.  Ostrich KG containing samples isolated as described in section 
4.2.2.(c) were digested at a 1:1 ratio (v/v) with a 50 mM Tris-HCl buffer at pH 8.0 
containing commercial porcine pancreatic kallikrein (50 µg/ml), 2 mM CaCl2, 2 mM 
ZnCl2 and 0.02 % NaN3 at 37oC for 60 minutes.  Digested samples were verified for 
kinin-liberation using SDS-PAGE and HPLC.  Samples for SDS-PAGE were dissolved 
in loading buffer.  For HPLC, 20-µl samples were injected onto the column using a 
Beckman 507 autosampler at a flow rate of 1 ml/min.  The column was washed for 5 
minutes with the equilibration buffer and elution proceeded with a linear gradient of 0  
50 % CH3CN, containing 0.075 % (v/v) TFA, over 40 minutes.  Since negative surfaces 
will cause the kinin to adhere to the surface, all glassware was siliconised.   
1.13.4 Kinin isolation from urine 
The frozen urine aliquots were thawed at 4oC and centrifuged at 11,000 g for 10 minutes 
at 4oC.  The supernatant was adjusted from pH 6.4 to pH 7.0 with Tris.  Sulfo-propyl-
Sephadex resin was equilibrated in a 50 mM Tris-HCl buffer at pH 7.0 containing 2 mM 
EDTA and 0.02 % NaN3.  The urine (12 l) was stirred in with the resin (500 ml) 
overnight at 4oC.  The resin was packed into a siliconized glass column at 1 ml/min. and 
washed with equilibration buffer until baseline (A280nm) was reached.  A step elution 
with a 0.1 M Tris-HCl buffer at pH 7.0, containing 2mM EDTA, 0.02 % NaN3 and 2 M 
NaCl was used to elute the kinin-containing fraction from the resin.  The pooled kinin 
fraction was diluted with distilled de-ionized water and loaded onto a reverse phase C-8 
preparative HPLC column at 1 ml/min.  The column was cleaned beforehand with 
distilled de-ionized water containing 0.075 % (v/v) TFA until baseline was reached.  
Kinin elution from the column was done as described in section 5.2.3.(a); 1 ml fractions 
being collected.  The collected fractions were pooled and subjected to the Capcell C-18 
analytical column for analysis [see section 5.2.3.(b)] and to N-terminal sequencing.   
. . . . . . .. . . 
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1.14. Results 
1.14.1 Kinin isolation from Ostrich urine 
Ostrich urine was analysed on HPLC for the presence of kinin as described in section 
5.2.3.(a).  During the analysis kinin-like peptides were detected in the region of the 
elution times of the standard kinins.  Kinin contains a net positive charge at pH 7.0 and 
this property was used to separate kinin from unwanted proteins present in urine.  A 
sulfo-propyl Sephadex resin was used to retain positively charged proteins from urine.  
These proteins and peptides were eluted with a step gradient of 2M NaCl and 
chromatographed by Partisil 5 C8 HPLC.  Protein was retained on the Partisil column 
(Figure 5.1), but when fractions collected were subjected to N-terminal sequencing as 
per section 4.2.2.(g), none of the fractions contained the kinin sequence.    
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Figure 5.1:  Preparative HPLC of ostrich urine on Partisil 5 C8.  A:  Elution profile of ostrich urine.  B:  
Ostrich urine fractions after SP-Sephadex chromatography.  Overlayed on the profile are the positions of 
elution for the standard kinins.   
 
1.14.2 Liberation of kinin from kininogen 
The final test for the presence of kininogen in a sample is the production of kinin in the 
presence of kallikrein.  The purpose of the experiment was to show that kinin was indeed 
liberated from the isolated kininogen, thus confirming its intactness with respect to its 
kinin moiety.  Samples were prepared and assayed for kinin production as described in 
section 5.2.3.(b).  SDS-PAGE runs were performed mainly to confirm that digestion was 
indeed complete.  As can be seen in figure 5.2, the kininogen bands (120-, 97- and 66-
kD) disappeared when the sample was incubated with commercial kallikrein.  The 
presence of kinin was ultimately detected by using the HPLC assay as described in 
section 5.2.3.(b) on a Capcell C18 analytical column (figure 5.3).   
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The aromatic side chain of phenylalanine compared to the non-polar side chain of 
leucine may contribute to a later elution time from the reverse phase column for 
mammalian BK compared to ornitho kinin.  The elution profile of ostrich kinin (figure 
5.3) shows this effect, which may indicate that we were detecting ostrich kinin in the 
digest.  The digested sample contained both LKG and HKG.  Commercial porcine 
pancreatic TK was used for the digestion of the sample, which would explain the 
presence of a kallidin-like molecule.  It is possible for TK to liberate a BK-like molecule 
from a kallidin-like molecule since the incubation time was 60 minutes at 37oC.   
1.15. Discussion 
1.15.1 Isolation of kinin 
A pilot attempt at the isolation of kinin was done on ostrich urine.  The results from this 
attempt showed that, based on elution times, kinin-like peptides may be present in 
ostrich urine (figure 5.1).  However, no positive proof was obtained upon N-terminal 
sequencing of fractions.  This procedure was however, not optimized.  Loading of 
ostrich urine onto the sulfo-propyl resin in the presence of NaCl and elution with a linear 
rather than a single step gradient should increase the purity of the fractions for HPLC 
analysis.  This would allow increased amounts of powdered urine to be loaded onto the 
resin and should therefore increase the yield of kinins eluted from the resin.  A purer 
yield of kinin loaded onto the Particil 5 C8 HPLC column would in turn increase the 
amount of purified kinin detected, allowing N-terminal sequence analyses and amino 
acid composition of the kinins to be achieved.   
1.15.2 Cleavage of ostrich kininogen by porcine pancreatic TK 
Papain affinity isolated ostrich plasma kininogen was digested with commercial porcine 
pancreatic TK as described in section 5.2.3.(b).  Figure 5.2 shows the undigested SDS-
PAGE pattern of the kininogen fraction and the digested fraction.  From these results it 
can be seen that kininogen was digested by porcine TK.  A distinctive kinin-like band 
appeared in the digested lane.  The digested fraction was also analyzed for the presence 
of kinin by HPLC (figure 5.3), where polypeptide peaks were obtained at elution times 
similar to those of commercial kinin standards.  However; no N-terminal sequence could 
be obtained on these fractions due to a very low polypeptide content.  The identity of 
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ostrich kinin, or even proof that we were able to isolate it, is therefore at best 
circumstantial.  However, the results in figure 5.3 confirm the release of three kinin-like 
peptides from ostrich plasma kininogens.  Therefore, these results provide evidence for 
the presence of plasma kininogens with intact kinin moieties in the affinity-isolated 
sample.   
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1.16. General 
Comparative blood coagulation studies on the ostrich, human, snake, sheep and chicken indicated that the 
coagulation system of the ostrich is less complex than the mammalian system.  Also apparent from this 
study of Frost et al. (1999) is that PK levels in the ostrich, measured with colourimetric substrates, are 
very low.  The ostrich- and reptilian-like systems are also comparable according to their blood clotting 
times (73s and 72.9s, respectively), but slower than mammalian times (15.1s for the human).   
1.17. Kallikreins 
In the present study it became evident that the KKS does exist in the ostrich.  The detection of kallikrein 
activity in the ostrich proved to be problematic.  We were able to detect kallikrein activity in the ostrich by 
using a fluorogenic assay system.   From these results the kidney and adrenal glands proved to be the best 
sources for the isolation of the kallikreins.  However, due to the apparently low levels of kallikrein in the 
ostrich, a better approach in obtaining active kallikrein would be to clone the kallikrein genes into 
expression vectors.  The isolation of ostrich kallikrein could not be successfully completed largely due to 
the difficulty of reliably assaying for the enzyme.   
1.18. Kininogens 
Isolating intact kininogens from plasma proved to be a difficult task due to proteolytic degradation upon 
isolation and storage of samples.  Despite the precaution of siliconising all glassware during handling of 
the ostrich kininogen, we could not prevent the degradation of the 120-kD HKG to a 97-kD form.  Lin et 
al. (2000) used a biotinylated heparin column to isolate HKG.  Heparin binds via Zn2+ ions to domain 5 of 
HKG and since heparin does not bind LKG this method can be used to separate HKG from LKG.  Elution 
of HKG from the resin was done with MgCl2.  Mashiko et al. (1998) used a Copper-chelating-Sepharose-
6B column to isolate HKG from porcine plasma.  HKG was eluted from the resin with 30 mM histidine.  
From tables 4.1 and 4.2, it is clear that the respective yields of active HKG and -LKG were significantly 
decreased by the papain-Sepharose-4B and Blue-Sepharose chromatography steps.  Using either 
biotinylated heparin or the copper-chelating step, instead of the papain-affinity step, may allow the 
recovery of a larger yield of intact HKG.  However, a better way of obtaining the intact protein would be 
to clone the ostrich KG gene into an expression vector.  Determining the amino acid sequence, in domain 
3, that is responsible for the acceleration of cell adhesion [see section 4.1.2.(c).(iii)] would allow 
investigation into the pharmacological properties of this peptide in wound healing (see section 1.3.3).  
Cloning of the ostrich KG gene would also allow one to specifically determine the physiological function 
of each domain in both KG molecules.  The N-terminal amino acid sequence of ostrich HKG was 
determined to be 91 % identical to chicken HKG and the N-terminal amino acid sequence of ostrich LKG 
was determined to be 78 % identical to chicken HKG (see table 4.3).  Homology to mammalian HKGs 
. . . . . . .. . . 
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was significantly lower (~40 %).  Hence, any pharmacological therapy for treating inflammation, infection 
or wound healing in ostriches, based on kininogen-related peptides, would require complete analysis of the 
molecule in ostriches first.   
1.19. Kinins 
Positive indication for the expected presence of ornitho kinin in ostrich urine (see figure 5.1), as discussed 
in section 5.3.2, was shown in figure 5.3.  Hagiwara et al. (1994) were able to detect BK in rat urine and 
used an enzyme immunoassay to assay for BK.  Isolation of ostrich kinin would allow us to optimize a 
similar system for the ostrich.  Using ostrich kininogen as substrate, ostrich kallikreins can then be 
detected even in crude extracts or fluids.  Hagiwara et al. (1994) also used a reverse phase C18 step prior to 
the assay.  The isolation of kinin from ostrich urine can be optimized by loading of the sample onto the 
SP-Sephadex- and reverse phase columns in the presence of salt and elution with a linear gradient.  This 
would improve the purity of the sample and increase the amount of kinin that can be isolated.   
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